1[COMPANY_003]
[COMPANY_003]
7$%/(2)&217(176
7,7/(3$*(    
7$%/(2)&217(176   
[ZIP_CODE]&2/$0(1'0(176800$5<2)&+$1*(6   
/,672)$%%5(9,$7,216   
&/,1,&$/678'<[ZIP_CODE]&2/   
 ,1752'8&7,21   
 %DFNJURXQG   
 5DWLRQDOHIRU&RQGXFW RIWKH6WXG\   
 678'<2%-(&7,9(6$1'+<327+(6(6   
 3ULPDU\2EMHFWLYH   
 6HFRQGDU\2EMHFWLYHV   
 $GGLWLRQDO2EMHFWLYHV   
 75,$/*29(51$1&(   
 75,$/'(6,*1   
 'HVLJQ'HVFULSWLRQ   
 7ULDO'XUDWLRQ   
 3RVW7ULDO$FFHVVWR7KHUDS\   
 75,$/3238/$7,21   
 ,QFOXVLRQ&ULWHULD   
 ([FOXVLRQ&ULWHULD   
 75,$/3/$1   
 7ULDO3URFHGXUHV2YHUYLHZ   
 3UH(QUROOPHQWDQG(QUR OOPHQW3URFHGXUHV   
 0HWKRGRI$VVLJQLQJ3DWLHQWVWR7 UHDWPHQW*URXSV9LVLW   
 7UHDWPHQWV$GPLQLVWHUHG   
 &RQFRPLWDQW7KHUDS\   
 3UHFDXWLRQVWR0LQLPL]H5DWHVRI+\SRJO\FHPLD   
 /DERUDWRU\DQG$QWKURSRPHWULF0HDVXUHPHQWV   
 &DOFLWRQLQ6DPSOH&ROOHFWLRQ   
 *HQHWLFDQG%LRPDUNHU 6DPSOH&ROOHFWLRQ   
  5HVRXUFH8WLOL]DWLRQ4XDOLW\RI/LI H'DWDIRU(FRQRPLF(YDOXDWL RQ  
2
  7HPSRUDU\RU3HUPDQHQW'LVFRQ WLQXDWLRQRI7ULDO0HGLFDWLRQ   
  3HUPDQHQW'LVFRQWLQXDWLRQRI7UL DO0HGLFDWLRQ3HU3URWRFRO   
  7ULDO7HUPLQDWLRQ9LVLW   
  3RVW7UHDWPHQW7HOHSKRQH&RQWDFW   
  :LWKGUDZDORI&RQVHQW   
  /RVWWR)ROORZ8S   
  %UHDNLQJWKH%OLQG   
  7ULDO+RWOLQH   
 75,$/0(',&$7,216   
 7ULDO0HGLFDWLRQ6XSSO\   
 )RUPXODWLRQ3DFNDJLQJDQG6WRUDJH   
 'LVSHQVLQJRI7ULDO0HGLFDWLRQ   
 'RVH$GPLQLVWUDWLRQ3URFH GXUHV5RXWHDQG6FKHGXOH   
 5DQGRPL]DWLRQ6FKHGXOHDQG%OLQGLQJ3URFHGXUHV   
 'UXJ$FFRXQWDELOLW\   
 ()),&$&<$66(660(176   
 3ULPDU\(IILFDF\(QGSRLQW   
 6HFRQGDU\(IILFDF\(QGSRLQWV   
 $GGLWLRQDO(IILFDF\(QGSRLQWV   
 67$7,67,&$/0(7+2'6   
 %DVHOLQH&KDUDFWHULVWLFV   
 6DPSOH6L]H   
 5DQGRPL]DWLRQ   
 3ULPDU\+\SRWKHVLV   
 3ULPDU\$QDO\VLV   
 6HFRQGDU\(IILFDF\$QDO\VHV   
 $QDO\VLV3RSXODWLRQV   
  ,QWHQW7R7UHDW3RSXODWLRQ   
  3HU3URWRFRO3RSXODWLRQ   
  6DIHW\3RSXODWLRQ   
 6DIHW\'DWD$QDO\VLV   
 6XEJURXS$QDO\VHV   
  ,QWHULP$QDO\VHV   
3
  (FRQRPLF$QDO\VLV   
 6$)(7<$66(660(176   
  'HILQLWLRQV   
  $GYHUVH(YHQW$VVHVVPHQW   
  5HFRUGLQJDQG5HSRUWLQJ$GYHUVH(YHQWV   
  5HFRUGLQJ$GYHUVH(YHQWV   
  6DIHW\5HSRUWLQJ   
  6SRQVRU5HVSRQVLELOLW\IRU5HSRUWL QJ6HULRXV$GYHUVH(YHQWV   
  &DOFLWRQLQ0RQLWRULQJ   
  2YHUGRVH   
  'HILQLWLRQRIDQ2YHUGRVHIRU7KLV3URWRFRO   
  5HSRUWLQJRI2YHUGRVH   
  5HSRUWLQJRI3UHJQDQF\   
  8QEOLQGLQJ   
 (7+,&$/$1'/(*$/$63(&76   
  *HQHUDO,QIRUPHG&RQVHQW   
  &RQVHQWDQG&ROOHFWLRQRI6SHFLPH QVIRU*HQHWLFDQG*HQRPLF$QD O\VLV  
  &RQVHQWDQG&ROOHFWLRQRI% LRPDUNHU6SHFLPHQV   
  (WKLFV&RPPLWWHHRU,QVWLWX WLRQDO5HYLHZ%RDUG   
  (WKLFDO&RQGXFWRIWKH6WXG\   
  5HJXODWRU\$XWKRULW\$SSU RYDOV$XWKRUL]DWLRQV   
  &RQILGHQWLDOLW\   
  5HFRUGV   
  5HFRUGV5HWHQWLRQ   
  &DVH5HSRUW)RUPV   
 75,$/0$1$*(0(17*29(51$1&(&200,77((6  
  ([HFXWLYH&RPPLWWHH(&   
  2SHUDWLRQV&RPPLWWHH2&   
  5HPLWRI2SHUDWLRQV&RPPLWWHH   
  'DWD6DIHW\0RQLWRULQJ%RDUG'60%   
  &OLQLFDO(YHQWV&RPPLWWHH&(&   
  6WUDWHJLF$GYLVRU\&RPPLWWHH   
4
 ',6&/2685(2)'$7$38%/,&$7,216$1'&/,1,&$/678'<
5(3257  
 5()(5(1&(6  
/,672)$33(1',&(6  
$SSHQGL[&OLQLFDO (YHQWV/LVW   
$SSHQGL[7ULDO3ODQ3URWRFRO%&%   
$SSHQGL[3URWRFRO$PHQGPHQW6X[COMPANY_003]U\RI&KDQJHV  
$SSHQGL[3URWRFRO$PHQGPHQ W6X[COMPANY_003]U\RI&KDQJHV   
$SSHQGL[3URWRFRO$PHQGPHQ W6X[COMPANY_003]U\RI&KDQJHV   
$SSHQGL[3URWRFRO$PHQGPHQ W6X[COMPANY_003]U\RI&KDQJHV   
$SSHQGL[3URWRFRO$PHQGPHQ W6X[COMPANY_003]U\RI&KDQJHV   
5
EXSCEL Protocol Amendment 06
PROTOCOL AMENDMENT 06: SUMMARY OF CHANGES
Exenatide QW Clinical Study Protocol D5551C00003, BCB109
PROTOCOL TITLE: A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO 
EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE 
WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Protocol Number: D5551C00003, BCB109
Amendment Number: 06Amendment Purpose: Date: 09 March 2016
The purpose of this non-substantial amendment is two-fold:
1. to update the protocol based on US Food and Drug Administration (FDA) recommendation for the study
analysis, and
2. to update the procedures for handling all Clinical Events (as defined in Protocol Appendix 1) to be
consistent throughout the study.
As per the protocol, the EXenatide Study of Cardiovascul ar Event Lowering Trial (EXSCEL) Executive Committee 
will monitor the accrual of the aggregate number of adjudicated primary endpoint events (confirmed cardiovascular-
related death, nonfatal myocardial infarction or nonfatal stroke) and will determine the primary endpoint event cut-
off date (i.e., the date at which the anticipated number of events is expected to have accrued).  The primary 
statistical analysis was initially planned to include all adjudic ated cardiovascular events with onset dates up to and 
including the primary endpoint event cut-off date.  As per FDA recommendation, the primary statistical analysis has been updated to include all adjudicated  primary endpoint events with onset dates up to and including the Trial 
Termination Visit date (rather than the primary endpoint event cut-off date).  Any events occurring between the 
Trial Termination Visit and the safety follow-up phone call (scheduled [ADDRESS_307392] dose of study medication) 
will not be adjudicated and will not be included in the primary analysis, as agreed by [CONTACT_1622].  The FDA also made 
recommendations for updating the censoring strategy, which has been incorporated in the protocol amendment.
The procedure for serious adverse event (SAE) reporting described in Protocol Section 10.3.[ADDRESS_307393] that Clinical Events (as define d in Protocol Appendix 1) occurring after the 
primary endpoint event cut-off date (e.g., during either the time period up to the Trial Termination Visit or during 
the safety follow-up period) will continue to be collected and reported in the same way as they have been throughout 
the study.  There will be no switch to collecting and mana ging Clinical Events as SAEs after the primary endpoint 
cut-off date as previously described in the protocol.  
This amendment will also address administrative changes in the study.
Administrative Changes:
!To inform that as of Janua ry 2015, the EXSCEL Executive Committee co-chair, , has
been replaced by 
!To inform that while Amylin LLC remains the s ponsor for the study, as of 1 February 2014, Amylin LLC is
wholly owned by [CONTACT_38227].
!To inform that as part of the ownership transfer  of Amylin, a new study c ode D5551C00003 was generated to
comply with [COMPANY_008] internal procedures.  Trial reference codes H80-MC-GWDQ, BCB109 and
D5551C00003 refer to the same clinical study, known as EXSCEL.
In the table below, the changes in individual sections are presented in the revised text with all deletions addressed as 
a strikethrough and all additions shown in bold.
6[COMPANY_003]
[COMPANY_003]
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
3 Trial 
GovernanceEXSCEL is a multinational pragmatic trial that 
will be conducted at approximately 800 sites worldwide.  It will be run jointly by [CONTACT_252724] (DCRI) and the 
University of Oxford Diabetes Trials Unit 
(DTU) Academic Research Organizations 
(AROs), in an academic collaboration with Amylin Pharmaceuticals, LLC (Amylin), a wholly owned subsidiary of Bristol-Myers Squibb.  EXSCEL will be Co-Chaired by 
 
 [CONTACT_252725].
The EXSCEL Executive Committee (EC) will 
have overall responsibility for the oversight and management of the trial (Figure 1).  The EC will consist of senior independent academic 
representatives who are experts in their field 
and sponsor representatives.  It will be Co-Chaired  EXSCEL is a multinational pragmatic trial that 
will be conducted at approximately 800 sites worldwide. It will be run jointly by [CONTACT_252726] (DCRI) and the 
University of Oxford Diabetes Trials Unit 
(DTU) Academic Research Organizations 
(AROs), in an academic collaboration with Amylin Pharmaceuticals, LLC (Amylin), a wholly owned subsidiary of [COMPANY_008]
Bristol-Myers Squibb. EXSCEL will be Co-
Chaired by
 
[CONTACT_252727].The EXSCEL Executive Committee (EC) will 
have overall responsibility for the oversight and 
management of the trial (Figure 1). The EC will 
consist of senior independent academic 
representatives who are experts in their field and sponsor representatives. It will be Co-Chaired 
by 
4.1 Design 
Description
Paragraph 2Approximately 14,000 patients meeting all 
enrollment criteria will be recruited in to the 
trial over approximately a five year period, randomly allocated to treatment with either EQW 2 mg or matching placebo subcutaneous 
injections once weekly in a 1:[ADDRESS_307394] (DSMB) advises otherwise.  It is anticipated that the EXSCEL 
Executive Committee will monitor the accrual 
of the aggregate number of adjudicated primary 
endpoint events and will determine the primary 
endpoint event cut-off date (i.e., the date at which the anticipated number of events is 
expected to have accrued); all patients will be 
expected to have follow-up through this date 
(see Section 6).Approximately 14,000 patients meeting all 
enrollment criteria will be recruited in to th e trial 
over approximately a five year period, randomly 
allocated to treatment with either EQW 2 mg or 
matching placebo subcutaneous injections once 
weekly in a 1:[ADDRESS_307395] (DSMB) advises otherwise. It 
is anticipated that the EXSCEL Executive 
Committee will monitor the accrual of the 
aggregate number of adjudicated primary endpoint events and will determine the primary endpoint event cut-off date (i.e., the date at which the anticipated number of events is 
expected to have accrued).  Based on the 
primary endpoint event cut-off date, a 
window of time for conduct of the Trial 
Termination Visit will be established ; all 
patients will be expected to have follow-up through this date until the Trial Termination 
Visit (see Section 6).
7[COMPANY_003][COMPANY_003]
[COMPANY_003][COMPANY_003]
EXSCEL Protocol Amendment [ADDRESS_307396] their vital status 
ascertained, if possible, as of the Trial 
Termination Visit data cut-off date for primary 
endpoint events.
6.1 Trial 
Procedures -
OverviewParagraph 3:
The trial is planned to continue until [ADDRESS_307397] been accrued.  It 
is anticipated that the EXSCEL Executive 
Committee will monitor the accrual of the aggregate number of adjudicated primary endpoint events and will determine the primary endpoint event cut-off date (i.e., the date at 
which the anticipated number of events is 
expected to have accrued; all patients will be 
expected to have follow-up through this date).  
Based on the primary endpoint event cut-off date, a window of time for conduct of the Trial Termination Visit will be established.Paragraph 3:
The trial is planned to continue until 
[ADDRESS_307398] been accrued. It is 
anticipated that the EXSCEL Executive 
Committee will monitor the accrual of the aggregate number of adjudicated primary endpoint events and will determine the primary endpoint event cut-off date (i.e., the date at 
which the anticipated number of events is 
expected to have accrued) all patients will be 
expected to have follow-up through this date).
Based on the primary endpoint event cut-off date, a window of time for conduct of the Trial 
Termination Visit will be established. All 
patients will be expected to have follow-up 
until this visit.
8
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
Paragraphs 5 and 6:
After the Trial Termination Visit patients will be contact[CONTACT_252728][INVESTIGATOR_252658] [ADDRESS_307399] their final assessment of 
serious adverse experiences and hospi[INVESTIGATOR_252659].Note that all serious adverse experiences, hospi[INVESTIGATOR_602], and reportable study events 
with an onset date after the primary endpoint 
event cut-off date established by [CONTACT_252729] (see Section 10.3.1).Paragraphs 5 and 6:
After the Trial Termination Visit patients will be 
contact[CONTACT_252730] , serious adverse experiences and 
hospi[INVESTIGATOR_252660] [ADDRESS_307400] their final assessment of Clinical Events , serious 
adverse experiences and hospi[INVESTIGATOR_252659].
Clinical Events (as defined in Protocol 
Appendix 1) will continue to be collected and reported in the same way as they have been 
throughout the entire study (i.e., prior to the 
cut-off date) Note that all serious adverse 
experiences, hospi[INVESTIGATOR_602], and reportable 
study events with an onset date after the primary 
endpoint event cut-off date established by [CONTACT_252731] (see Section 10.3.1).
[ADDRESS_307401] of the
Trial Termination Visits will be established; this 
window will be a period of time following the
primary endpoint event cut-off date. At the 
Trial Termination Visit, all patients must bediscontinued from trial medication; the 
investigator should ensure that the patient 
receives appropriate standard of care. For 
procedural details of the Trial Termination Visit, refer to Appendix 2.  
â€¦.
If a patient fails to return or otherwise becomes 
difficult to contact, it is the investigatorâ€™sresponsibility to make every effort to maintain 
contact [CONTACT_252732]/or endpoint 
adjudication as of the primary endpoint event 
cut-off date.Investigators will be informed by [CONTACT_252733], and will schedule allpatients for the Trial Termination
Visit. Based on the primary endpoint event cut-
off date, a window of time for conduct of the
Trial Termination Visits will be established; this 
window will be a period of time following the 
primary endpoint event cut-off date. All patients 
will be expected to have follow-up until this 
visit. At the Trial Termination Visit, all patients 
must be discontinued from trial medication; the 
investigator should ensure that the patient receives appropriate standard of care. For 
procedural details of the Trial Termination Visit, refer to Appendix 2.  
â€¦.
If a patient fails to return or otherwise becomes 
difficult to contact, it is the investigatorâ€™s
responsibility to make every effort to maintain contact [CONTACT_252734]/or endpoint adjudication as of the Trial Termination Visit
primary endpoint event cut-off date.
6.[ADDRESS_307402] been discontinued from trial medication for more 
than 70 days as of the Trial Termination Visit, the Trial Termination Visit will be the final 
study follow-up. Note that all serious adverse 
experiences, hospi[INVESTIGATOR_602], and reportable study events with an onset date after the 
primary endpoint event cut-off date established 
by [CONTACT_252735] (see 
Section 10.3.1).After the Trial Termination Visit, patients will 
be contact[CONTACT_252736] , serious adverse experiences 
and hospi[INVESTIGATOR_252660] [ADDRESS_307403] been 
discontinued from trial medication for more than 
70 days as of the Trial Termination Visit, the 
Trial Termination Visit will be the final study 
follow-up. Clinical Events (as defined in 
Protocol Appendix 1) will continue to be 
collected and reported in the same way as 
they have been throughout the entire study
(i.e., prior to the cut-off date) Note that all 
serious adverse experiences, hospi[INVESTIGATOR_602], 
and reportable study events with an onset date 
after the primary endpoint event cut-off date 
established by [CONTACT_252737]
(see Section 10.3.1).
8.3 Additional 
Efficacy 
Endpointsâ€¢ Number of epi[INVESTIGATOR_252661].â€¢Number of epi[INVESTIGATOR_252662].
10
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
9.5 Primary 
AnalysisThe primary statistical analysis will be based 
upon adjudicated CV events with patients whodiscontinue prematurely from treatment followed until the end of the study, i.e.until the 
requisite number of primary composite events 
has been accrued. It is anticipated that the 
Executive Committee will monitor the accrual of the aggregate number of primary composite CV events to determine the primary endpoint event cut-off date (i.e., the date at which the anticipated number of events is expected to 
have accrued). All patients will be expected to 
have follow-up through this date. Analysis of 
the primary composite cardiovascular outcome 
will be based on the time from randomization to 
the occurrence of the first event, with patients analyzed according to their randomized 
treatment. The primary analysis will include all 
adjudicated CV events with onset dates up to 
and including the primary endpoint event cut-
off date.The primary statistical analysis will be based 
upon adjudicated CV events with patients who 
discontinue prematurely from treatment followed 
until the end of the study, i.e. the Trial 
Termination Visit and until the requisite 
number of primary composite events has been 
accrued. It is anticipated that the Executive Committee will monitor the accrual of the aggregate number of primary composite CV events to determine the primary endpoint event cut-off date (i.e., the date at which the 
anticipated number of events is expected to have 
accrued). Based on the primary endpoint 
event cut-off date, a window of time for 
conduct of the Trial Termination Visit will be 
established.   All patients will be expected to 
have follow-up through this date until this visit . 
Analysis of the primary composite 
cardiovascular outcome will be based on the 
time from randomization to the occurrence of the 
first event, with patients analyzed according to 
their randomized treatment. The primary 
analysis will include all adjudicated CV events 
with onset dates up to and including the Trial 
Termination Visit primary endpoint event cut-
off date. Note that any event occurring 
between the Trial Termination Visit and the 
safety follow-up date ([ADDRESS_307404] dose of trial 
medication) will not be adjudicated and will not be included in the primary analysis.  Events occurring during this period will be summarized descriptively.  
9.7.[ADDRESS_307405] discontinued study medication 
or the study.  For the ITT population, patients will be analyzed as randomized.
11
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
[IP_ADDRESS] On-
Treatment 
AnalysisAn on-treatment analysis using the ITT 
population will be performed for the primary and secondary analyses as sensitivity analyses.This analysis will include only those events that 
occurred within [ADDRESS_307406]. The patients 
will be analyzed according to the treatment 
group to which they were randomized. The 
on-treatment censoring scheme will also be 
applied for analysis for on-treatment + n 
days, where n=7, 30, and 70.
9.7.[ADDRESS_307407] one 
dose of study medication and will include in 
their analysis all data collected prior to any major protocol violations (or primary endpoint 
event cut-off date, whichever occurs first), such 
as:
!Initiation of an open-label prohibited 
medication, i.e. a GLP-[ADDRESS_307408]. 
Evaluation will include all data up to the 
day of the initiation of the prohibited 
medication.
!Early discontinuation from study 
medication.  Evaluation will include events which occurred from randomization to [ADDRESS_307409] one 
dose of study medication and will include in their analysis all data collected prior to any major protocol violations (or the Trial 
Termination Visit primary endpoint event cut-
off date, whichever occurs first), such as:
! Initiation of an open-label prohibited 
medication, i.e. a GLP-[ADDRESS_307410]. Evaluation will include all data up to the day 
of the initiation of the prohibited 
medication.
! Early discontinuation from study 
medication.  Evaluation will include events which occurred from randomization to [ADDRESS_307411].
9.8 Safety Data 
AnalysisSafety parameters will be summarized and 
presented in tables for the safety population.  Serious adverse events will be listed and tabulated by [CONTACT_252738] (HGLT), as 
assigned by [CONTACT_74348].Safety parameters will be summarized and 
presented in tables for the safety population.
Serious adverse events will be listed and tabulated as described in the SAP by [CONTACT_252739] (HGLT), as assigned by [CONTACT_252740].
[ADDRESS_307412] on the risk of developi[INVESTIGATOR_252663].  The 
following subgroups will be assessed:
!Class of AHA therapy at entry (mono or 
combination)
!Race (Black, Caucasian, Asian, Other)
!Region (North/South America, Europe or 
South Africa, Rest of world)
!Gender (Male, Female)
!Age (<65 or â‰¥65)
!Baseline HbA1c (<8.0% or â‰¥8/0%)
!Baseline BMI (<30 or â‰¥30 kg/m
2)
!Duration of diabetes (<5 years or â‰¥5 years)
!Baseline eGFR (<60 mL/min or â‰¥60 
mL/min)
!History of previous cardiovascular event 
(e.g., previous MI or stroke)Subgroup analyses for the primary CV 
composite endpoint will be performed on the ITT population in order to explore whether the 
treatment effect on the risk of developi[INVESTIGATOR_252664].  The 
following subgroups will be assessed:
!Class of AHA therapy at entry (mono or 
combination)
!Race ( Indian [American] or Alaska 
Native, Asian, Black, Native Hawaiian or 
Other Pacific Islander, White, Hispanic, 
Other (Black, Caucasian, Asian, Other)
!Geographic region ( North America, Latin 
America, Europe and Asia Pacific) 
(North/South America, Europe or South 
Africa, Rest of world)
!Gender (Male, Female)
!Age (<65 or â‰¥65)
!Baseline HbA1c (<8.0% or â‰¥8./0%)
!Baseline BMI (<30 or â‰¥30 kg/m2)
!Duration of diabetes (<5, 5-14, â‰¥15 years or 
â‰¥5 years)
!eGFR groups (in mL/min/1.73 m2)
âˆ€(<60 or â‰¥60)
âˆ€Stage 1: 90+, Stage 2: 60-89, Stage 3: 
30-59, Stage 3a: 45-59, Stage 3b: 30-44, Stage 4: 15-29, Stage 
5: <15  Baseline eGFR (<60 mL/min or 
â‰¥60 mL/min)
!History of previous cardiovascular event 
(e.g., previous MI or stroke)
[ADDRESS_307413] available visit. A full 
analysis plan for the economic analysis will be 
prepared and reported separately from this 
protocol.
For the main clinical study report (CSR), the 
quality of life data will be summarized 
descriptively for baseline and changes from 
baseline by [CONTACT_3148].
14
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
10.3.1 Recording 
Adverse EventsSAEs will be recorded in the Clinical Events 
or SAE eCRF modules as appropriate (see 
Table 1) through the primary endpoint event cut-off date; ALL SAEs with onset dates 
AFTER the primary endpoint event cut-off date 
will be recorded in the SAE eCRF module. 
Guidelines for events which qualify as Clinical Events are provided in Appendix 1. Events to be 
recorded in the Clinical Events eCRF module 
include SAEs that are: (1) Obvious trial 
endpoints, (2) Cardiovascular Events of Interest, 
(3) Expected Events and Diabetic 
Complications.
Table [ADDRESS_307414] of events to be recorded in each 
eCRF reporting module*
eCRF 
reporting 
module to 
be usedList of events to be recorded in this 
eCRF reporting module:
Clinical Event eCRF
(events with onset date up 
to and 
including the 
primary 
endpoint event cut-off 
date)- Clinical Events that meet the criteria 
of an SAE (i.e. serious adverse event) 
and are listed in Appendix 1
- All non-serious (or serious) events 
of percutaneous coronary intervention 
(PCI), stress tests, severe 
hypoglycemia, diabetic eye disease, foot ulcer, microalbuminuria, 
macroalbuminuria, 
hyperlipi[INVESTIGATOR_035]/dyslipi[INVESTIGATOR_035], 
hypertension, or gout
- All neoplasia events
- All pancreatitis events
SAE eCRF- Any event meeting the criteria of an 
SAE (see Section 10.1 for definition 
of SAE) that are notlisted in 
Appendix 1 and all events above with 
an onset date after the primary 
endpoint event cut-off date
- All epi[INVESTIGATOR_81719]
- All epi[INVESTIGATOR_252665]/cancer
- Any AE or SAE resulting from an 
overdose of study drug
- Any event that is recorded in the 
Clinical Event eCRF, that the 
investigator considers a S[LOCATION_003]R, with 
the exception of possible Primary or Secondary trial endpoints (i.e. all 
events listed in Appendix 1, Section I)
* Trial sites will be provided with an â€˜EXSCEL 
Event Reportingâ€™ flow chart that can be referenced 
to help identify which events should be reported in 
which eCRF reporting module.SAEs will be recorded in the Clinical Events or 
SAE eCRF modules as appropriate (see Table 1) 
throughout the trial (including the [ADDRESS_307415] dose of study 
medication) through primary endpoint event 
cut-off date; ALL SAEs with onset dates 
AFTER the primary endpoint event cut-off date 
will be recorded in the SAE eCRF module.
Guidelines for events which qualify as Clinical 
Events are provided in Appendix 1. Events to be recorded in the Clinical Events eCRF module 
include SAEs that are: (1) Obvious trial 
endpoints, (2) Cardiovascular Events of Interest, (3) Expected Events and Diabetic Complications.
Table [ADDRESS_307416] of events to be recorded in each 
eCRF reporting module*
eCRF 
reporting 
module to be 
usedList of events to be recorded in this 
eCRF reporting module:
Clinical Event eCRF
(events with 
onset date up 
to and 
including the 
primary 
endpoint 
event cut-off 
date)- Clinical Events that meet the criteria 
of an SAE (i.e. serious adverse event) 
and are listed in Appendix 1
- All non-serious (or serious) events 
of percutaneous coronary intervention 
(PCI), stress tests, severe 
hypoglycemia, diabetic eye disease, foot ulcer, microalbuminuria, 
macroalbuminuria, 
hyperlipi[INVESTIGATOR_035]/dyslipi[INVESTIGATOR_035], 
hypertension, or gout
- All neoplasia events
- All pancreatitis events
SAE eCRF- Any event meeting the criteria of an 
SAE (see Section 10.1 for definition of 
SAE) that are notlisted in Appendix 1 
and all events above with an onset date 
after the primary endpoint event cut-
off date
- All epi[INVESTIGATOR_81719]
- All epi[INVESTIGATOR_252665]/cancer
- Any AE or SAE resulting from an 
overdose of study drug
- Any event that is recorded in the 
Clinical Event eCRF, that the 
investigator considers a S[LOCATION_003]R, with 
the exception of possible Primary or Secondary trial endpoints (i.e. all 
events listed in Appendix 1, Section I)
* Trial sites will be provided with an â€˜EXSCEL 
Event Reportingâ€™ flow chart that can be referenced 
to help identify which events should be reported in 
which eCRF reporting module.
15
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
10.3.2 Safety 
ReportingThe DSMB will monitor the totality of collected 
safety data (i.e. events recorded on both the 
Clinical Events and SAE eCRFs) on a semi-annual basis regardless of event classification.SAEs recorded on the Clinical Events eCRF 
represent those events which are components of 
the composite CV endpoint, other trial endpoints, potential components of the CV endpoint that require adjudication or are expected sequelae of T2DM. SAEs recorded as Clinical Events, including death related to an 
event in the Clinical Events List , will not be 
reported to the Sponsor, regulatory agencies or 
ethics committees, regardless of relationship to 
trial medication even though they may be 
considered possibly, probably or definitely drug-related and meet SAE criteria.  In addition 
to the un-blinded review by [CONTACT_4318], events 
reported via this module that may be associated with a trial endpoint will be adjudicated by [CONTACT_15741]. As described above, all SAEs that are not 
included in the Clinical Events List and 
â€œClinical Eventsâ€ with onset dates after the 
primary endpoint event cut-off date will be 
recorded by [CONTACT_252741]. These events must be recorded in this 
module (or faxed to the number provided on the 
SAE report form if EDC is unavailable) within 
[ADDRESS_307417] to expedited reporting 
as per current legislation. Brief information on the clinical course of the event, treatment, and relevant diagnostic, laboratory or other 
investigations will be collected on the eCRF.
All epi[INVESTIGATOR_252666]. All events recorded in the SAE eCRF module will be 
reported to the appropriate regulatory agencies 
in a manner and timeframe consistent with all 
applicable laws and regulations (Section 10.3.3). All S[LOCATION_003]RS will be reported in an 
expedited manner with the exception of possible 
trial endpoints as detailed in Section I of 
Appendix 1, which will be handled as Clinical 
Events.The DSMB will monitor the totality of collected 
safety data (i.e. events recorded on both the Clinical Events and SAE eCRFs) on a semi-
annual basis regardless of event classification. 
SAEs recorded on the Clinical Events eCRF 
represent those events which are components of 
the composite CV endpoint, other trial endpoints, potential components of the CV endpoint that require adjudication or are expected sequelae of T2DM. SAEs recorded as Clinical Events, including death related to an 
event in the Clinical Events List, will not be 
reported to the Sponsor, regulatory agencies or 
ethics committees, regardless of relationship to 
trial medication even though they may be 
considered possibly, probably or definitely drug-
related and meet SAE criteria. This will be 
applicable throughout the duration of trial 
including the [ADDRESS_307418] and â€œClinical Eventsâ€
with onset dates after the primary endpoint event 
cut-off date will be recorded by [CONTACT_252742]. These events must be 
recorded in this module (or faxed to the number 
provided on the SAE report form if EDC is 
unavailable) within [ADDRESS_307419] to expedited reporting as per current 
legislation. Brief information on the clinical 
course of the event, treatment, and relevant 
diagnostic, laboratory or other investigations will 
be collected on the eCRF. All epi[INVESTIGATOR_252667]. All events recorded in the 
SAE eCRF module will be reported to the 
appropriate regulatory agencies in a manner and timeframe consistent with all applicable laws and regulations (Section 10.3.3). All S[LOCATION_003]RS
will be reported in an expedited manner with the 
exception of possible trial endpoints as detailed 
in Section I of Appendix 1, which will be 
handled as Clinical Events.
16
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 05 TEXT AMENDMENT 06 TEXT
12.1 Executive 
Committee (EC)The EC will be responsible for overall 
management and oversight of the trial.  The EC will be composed of senior independent academic representatives who are experts in 
their field and representatives from the sponsor.  
The Committee will be -  
 
n EC charter will outline 
the committee membership and structure and delineate operating procedures.The EC will be responsible for overall 
management and oversight of the trial. The EC will be composed of senior independent 
academic representatives who are experts in their 
field and representatives from the sponsor. The 
Committee will be
 
. An EC 
charter will outline the committee membership and structure and delineate operating procedures.
Appendix 2 TRIAL PLAN 
(PROTOCOL 
BCB109)Table 1
Footnote 9:
[9] Patients will be contact[CONTACT_252743][INVESTIGATOR_252660] [ADDRESS_307420] dose of trial medication.  Note that all serious adverse experiences, hospi[INVESTIGATOR_602], and reportable 
study events with an onset date after the 
primary endpoint event cut-off date established 
by [CONTACT_252744] (see Section 10.3.1).Table 1
Footnote 9:
[9] Patients will be contact[CONTACT_252745] , serious adverse 
experiences and hospi[INVESTIGATOR_252668] [ADDRESS_307421] 
dose of trial medication. Note that all serious 
adverse experiences, hospi[INVESTIGATOR_602], and 
reportable study events with an onset date after 
the primary endpoint event cut-off date 
established by [CONTACT_252737] 
(see Section 10.3.1).
17[COMPANY_003]P
P[COMPANY_003]
EXSCEL Protocol Amendment [ADDRESS_307422] Modification of Diet in Renal Disease Study Group method for eGFR
MI Myocardial infarction
OC Operations CommitteePCI Percutaneous coronary intervention
SAE Serious Adverse Event 
S[LOCATION_003]R Suspected Unexpected Serious Adverse ReactionSBP Systolic blood pressure 
T2DM Type 2 diabetes mellitus
TC Total cholesterol
TG TriglyceridesTIA Transient ischemic attack[LOCATION_006]PDS [LOCATION_008] Prospective Diabetes Study
18
EXSCEL Protocol Amendment 06
CLINICAL STUDY PROTOCOL
1 INTRODUCTION1.1 Background
Type 2 diabetes mellitus is a leading public health issue. Often regarded as a mild disease, it is 
the fourth leading cause of death in developed countries and the number of people worldwide
with diabetes is predicted to exceed 300 million by [CONTACT_2892] 2025.
1  Diabetes remains the leading 
cause of blindness, end stage renal disease, and lower extremity amputations and confers a two 
to four times greater risk of heart disease and strokes.
The majority of people with type 2 diabetes mellitus (T2DM) die as a result of cardiovascular 
disease (CVD). Epi[INVESTIGATOR_252669]-diagnosed 
T2DM showed that potentially modifiable risk f actors for CVD were a raised LDL cholesterol, a 
low HDL cholesterol, hyperglycemia, hypertension, and smoking.2Elevated glucose levels were 
also the major determinant of microvascular complications. A number of trials in people with 
T2DM have shown that their CVD risk can be reduced by [CONTACT_252746],3,4blood 
pressure,5,6glycated hemoglobin,7,8or all three risk factors.[ADDRESS_307423], has been shown in randomized clinical trials to improve 
glycemic control, augment endogenous insulin secretion, to reduce blood pressure and promote 
weight loss with a meta-analysis of exenatide twice-daily (BY[CONTACT_252747]) trials10showing a trend to 
lower relative risk for CV events versus pooled comparators of 0.70 (95% confidence interval 
0.38 - 1.31). BY[CONTACT_252747] (exenatide) injection is currently available in the US and in many 
countries worldwide for people with type 2 diabetes who are unable to achieve good glycemic 
control with common oral therapi[INVESTIGATOR_014]. The addition of BY[CONTACT_252748]/exercise, metformin, or 
metformin+pi[INVESTIGATOR_252670] (exenatide enhances insulin secretion in a glucose-dependent 
manner, thus minimizing the risk of hypoglycemia in the absence of an insulin secretagogue).11
Exenatide once weekly (EQW; BY[CONTACT_28578]), is an extended release formulation of exenatide 
that is administered once weekly rather than twice daily.  EQW has been approved by [CONTACT_252749] [ADDRESS_307424] to metformin, a sulfonylurea (SU), a 
thiazolidinedione (TZD), a combination of metformin and SU, or a combination of metformin and TZD therapy to improve glycemic control in adult patients with type 2 diabetes mellitus.
In a 30-week, randomized, open-label trial, EQW treatment resulted in a significantly greater 
improvement in glycemic control, as measured by [CONTACT_252750] (HbA
1c), compared to 
exenatide administered twice daily.12  Furthermore, treatment with EQW for one year (52 weeks) 
showed net reductions of 2.0% in HbA 1c, 0.06 mmol/l (2.2 mg/dl) LDL cholesterol, [ADDRESS_307425] the occurrence of 
cardiovascular events in patients mediated by [CONTACT_252751], as well 
as reducing glycemia. 
EXSCEL (EXenatide Study of Cardiovascular Event Lowering) is a pragmatic, long-term, 
placebo-controlled, double-blinded trial which seeks to characterize the effects of EQW on 
cardiovascular-related outcomes in patients with ty pe [ADDRESS_307426] of EQW, used in addition to the 
current usual care for glycemic control, on major macrovascular events when administered to 
patients with type 2 diabetes.
Objective: To compare the impact of including EQW in addition to usual care vs.usual care
without EQW on major CV outcomes as measured by [CONTACT_252752]-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.
Hypotheses:
Efficacy:   EQW, when used in addition to usual care, is superior to usual care without EQW
with regard to the risk of developi[INVESTIGATOR_007] a confirmed event in the primary CV composite endpoint. 
Safety:   EQW, when used in addition to usual car e, is non-inferior to usual care without EQW
with regard to the risk of developi[INVESTIGATOR_007] a confirmed event in the primary CV composite endpoint.
2.[ADDRESS_307427] of EQW treatment used in 
addition to the current usual care for glycemic control on:
1) All cause mortality
2) Each of the components of the primary composite CV endpoint3) Hospi[INVESTIGATOR_252671] (ACS)4) Hospi[INVESTIGATOR_126042] (CHF)
2.[ADDRESS_307428] of EQW treatment used in addition 
to the current usual care for glycemic control on:
1) Revascularization procedures.  This will include percutaneous coronary intervention (PCI)
with or without stenting, coronary artery by[CONTACT_15806], revascularization and/or stenting for peripheral arterial disease, carotid endarterectomy, or carotid stenting
2) Time to initiation of first co-interventional agent (i.e., next antihyperglycemic agent [AHA]
or chronic insulin therapy)
3) Number of epi[INVESTIGATOR_116651]
20
EXSCEL Protocol Amendment 06
4) Absolute values of and changes in markers of cardiovascular risk including: HbA 1c, body 
weight, blood pressure, lipid profile
5) Quality of life assessed by [CONTACT_20367]-5D (EuroQol 5 Dimension) questionnaire6) Medical resource use and total direct medical costs7) Incremental cost-effectiveness analysis of exenatide once weekly as part of usual care 
compared with usual care without exenatide
3 TRIAL GOVERNANCE 
EXSCEL is a multinational pragmatic trial that will be conducted at approximately 800 sites 
worldwide. It will be run jointly by [CONTACT_252724] (DCRI) and the 
University of Oxford Diabetes Trials Unit (DTU) Academic Research Organizations (AROs), in 
an academic collaboration with Amylin Pharmaceuticals, LLC (Amylin), a wholly owned 
subsidiary of [COMPANY_008]. EXSCEL will be Co-Chaired
and sponsored and funded by [CONTACT_252753].
The EXSCEL Executive Committee (EC) will have overall responsibility for the oversight and 
management of the trial ( Figure 1 ). The EC will consist of senior independent academic 
representatives who are experts in their field and sponsor representatives.  It will be Co-Chaired
by [CONTACT_252754] (see Section 12.1).
Figure 1: EXSCEL Governance
21[COMPANY_003]
EXSCEL Protocol Amendment [ADDRESS_307429] type 2 diabetes with an HbA 1c#6.5% and 
âˆƒ10.0 % on up to three (i.e., 0-3) oral antihyperglycemic agents (AHAs) or insulin either alone or 
in combination with up to 2 (i.e., 0-2) oral AHAs.  Patients enrolled will be at a wide range of 
CV risk with approximately 70% having had a prior CV event (see Section 6.3). 
Approximately 14,000 patients meeting all enrollment criteria will be recruited in to the trial 
over approximately a five year period, randomly allo cated to treatment with either EQW 2 mg or 
matching placebo subcutaneous injections once weekly in a 1:[ADDRESS_307430] (DSMB) advises otherwise.  It is anticipated 
that the EXSCEL Executive Committee will monitor the accrual of the aggregate number of 
adjudicated primary endpoint events and will d etermine the primary endpoint event cut-off date 
(i.e., the date at which the anticipated number of events is expected to have accrued). Based on 
the primary endpoint event cut-off date, a window of time for the conduct of the Trial 
Termination Visit will be established; all patients will be expected to have follow-up until the 
Trial Termination Visit (see Section 6).
The trial will assess the impact of EQW therap y upon CV ou tcomes in a large population from a 
heterogeneous group of countries and practice environments; patients will be enrolled in the 
Americas (North/South America), Europe and Asia/Australasia. Given that this population will 
be at elevated CV risk, it is anticipated that patients will see their usual care provider at least 
twice per year for routine care. Trial follow up will consist of a blend of trial visits and phone 
calls during the double-blind placebo-controlled treatment period. 
There is no requirement to achieve glycemic equipoise between randomized groups but all 
patients during the double-blind treatment period will have their AHA regimens adjusted as 
deemed necessary by [CONTACT_252755], 
including insulin, but excluding GLP-[ADDRESS_307431] received counseling regarding appropriate diet and 
level of physical activity as part of usual care for type 2 diabetes. Per usual care, HbA
1cvalues 
should be measured locally. An NGSP (National Glycohemoglobin Standardization Program) 
certified HbA 1cassay14should be used if available.
4.[ADDRESS_307432] Trial Access to Therapy
At the end of the trial, the sponsor will not continue to supply study drug to 
patients/investigators. The investigator should ensure that the patient receives appropriate 
standard of care to treat the condition under study according to national treatment guidelines.
[ADDRESS_307433] meet the following criteria to be enrolled in this trial.
a) Patient has type 2 diabetes mellitus 
b) Patient will be able to see a usual care provider at least twice a year 
c) Patient has an HbA 1c of #6.5 % and âˆƒ10.0% and is currently using one of the following 
treatment regimens:
!Treatment with up to three (i.e., 0-3) oral AHAs (concomitant use of DPP-4 inhibitors is 
permitted)
!Insulin therapy, either alone or in combination with up to two (i.e., 0-2) oral AHAs (use of 
basal and prandial insulins is permitted in any combination of individual or premixed 
insulins)
All patients should be on a stable diabetes management regimen, as assessed by [CONTACT_1275], at the time of enrollment.  
HbA1c values must be from within the [ADDRESS_307434] recent reported value should be used.  A patient whose HbA 1cis >10.0% 
may, at the discretion of the investigator, have their oral AHA or insulin therapy adjusted and be 
re-screened once for HbA 1c randomization eligibility ( #6.5 % and âˆƒ10.0%).
d) Patients with any level of CV risk and meeting all other inclusion criteria may be enrolled. 
Recruitment will be constrained (see Section 6.3) such that approximately 30% will not have 
had a prior CV event and 70% will have had a prior CV event
A prior CV event is defined as at least one of the following :
!History of a major clinical manifestation of coronary artery disease i.e.myocardial infarction, 
surgical or percutaneous (balloon and/or stent) coronary revascularization procedure, or 
coronary angiography showing at least one stenosis #50% in a major epi[INVESTIGATOR_252672]
!Ischemic cerebrovascular disease, including: 
âˆ€History of ischemic stroke; strokes not known to be hemorrhagic will be allowed as part 
of this criterion; transient ischemic attacks (TIAs) are not included
23
EXSCEL Protocol Amendment 06
âˆ€History of carotid arterial disease as documented by #50 % stenosis documented by 
[CONTACT_252756], magnetic resonance imaging (MRI), or angiography, with or withoutsymptoms of neurologic deficit
!Atherosclerotic peripheral arterial disease, as documented by [CONTACT_252757], current symptoms of intermittent claudication confirmed by [CONTACT_252758]-brachial pressure index or toe brachial pressure index less than 0.9, or history of surgical or percutaneous revascularization procedure 
e) Female patients must not be breast feeding and agree to use an effective method of 
contraception or must not otherwise be at risk of becoming pregnant
f) Patient understands the trial procedures, alternative treatments available, the risks involved 
with the trial, and voluntarily agrees to participate by [CONTACT_11682] 
g) Patient agrees to provide permission to obtain all medical records necessary for complete 
data ascertainment during the follow-up period, and agrees to communication between the trial site and the usual care provider in order to facilitate routine care
h) Patient is 18 years or older at enrollment
5.2 Exclusion Criteria
Each patient meeting any of the following criteria will be excluded from this trial.
a) Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis
b) Patient has a history ( #2 epi[INVESTIGATOR_1841]) of severe hypoglycemia within 12 months of enrollment
c) Patient has ever been treated with an approved or investigational GLP-[ADDRESS_307435] e.g.,
BY[CONTACT_252747] (exenatide), BY[CONTACT_28578] (EQW), VICTOZA (liraglutide), LYXUMIA (lixisenatide), albiglutide, taspoglutide, or dulaglutide
d) Patient is enrolled in another experimental protocol which involves the use of an 
investigational drug or device, or an intervention that would interfere with the conduct of the 
trial
e) Patient has a planned or anticipated revascularization proceduref) Pregnancy or planned pregnancy during the trial period  g) Patient has medical history that indicates a life expectancy of <2 years or might limit the 
individualâ€™s ability to take trial treatments for the duration of the trial 
h) Patient has a history or current evidence of any condition, therapy, laboratory abnormality, or 
other circumstance which, in the opi[INVESTIGATOR_252673], might pose an unacceptable risk to the patient, confound the resu lts of the trial e.g. if patient cannot comply 
with requirements of the trial, or likely to interfere with the patientâ€™s participation for the full duration of the trial
i) Patient has end-stage renal disease or an es timated glomerular filtration rate (eGFR) derived 
from serum creatinine (using the simple MDRD-4 formula) of <30 mL/min/1.73m
2
(seeAppendix 2 )
j) Patient has a known allergy or intolerance to exenatidek) Patient has a history of gastroparesisl) Personal or family history of medullary th yroid cancer or MEN2 (Multiple Endocrine 
Neoplasia Type 2) or calcitonin level of > 40 ng/L at baseline
24
EXSCEL Protocol Amendment 06
NOTE: Serum for calcitonin measurement will be drawn at baseline.  Patients may be 
randomized and initiate study medication prior to the results of the calcitonin measure being 
available.  If a randomized patient is found to have an exclusionary serum calcitonin 
concentration, they will stop study medication a nd patients will continue to have follow-up and 
be part of the Intent-to-Treat analysis.
m) Patient has previously been randomized in EXSCEL
n) Patient has a history of pancreatitiso) Is an employee of Amylin Pharmaceuticals, LLC, Bristol-Myers Squibb Company, or 
[COMPANY_008]
Eligibility criteria for this study have been carefully  considered to ensure the safety of the study 
patients and that the results of the study can be  used. It is imperative that patients fully meet all 
eligibility criteria.
6T R I A L  P L A N
6.1 Trial Procedures - Overview
A schedule of procedures to be performed during the trial is found in Appendix 2 . The intent of 
this large, pragmatic, global trial is to integrate the trial-specific procedures into usual clinical 
care visits and to use routine clinical care asse ssments and laboratory values whenever possible 
as an efficient strategy for protocol implementation and data collection. At randomization (Visit 
1) patients will be provided with the patientsâ€™ instruction for use (IFU) and will be trained by 
[CONTACT_252759]. Patients will be seen at one week 
(Â±3 days) and have their self-injection observed. Then patients will be seen at 2 months (Â± 2 
weeks) after randomization to again confirm competency with dosing study medication. The next 
visit will be six months (Â±1 month) after randomization. Thereafter, patients will be seen every 
six months (Â±1 month) until study close out ( Figure 2 ).  
At all visits post randomization there will be an assessment of Clinical Events and Serious 
Adverse Events (see Section 10.3.1 ), as well as a review of concomitant medication, and 
adherence to study therapy. At semi-annual a nd annual visits, additional procedures will include 
blood pressure, body weight, heart rate, review of laboratory values and dispensing of study drug 
as described in Appendix 2.
The trial is planned to continue until [ADDRESS_307436] been accrued.  It is anticipated that the EXSCEL Executive Committee will monitor 
the accrual of the aggregate number of adjudicated primary endpoint events and will determine 
the primary endpoint event cut-off date (i.e., the date at which the anticipated number of events 
is expected to have accrued).  Based on the primary endpoint event cut-off date, a window of 
time for conduct of the Trial Termination Visit will be established. All patients will be expected 
to have follow-up until this visit.
NOTE :  Patients who have temporarily or permanently discontinued trial medication should 
continue with their regular visit schedule.  ALL patients should have a Trial Termination Visit
(including patients who have previously discontinued trial medication).
[ADDRESS_307437] their final assessment of Clinical 
Events, serious adverse experiences and hospi[INVESTIGATOR_252674].
Clinical Events (as defined in Protocol Appendix 1 ) will continue to be collected and reported in 
the same way as they have been throughout the entire study (i.e., prior to the cut-off date) (see 
Section 10.3.1 ).
Figure 2: EXSCEL Study Design
6.[ADDRESS_307438] 3 months, obtained as part of usual care prior to 
Visit 1 (recommended guidance for management of serum creatinine values will be provided to 
each site). For patients who require a repeat visit e.g.key lab data not available at Visit 1, 
randomization will be delayed until all information is available.  It should be noted that patients 
may still be randomized at Visit 1 even if calcitonin results are pending.~14,[ADDRESS_307439] year
1 w 2 mo 6 mo 1 yPrimary endpoint 
event cut-off date
(determined by [CONTACT_177479])
Post-treatment 
safety follow-up 
contact (70 days after study drug 
discontinuation, 
if applicable)
Trial Termination Visit
(defined period after 
primary endpoint cut-off) 
26
EXSCEL Protocol Amendment 06
6.3 Method of Assigning Patients to Treatment Groups (Visit 1)
An Interactive Voice Response System (IVRS) will be used to enroll those patients satisfying all 
inclusion and exclusion criteria. This automated system will randomize eligible patients and 
dispense double-blind trial medication.  Each site user will be given an identification number and 
a password to access the IVRS. Patients will be randomly allocated at Visit 1 in a 1:[ADDRESS_307440] had a prior CV event, to receive one of the following t wo 
interventions:
Treatment 1:   EQW 2 mg subcutaneous injection, administered once weekly 
Treatment 2:  Matching placebo subcutaneous injection, administered once weekly
The IVRS will be programmed to ensure the expected overall proportion of randomized patients 
with a prior CV event is approximately 70%.  With  transition to Amylin-labeled trial medication 
(beginning in 2013), the IVRS was programmed to ensure at least 80% of newly randomized
patients have a history of a prior CV event (previously was programmed to ensure approximately 
60% of patients had a prior CV event).
The generation of the randomized allocation schedule for trial treatment assignment will be the 
responsibility of the IVRS provider. Prior to database lock, these codes will be provided in strict 
confidence only to the facility packaging trial medication and to the DSMB independent 
statistical group. Immediately upon database lock the codes will be transmitted to the DTU and 
DCRI data management groups for incorporation into the trial database.
6.[ADDRESS_307441] be discontinued if a patientâ€™s eGFR drops below 
30 mL/min/1.73 m2, based on two consecutive serum creatinine determinations (See Section 
6.12). As part of standard of care, serum creatinine should be, at minimum, among labs drawn 
annually.  If serum creatinine has not been performed on an annual basis, then study personnel 
should prompt usual care providers to perform serum creatinine measurement. If serum 
creatinine remains unavailable, then it should be performed at the next visit by [CONTACT_3462].  
If the investigator recognizes that the eGFR has decreased sufficiently to necessitate trial 
medication cessation, he/she should determine whether or not repeat/confirmatory testing has 
occurred and undertake this if necessary. If the need for drug discontinuation is confirmed, the 
situation will be explained to the patient and the patient will be asked to stop the study drug and 
encouraged to continue follow up off study drug until the end of the trial. If deemed necessary 
by [CONTACT_093], an unscheduled visit can be performed to discuss study drug discontinuation 
and the importance of subsequent follow up. Drug discontinuation will be managed at the trial
27
EXSCEL Protocol Amendment 06
site through the IVRS system. Drug discontinuation visit procedures should be followed as 
outlined in Section 6.11. 
6.5 Concomitant Therapy
Concomitant medications will be used at the discretion of the usual care provider (or investigator 
if also the usual care provider), who will be informed of the patientâ€™s enrollment in the trial, the 
use of blinded trial medication, and that use of GLP-[ADDRESS_307442]  therapy remains, then study drug should be 
discontinued to avoid potential double dosing. Usual care providers will be encouraged to 
follow guidelines for care based upon local and institutional practice patterns and any relevant 
published practice guidelines. AHAs will be captured by [CONTACT_252760], while other relevant concomitant medications may be collected only as drug classes. 
During the double-blind treatment period, investigators are expected to monitor patientsâ€™ AHA 
regimens and communicate with usual care providers, who will be responsible for adjusting the 
AHA regimen in order to achieve locally-appropriate HbA 1cgoals based on clinical care practice 
guidelines published by [CONTACT_252761]. These goals will be individualized, 
with the understanding that currently applicable glycemic guidelines may vary among different 
geographic regions. With adherence to local custom and laws (including privacy regulations 
such as HIPAA), types of communication may be informal e.g.email or telephone exchanges, to 
enhance frequency and ease of two-way communication.
Usual care providers should be notified that  adjustments to th e AHA regimen are not 
recommended until HbA 1clevels begin to reflect the effect of randomized therapy. Any AHA 
agent, with the exception of GLP-1 receptor agonists, is acceptable. If HbA 1cgoals are not met 
following adjustment with oral AHAs in patients not receiving insulin, an insulin regimen may 
be initiated, preferably without discontinuing or down-titrating some or all of the existing AHAs, 
as clinically appropriate. Patients already receiving insulin therapy may up-titrate insulin during 
the trial if necessary. Ideally, patients should generally remain on the baseline AHA therapi[INVESTIGATOR_252675], unless the baseline AHA is no longer clinically appropriate. 
However, this should be at the discretion of the usual care provider.  In addition, patients should 
be reminded to keep taking their blinded trial medication following initiation of insulin.
6.6 Precautions to Minimize Rates of Hypoglycemia
At the screening/randomization visit and all subsequent visits, the symptoms and appropriate 
management of hypoglycemia will be reviewed with patients. Patients who experience severe 
hypoglycemia will be asked to notify both their usual care provider, as well as trial personnel.  
Usual care providers will be responsible for the adjustment of non-trial AHA medications in 
order to prevent or minimize the o ccurrence of further hypoglycemia.  
All epi[INVESTIGATOR_252676]. Severe hypoglycemia 
(hypoglycemia requiring assistance) refers to instances in which the patient was sufficiently 
28
EXSCEL Protocol Amendment 06
disoriented or incapacitated as to require help from either a family member or from medical 
personnel (whether or not this assistance was actually provided).  For example, if a family 
member or other by[CONTACT_252762] a snack or drink to help raise his blood sugar even 
though the patient was capable of doing this himself, the epi[INVESTIGATOR_252677].  
Combination therapi[INVESTIGATOR_252678].  To 
minimize this risk, patients whose diabetes is well controlled may require a reduction in the 
insulin or sulfonylurea dose when allocated study medication.  EXSCEL will employ both 
patient- and investigator-directed education to minimize the risk of hypoglycemia.  Patients 
receiving sulfonylurea/insulin combinations will be explicitly reminded of the symptoms and 
proper management of hy poglycemia be fore starting study drug.
6.7 Laboratory and Anthropometric Measurements
Laboratory values i.e.HbA 1c, serum creatinine, lipid profile [LDL-C, TC, TG, HDL-C]) will be 
obtained where available as per the patientâ€™s usual care assessments. Blood pressure, heart rate, 
height, and body weight will be collected by [CONTACT_252763] 2.
6.8 Calcitonin Sample Collection
Serum calcitonin concentrations will be monitored throughout the patientâ€™s participation in the 
trial (See Section 10.4).  Samples will be collected at baseline, annually and at the Trial 
Termination visit.  
6.9 Genetic and Biomarker Sample Collection
In a subset of sites, patients enrolled in the trial will be asked to consent separately to provide a 
whole blood sample for future pharmacogenomic analyses. The objective of collecting blood 
samples from which genetic analyses can be performed is to investigate the relationships 
between genetic make-up and clinical events. These samples will be drawn at baseline, or at any 
point in the trial at which consent is obtained from the patient.
In addition, a subset of patients enrolled in the trial will be asked to consent separately to provide 
one serum sample, one plasma sample, and one urine sample for future biomarker analyses. 
These specimens (preferably fasting) will be obtained at baseline (prior to drug exposure), year [ADDRESS_307443]-effectiveness analysis. This instrument will 
be administered at baseline, at 6 months, at subsequent annual visits, and at the Trial Termination 
visit.
29
EXSCEL Protocol Amendment 06
An outline statistical analysis plan for this evaluation is reported in Section 9.11; a detailed 
analysis plan and study report will be developed and reported separately.
6.11 Temporary or Permanent Discontinuation of Trial Medication
Following randomization, it is expected that patients will remain on study medication for the 
duration of trial participation. However, it is recognized that patients may need to discontinue 
trial medication, in some cases permanently, for when protocol-specified reasons apply 
(Section 6.12), due to the judgment of the primary investigator or the decision of the patient.  
The Trial Hotline should be contact[CONTACT_252764] a site is considering interrupting or 
discontinuing trial medication (Section 6.18).
Unless resumption of trial medication is considered unsafe or is refused by [CONTACT_941] p atient, the 
patient will be expected to resume regular use of the blinded trial medication after a period of 
temporary discontinuation.  Should a patient stop taking trial medication, either permanently or 
temporarily, the reasons for discontinuation and length of time the patient stopped taking trial
medication will be assessed and recorded.
All randomized patients who permanently discontinue trial medication should have a drug 
termination visit as part of their next scheduled study visit (unless a separate drug termination 
visit at that point is deemed necessary by [CONTACT_093]). Necessary procedures are indicated 
in Appendix 2.   All efforts should be made to reinforce with patients that this would be a 
medication discontinuation visit, not a trial discontinuation visit; patients should continue with 
their regular visit schedule until the end of the trial, including semi-annual in-person visits, as 
well as the annual calcitonin measurement. If patients cannot attend visits in person, they will be 
followed via telephone contact [CONTACT_252765].  
NOTE:  After trial medication is discontinued due to pregnancy, re-initiation of study 
medication can be considered following completion of the pregnancy and breastfeeding (if 
applicable).
6.[ADDRESS_307444] abnormality resulting in discontinuation.
a) Severe Hypoglycemia: repeated (2 or more) epis odes since the prior trial visit of severe 
hypoglycemia i.e.in which patient required medical assistance, despi[INVESTIGATOR_146487]-titration or 
interruption/discontinuation of non-trial AHAs.
!Note :  The patient and the Investigator will notify the usual care provider o f severe 
hypoglycemic events. The usual care provider should make a thorough attempt to down-
titrate and/or modify co-interventional and baseline therapi[INVESTIGATOR_252679].
b) Any medical condition or personal circumstance which, in the opi[INVESTIGATOR_871], 
exposes the patient to additional risk by [CONTACT_252766]. 
30
EXSCEL Protocol Amendment 06
c) Severe, irreversible renal dysfunction (confirmed by [CONTACT_252767] 
<30 ml/min/1.73m2) or renal replacement therapy.
d) Annual calcitonin measurement #50 ng/L 
6.[ADDRESS_307445] of the 
Trial Termination Visits will be established; this window will be a period of time following the 
primary endpoint event cut-off date.  All patients will be expected to have follow-up until this 
visit.  At the Trial Termination Visit, all patients must be discontinued from trial medication; the 
investigator should ensure that the patient receives appropriate standard of care. For procedural 
details of the Trial Termination Visit, refer to  Appendix 2.
NOTE:  All patients should have a Trial Termination Visit. Patients who have discontinued 
trial medication prior to the end of the trial must, at minimum, have a Trial Termination
telephone contact.
If a patient fails to return or otherwise becomes difficult to contact, it is the investigatorâ€™s 
responsibility to make every effort to maintain contact [CONTACT_252768]/or endpoint adjudication as of the Trial Termination Visit.
6.[ADDRESS_307446] been 
discontinued from trial medication for more than 70 days as of the Trial Termination Visit, the 
Trial Termination Visit will be the final study follo w-up.  Clinical Events (as defined in Protocol 
Appendix 1 ) will continue to be collected and reported in the same way as they have been 
throughout the entire study (i.e., prior to the cut-off date) (see Section 10.3.1 ).
6.[ADDRESS_307447] with him/her or persons previously 
authorized by [CONTACT_252769]. 
Patients should notify the investigator of the d ecision to withdraw consent from future follow-up 
in writing, whenever possible. The withdrawal of consent should be explained in detail in the 
medical records by [CONTACT_252770]. In the event that 
vital status (whether the patient is alive or dead) is being measured, publicly available 
information should be used to determine vital status only as appropriately directed in accordance 
with local law.
31
EXSCEL Protocol Amendment 06
When a patient withdraws consent from future follow-up prior to trial completion, all applicable 
activities scheduled for the final trial visit should be performed at that time (Section 6.13).
6.[ADDRESS_307448] to follow-up is defined by [CONTACT_252771] a 
minimum of three documented phone calls, as well as lack of response by [CONTACT_252772]. All attempts should be docu mented in the patientâ€™s medical records. If it is 
determined that the patient has died, the site will use permissible local methods to obtain the date 
and cause of death.
If an investigatorâ€™s use of a third-party representative to assist in the follow-up portion of the 
study has been included in the patientâ€™s informed consent, then the investigator may use a 
Sponsor-retained third-party representative to assi st site staff with obtaining patientâ€™s contact 
[CONTACT_53983]-up portion of the 
study. Where specific consent has been obtained from the participant, the site staff and 
representative will consult publicly available sources, such as public health registries and 
databases, in order to obtain updated contact [CONTACT_3031]. If after all attempts, the patient
remains lost to follow-up, then the last known alive date as determined by [CONTACT_252773]â€™s medical records.
6.17 Breaking the Blind
The IVRS will be used to unblind patients to the randomized treatment assignment only if 
absolutely necessary. Disclosure envelopes will not be supplied with the clinical supplies. Drug 
identification information is to be unmasked ONLY if necessary for the welfare of the patient. 
Prior to unblinding, the investigator is required to speak with a trial hotline physician (Section 
6.18).  Patients whose treatment has been unblinded can continue to receive trial medication and 
can continue to be followed in the trial as described in this protocol.
6.18 Trial Hotline
Clinicians at DCRI and DTU operate the trial hotline. It is available at all times to answer urgent 
clinical questions from sites concerning enrolled patients as well as questions to determine 
whether a particular patient qualifies for enrollment or performance of study procedures.
7 TRIAL MEDICATIONS
7.1 Trial Medication Supply 
Investigational Materials will be provided by [CONTACT_252774] 2 mg and matching placebo.
7.2 Formulation, Packaging, and Storage
EQW (formulation AC2993 F17) is an extended rele ase formulation of exenatide and consists of 
5% exenatide, sucrose, and 50:50 poly D,L lactic-co-glycolic acid (PLG).  The vial containing 
the white to off white dry powder (2.8 mg of exenatide in EQW microspheres to deliver 2 mg of 
exenatide) must be stored in a refrigerator between 2ÂºC and 8ÂºC (36Â°F and 46Â°F) and protected
[ADDRESS_307449] be stored between 2Â°C and 25Â°C (36Â°F and 77Â°F). The 
EQW or matching placebo dose is prepared by [CONTACT_252775]. Specific instructions for dose preparation of the injection will be provided in the 
Instructions for Use (IFU). The reconstituted dose of study medication (EQW or matching 
placebo) should not be stored for future use. The injection must be administered immediately 
after preparation of the dose.
7.3 Dispensing of Trial Medication
Study materials will be provided to patients by [CONTACT_093], medically qualified 
subinvestigator, or other qualified study-site personnel.  Under no circumstance will the 
investigator or subinvestigators allow the study medication to be used other than as directed by 
[CONTACT_252776].
A supply of study medication will be dispensed for each patient, according to their assigned 
treatment group (EQW or Placebo).  A [ADDRESS_307450] y of study medication will be distributed to 
patients at the study site during Visit 1 and at subsequent visits indicated in Appendix 2 . Patients 
should bring used and unused study medication vials to the site at each visit so medication 
compliance can be assessed.
7.4 Dose Administration Procedures, Route, and Schedule
Doses of EQW or matching placebo are to be injected into subcutaneous (SC) tissue of the 
abdomen, thigh, or back of the upper arm. The site of injection should be rotated on a regular 
basis so that the same site is not used repeatedly. The same anatomical region can be used for 
the injection but the site should be rotated (e.g. different quadrants of the abdomen can be used 
in a weekly rotation).
At Visit 1 (Day 0), a medically qualified staff member will demonstrate the preparati on of EQW 
or matching placebo for the patient or a designated caregiver and will administer the first dose of 
study medication. Patients will subsequently self administer study medication (or have it 
administered by a caregiver) once weekly (Â± 3 days) relative to the date of the first dose of EQW 
or matching placebo (Visit 1 [Day 0]). Patients will be seen one week as well as two months 
after randomization to confirm competency with study medication.  On weeks with no scheduled 
study-site visits, patients may opt to return to the study site to have the injection procedure 
monitored by [CONTACT_3449]-site personnel, although such visits will not be required. During scheduled 
study visits, patients must bring their study medicati on treatment kit with them to the clinic and 
will self administer EQW or matching placebo as directed by [CONTACT_3449]-site personnel.
Adjustments to dosing regimens are not permitted.  If a patient is unable to tolerate study 
medication (e.g., patient experiences adverse events that are judged by [CONTACT_252777]) the termination of study medication can be considered. Patients who terminate 
33
EXSCEL Protocol Amendment 06
study medication will be followed up, per the protocol, for the remainder of the study unless the 
patient opts to withdraw consent for further follow-up.
7.5 Randomization Schedule and Blinding Procedures 
Patients who meet all study requirements based on inclusion and exclusion criteria will be 
randomized at Visit 1 (Day 0). Patients will be randomly assigned to 1 of 2 treatment groups 
(EQW or Placebo). Randomization will be in the ratio of 1:1 (EQW:Placebo) and will be carried 
out centrally in a manner blocked within site and stratified by [CONTACT_84195] a participant has or has 
not had a prior cardiovascular event, to achieve a balanced distribution of patients across 
treatment groups.
Sufficient study medication will be provided to the study site for enrollment of all patients. Study 
medication kits will be labeled with unique package numbers (this is not the patient
randomization number).  At Visit 1 (Day 0), study site personnel must contact [CONTACT_252778] (IVRS) to randomly assign patients.  The study-site personnel must call 
the IVRS at all subsequent visits (except Visits 2, 3 and Trial Termination) to record the visit and 
confirm the kit assignment. The calls to the IVRS will ensure the resupply of additional kits
required for upcoming visits. If medication is allocated to a patient incorrectly, the sponsor must 
be notified. At Trial Termination, the site must call the IVRS to record study termination.  The 
sponsor, the study-site personnel, and the patients will be blinded to treatment allocation.
7.[ADDRESS_307451] IVRS to verify receipt of study medication. The sponsor (or designee) should be notified 
immediately about any irregularities, discrepancies, or damage.
A drug accountability log will be provided to record all study medication dispensed to or 
returned from each patient. Upon completion of the study, all used and unused EQW or 
matching placebo vials and copi[INVESTIGATOR_252680] (or designee). A clinical supplies return authorization form will be prepared by [CONTACT_252779]. The clinical supplies return form should be 
enclosed with the return drug ship ment; however, if the site manager/CRA approves, the site can 
destroy the material instead of returning the used and unused study drug. The study site 
personnel must maintain documentation of any missing or unreturned study medication.
8 EFFICACY ASSESSMENTS
Trial endpoints will be defined based on clinical standards, regulatory precedent, and historical 
trials. The definitions of the events to be adjudicated by [CONTACT_252780] (CEC) and the committee procedures will be included in the CEC Charter (Section 
12.4). Patients will be asked at each trial visit about procedures and hospi[INVESTIGATOR_252681]. 
34
EXSCEL Protocol Amendment 06
8.1 Primary Efficacy Endpoint
!Time to first confirmed CV event in the primary composite CV endpoint
Defined as the time from randomization to firs t confirmed CV-related death, nonfatal MI or 
nonfatal stroke.  
8.2 Secondary Efficacy Endpoints
!Time to all-cause mortality
Defined as time from randomization to death due to any cause. 
!Time to first confirmed CV event for each component of the primary composite 
endpoint
Defined as time from randomization to a confirmed CV-related death, fatal or nonfatal MI, or 
fatal or nonfatal stroke. 
!Time to hospi[INVESTIGATOR_252682] a confirmed hospi[INVESTIGATOR_252683], 
ST-elevation myocardial infarction or non-ST-elevation myocardial infarction.
!Time to hospi[INVESTIGATOR_252684], inotropes, or vasodilator 
therapy. 
8.3 Additional Efficacy Endpoints
!Time to revascularization procedure
Defined as time from randomization to time of first cardiovascular or peripheral 
revascularization procedure.  This will include percutaneous coronary intervention with or 
without stenting, coronary artery by[CONTACT_15806], revascularization and/or stenting for 
peripheral arterial disease, carotid endarterectomy, or carotid stenting.
!Time to initiation of first co-interventional agent 
âˆ€Additional AHA
âˆ€Chronic insulin therapy
!Absolute values and change from baseline in:
âˆ€HbA1c
âˆ€Body weight
âˆ€Blood pressure
âˆ€Lipid profile 
!Quality of life assessed by [CONTACT_20367]-5D (EuroQol 5 Dimension) questionnaire
!Medical resource use and total direct medical costs
!Incremental cost-effectiveness analysis of exenatide once weekly as part of usual care 
compared with usual care without exenatide
35
EXSCEL Protocol Amendment 06
9 STATISTICAL METHODS
This section outlines the statistical analysis strategy related to the primary and secondary study 
objectives with the full details given in a separate Statistical Analysis Plan (SAP). If any 
substantive changes are made to these objectives or the statistical methods after the study has 
begun then the protocol will be amended, provided that it is prior to any unblinding, consistent 
with ICH Guideline E9. The study database will only be locked and unblinded once 
medical/scientific review has been performed, protocol violations have been identified and the 
data have been declared final and complete. The statistical analyses for this study will be the 
responsibility of the University of Oxford Diabetes Trials Unit. 
9.[ADDRESS_307452] confirmed CV event defined as 
a CV-related death, nonfatal MI or nonfatal stroke.  The study is designed to assess the primary 
efficacy objective of superiority of EQW to placebo through the following hypothesis:
H0:  upper limit of the 95% CI of the HR [exenatide:placebo] #1
versus
H1: upper limit of the 95% CI of the HR [exenatide:placebo] <[ADDRESS_307453] the above hypothesis with 85% power and 2-sided Î±=0.05, a total number of 1360 
composite CV events are required assuming a risk reduction of 15% on EQW compared with
placebo.  With this number of events, the power will be much larger than 90% to assess the 
primary safety objective of non-inferiority of EQW compared with placebo.
In addition, with the following assumptions made for this study,
!An annual composite cardiovascular primary endpoint event rate estimated to be around 
2.2% per year for the population to be enrolled
!A planned accrual period of 5-6 years
!An estimated annual lost-to-follow up rate of 1%
!An anticipated treatment discontinuation rate of 5% per year
it is expected that a total of [ZIP_CODE] patients need to be randomized in a 1:1 ratio into EQW and 
placebo to achieve the targeted 1360 confirmed composite CV events.
9.3 Randomization
Randomization via an Interactive Voice Response System (IVRS) will be 1:1 EQW to Placebo, 
blocked within each site, and stratified by [CONTACT_84195] a participant has or has not had a prior 
cardiovascular event (see Section 5.1).
[ADDRESS_307454] to the 
primary composite cardiovascular endpoint, with patients analyzed as randomized.
9.5 Primary Analysis
The primary statistical analysis will be based upon adjudicated CV events with patients who 
discontinue prematurely from treatment followed until the end of the study, i.e. the Trial 
Termination Visit and until the requisite number of primary composite events has been accrued. 
It is anticipated that the Executive Committee will monitor the accrual of the aggregate number 
of primary composite CV events to determine the primary endpoint event cut-off date (i.e., the 
date at which the anticipated number of events is expected to have accrued). Based on the 
primary endpoint event cut-off date, a window of time for conduct of the Trial Termination Visit 
will be established.  All patients will be expected to have follow-up until this visit.  Analysis of 
the primary composite cardiovascular outcome will be based on the time from randomization to 
the occurrence of the first event, with patient s analyzed according to their randomized treatment. 
The primary analysis will include all adjudicated CV  events with onset dates up to and including 
the Trial Termination Visit date.  Note that any event occurring between the Trial Termination 
Visit and the safety follow-up date ([ADDRESS_307455] dose of trial 
medication) will not be adjudicated and will not be included in the primary analysis. Events 
occurring during this period will be summarized descriptively.
Kaplan-Meier curves for time to the first occurrence of a primary composite endpoint event will 
be used to depi[INVESTIGATOR_252685]. The hazard ratio for the time to first occurrence of the primary composite endpoint event
for the EQW treated group to that of the placebo treated group and its 95% confidence interval 
will then be estimated using a Cox proportional hazards model stratified by [CONTACT_252781] (prior CV event or no prior CV event) and using treatment group as covariate.
The primary safety hypothesis will be assessed by a non -inferiority analysis with the non-
inferiority margin of 1.30, i.e., non-inferiority will be concluded if the upper limit of the 
confidence interval is less than 1.30.
The primary efficacy hypothesis of superiority will be then assessed by [CONTACT_941] 95% confidence 
interval for the hazard ratio of EQW to placebo, i.e., superiority will be concluded if the 95% 
confidence interval does not include 1 (upper limit of 95% confidence interval < 1). 
9.6 Secondary Efficacy Analyses
The secondary efficacy endpoints are the time to confirmed occurrence of:
1) All cause mortality
37
EXSCEL Protocol Amendment 06
2) CV-related death
3) Fatal or nonfatal myocardial infarction
4) Fatal or nonfatal stroke5) Hospi[INVESTIGATOR_252671] (ACS)
6) Hospi[INVESTIGATOR_126042] (CHF)
Details of the testing strategy of the secondary efficacy endpoints will be provided in the
Statistical Analysis Plan (SAP).
9.7 Analysis Populations
The three predefined analysis populations are:
1) The Intent to Treat (ITT) Population
2) The Per Protocol Population3) The Safety Population
9.7.[ADDRESS_307456] 
discontinued study medication or the study.  F or the ITT population, patient s will be analyzed as 
randomized.
[IP_ADDRESS] On-Treatment Analysis
An on-treatment analysis using the ITT population will be performed for the primary and 
secondary analyses as sensitivity analyses.  This analysis will include only those events that 
occurred through the last dose of study medication or the Trial Termination Visit date, whichever 
occurs first.  The patients will be analyzed according to the treatment group to which they were 
randomized.  The on-treatment censoring scheme will also be applied for analysis for on-
treatment + n days, where n=7, 30, and 70.
9.7.[ADDRESS_307457] one dose 
of study medication and will include in their analysis all data collected prior to any major 
protocol violations (or the Trial Termination Visit date, whichever occurs first), such as: 
!Initiation of an open-label prohibited medication, i.e. a GLP-[ADDRESS_307458].  Evaluation 
will include all data up to the day of the initiation of the prohibited medication.
!Early discontinuation from study medication.  Evaluation will include events which occurred 
from randomization to [ADDRESS_307459]. 
!Taking incorrect study medication for more than three months.
[ADDRESS_307460] 1 dose of study 
therapy; in addition, if a patient is found to have taken a study therapy for the entire duration of 
the study, different from that to which he/she was randomized, then the patient is counted in the 
treatment group of the drug he/she actually received. Serious AEs, including those which lead to 
discontinuation of study medication, occurring between randomization and [ADDRESS_307461] on the risk of developi[INVESTIGATOR_252686].  The following subgroups will be assessed:
!Class of AHA therapy at entry (mono or combination)
!Race (Indian [American] or Alaska Native, Asian, Black, Native Hawaiian or Other Pacific 
Islander, White, Hispanic, Other)
!Geographic region (North America, Latin America, Europe and Asia Pacific)
!Gender (Male, Female)
!Age (<65 or #65)
!Baseline HbA 1c(<8.0% or #8/0%)
!Baseline BMI (<30 or #30 kg/m2)
!Duration of diabetes (<5, 5-14, #15 years)
!eGFR groups (in mL/min/1.73 m2)
âˆ€(<60 or #60)
âˆ€Stage 1: 90+, Stage 2: 60-89, Stage 3: 30-59, Stage 3a: 45-59, Stage 3b: 30-44, Stage 4: 
15-29, Stage 5: <15
!History of previous cardiovascular event (e.g., previous MI or stroke)
The hazard ratios, 95% CIs, and appropriate summary statistics for each of the subgroups (by 
[CONTACT_1570]) will be provided and the hazard ratios examined for interaction effects. The 
[ADDRESS_307462] would be treatment Ã— stratified variable, in additive format with treatment + 
stratified variable. For example, the stratified variable means the categorical variable â€˜Regionâ€™. 
9.[ADDRESS_307463] for superiority using a 
Haybittle-Peto spending function where the study termination guideline for overwhelming 
superiority will be p-value < 0.[ADDRESS_307464] interim analysis and p-value <0.[ADDRESS_307465] available visit. A full analysis plan for the economic analysis will be prepared and reported 
separately from this protocol.
For the main clinical study report (CSR), the quality of life data will be summarized 
descriptively for baseline and changes from baseline by [CONTACT_3148].
10 SAFETY ASSESSMENTS
10.1 Definitions
Adverse Event (AE)
An adverse event is defined as any unfavorable and unintended sign, symptom, disease or change 
in the structure, function, or chemis try of the body temporally associated with the use of the 
investigational product, whether or not considered related to the use of the product. Any 
40
EXSCEL Protocol Amendment 06
worsening (i.e., any clinically significant advers e change in frequency and/or i ntensity) of a 
preexisting condition which is temporally associated with the use of the investigational product, 
is also an adverse event.  Adverse events include those reported spontaneously by [CONTACT_252782]-directed questioning from study site personnel. Changes as a result of 
normal growth and development which do not vary significantly in frequency or severity from 
expected levels are not to be considered adverse events (e.g. the onset of menopause occurring at 
a physiologically appropriate time).  
Serious Adverse Event (SAE)
This is defined as any untoward medical occurrence or effect in a patient treated on a study 
protocol which does not necessarily have a causal relationship with the study treatment, that also, 
at any dose:
!Results in death
!Is life-threatening
!Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions
!Requires in-patient hospi[INVESTIGATOR_72010]
!Results in a congenital anomaly or birth defect
!Is otherwise medically significant (i.e. withdrawal reactions, all accidental or intentional 
overdoses of study medication whether they result in an adverse event or not, or any event 
which the investigator considers significant but which is not covered by [CONTACT_31714])
Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R)
This is defined as a serious adverse event, the n ature or severity of which is not consistent with 
the known study treatment information.  
10.2 Adverse Event Assessment
Adverse events will be monitored over the course of the trial, starting from the time of 
randomization and through the duration of the patientâ€™s participation, including the [ADDRESS_307466]-trial medication follow-up period.  Adverse events reported by [CONTACT_252783] a given event meets the criteria for a serious event (described 
in Section 10.1).  Any adverse event that does not meet the definition of a serious event will be 
considered non-serious and will not be recorded in the eCRF, with the exception of events noted 
in Section 10.3.
10.3 Recording and Reporting Adverse Events
10.3.1 Recording Adverse Events
SAEs will be recorded in the Clinical Events or SAE eCRF modules as appropriate (see Table 
1) throughout the trial (including the [ADDRESS_307467] dose of study 
medication). Guidelines for events which qualify as Clinical Events are provided in Appendix 1 . 
Events to be recorded in the Clinical Events eCRF module include SAEs that are: (1) Obvious 
41
EXSCEL Protocol Amendment 06
trial endpoints, (2) Cardiovascular Events of Interest, (3) Expected Events and Diabetic 
Complications.
In addition, non-serious adverse events of percutaneous coronary intervention (PCI), stress tests, 
severe hypoglycemia, diabetic eye disease, foot ulcer, microalbuminuria, macroalbuminurea, 
hyperlipi[INVESTIGATOR_035]/dyslipi[INVESTIGATOR_035], hypertension, or gout also will be recorded in the Clinical Events 
eCRF module (see Appendix 1 ).
Any SAE which is not included among the expected events on the Clinical Events List will be 
recorded in the SAE eCRF module.  
Events of neoplasia and pancreatitis should be reported on the SAE eCRF even if the event does 
not meet seriousness criteria.
Note: The events listed in Appendix 1 are Clinical Events that are trial endpoints or expected 
events for this population, and do not generally fit the definition of a S[LOCATION_003]R, including those 
events with an outcome of death.  However, if the investigatorâ€™s assessment of an event is that it 
meets S[LOCATION_003]R criteria despi[INVESTIGATOR_252687] a Clinical Event, the event may be reported as a 
S[LOCATION_003]R via the SAE eCRF as long as it is not any of the possible trial endpoints listed in 
Appendix 1, Section I).
Table 1: List of events to be recorded in each eCRF reporting module*
eCRF reporting module
to be usedList of events to be recorded in this eCRF reporting module:
Clinical Event eCRF- Clinical Events that meet the criteria of an SAE (i.e. serious adverse event) and are 
listed in Appendix 1
- All non-serious (or serious) events of percutaneous coronary intervention (PCI), 
stress tests, severe hypoglycemia, diabetic eye disease, foot ulcer, microalbuminuria, 
macroalbuminuria, hyperlipi[INVESTIGATOR_035]/dyslipi[INVESTIGATOR_035], hypertension, or gout
- All neoplasia events
- All pancreatitis events
SAE eCRF- Any event meeting the criteria of an SAE (see Section 10.1 for definition of SAE)
that are notlisted in Appendix 1
- All epi[INVESTIGATOR_81719]
- All epi[INVESTIGATOR_252688]/cancer
- Any AE or SAE resulting from an overdose of study drug
- Any event that is recorded in the Clinical Event eCRF, that the investigator considers 
a S[LOCATION_003]R, with the exception of possible Primary or Secondary trial endpoints (i.e. all events listed in Appendix 1, Section I)
* Trial sites will be provided with an â€˜EXSCEL Event Reportingâ€™ flow chart that can be referenced to help 
identify which events should be reported in which eCRF reporting module. 
The Clinical Events List will be reviewed and the eCRF will be completed during every visit to 
determine if a patient has experienced one or more of the listed events. SAEs should be 
42
EXSCEL Protocol Amendment 06
reviewed for all patients randomized regardless of whether the patient is currently on trial 
medication.
10.3.2 Safety Reporting
The DSMB will monitor the totality of collected safe ty data (i.e. events recorded on both the 
Clinical Events and SAE eCRFs) on a semi-annual basis regardless of event classification.  SAEs
recorded on the Clinical Events eCRF represent those events which are components of the 
composite CV endpoint, other trial endpoints, potential components of the CV endpoint that 
require adjudication or are expected sequelae of T2DM.  SAEs recorded as Clinical Events, 
including death related to an event in the Clinical Events List, will not be reported to the 
Sponsor, regulatory agencies or ethics committees, regardless of relationship to trial 
medication even though they may be considered possibly, probably or def initely drug-related 
and meet SAE criteria. This will be applicable throughout the duration of trial including the 
[ADDRESS_307468] be recorded in this module (or faxed to the number provided on the 
SAE report form if EDC is unavailable) within [ADDRESS_307469] to expedited reporting as 
per current legislation.  Brief information on the clinical course of the event, treatment, and 
relevant diagnostic, laboratory or other investigations will be collected on the eCRF. All 
epi[INVESTIGATOR_252689].  All events recorded in the SAE eCRF module will be reported to the 
appropriate regulatory agencies in a manner and timeframe consistent with all applicable laws 
and regulations (Section 10.3.3 ).All S[LOCATION_003]RS will be reported in an expedited manner with the 
exception of possible trial endpoints as detailed in Section I of Appendix 1, which will be 
handled as Clinical Events.
Note that pancreatitis and pancreatic neoplasms / malignancies are events of special interest for 
GLP-1 based therapi[INVESTIGATOR_014], such as exenatide.  As described above, all events of pancreatitis and all 
neoplasms (including pancreatic cancer) are to be reported on both the Clinical Events eCRF and 
the SAE eCRF, even if the event does not meet seriousness criteria. These events are reviewed 
by [CONTACT_252784].
Additionally, any SAE cons idered by [CONTACT_19427] a qualified physician to be possibly, 
probably, or definitely related to the investigational product that is brought to the attention of the 
investigator after study closeout must be reported within the above timeline.  All patients with 
serious adverse events must be followed to assess outcome until resolution or until designated 
permanent.
43
EXSCEL Protocol Amendment 06
10.3.3 Sponsor Responsibility for Reporting Serious Adverse Events
The Sponsor will ensure that all appropriate regulatory agencies confirm that the approach for 
monitoring Clinical Events, described in the Safety Assessments Section is acceptable to them.  
SAEs that are not recorded as Clinical Events w ill be reported to regulatory agencies, IRB/IECs, 
and investigators in accordance with all applicable global laws and regulations.
10.[ADDRESS_307470] indicated an increased incidence of thyroid C-cell tumors (adenomas, 
carcinomas) with EQW treatment. The relevance of th ese findings to human safety is currently 
unknown and is being investigated.  In clinical studies, there was no difference between 
exenatide (BID or once weekly) and comparators with respect to thyroid neoplasms.  A detailed 
summary of findings in rodents and clinical studies is available in the Ex enatide Investigator 
Brochure. Measurement of calcitonin has been added to newly initiating clinical trials of EQW 
to characterize any effects of exenatide or comparator treatment on calcitonin levels over time to 
better assess evidence of a biologic effect on c-cells. In clinical trials, no difference in calcitonin 
was observed between exenatide and comparators.
Calcitonin concentrations will be monitored at baseline, annually and at the Trial Termination
visit.  Investigators and participants will be blinded to calcitonin values.  If the baseline value 
exceeds 40 ng/L, the site will be informed and directed to have the patient terminate study 
medication.  If a concerning calcitonin value ( #50 ng/L) is identified during trial follow-up, the 
site investigator will be notified and they should call the Trial Hotline for advice, where they will 
be instructed to alert the usual care provider and permanently discontinue study medication.  
Calcitonin concentrations will be monitored by [CONTACT_4318], which will include a thyroid expert.  
10.[ADDRESS_307471] the investigational site, and/or 
healthcare provider in the event of an overdose.
10.5.2 Reporting of Overdose
If an adverse experience(s) is associated with (â€œresults fromâ€) the overdose of study medication, 
the adverse experience(s) is collected as a serious adverse experience, even if no other criteria for 
seriousness are met.
If a dose of study drug meeting the protocol definition of overdose is taken without any 
associated clinical symptoms or abnormal laboratory results, the overdose is reported as an Event 
of Clinical Interest (ECI), using the terminology â€œaccidental or intentional overdose without 
adverse effect.â€
All reports of overdose with and without an adverse experience must be reported within 1 day of 
the siteâ€™s knowledge of the event.
44
EXSCEL Protocol Amendment 06
10.6 Reporting of Pregnancy
Although not considered an adverse experience, it is the responsibility of investigators or their 
designees to report any pregnancy in a patient (spontaneously reported to them) which occurs 
during the trial or within [ADDRESS_307472] 
stop taking blinded trial medication and be followed to the completion/termination of the 
pregnancy. All occurrences of pregnancy must be reported via the Pregnancy Surveillance
Form. If the pregnancy continues to term, the outcome (health of infant) must also be reported.
10.[ADDRESS_307473] the trial hotline physician, available 24hrs/day to discuss the case and 
determine the course of action; however, it is the prerogative of the treating physician to insist 
that their patient should be unblinded.  Patients whose treatment has been unblinded can continue 
to receive trial medication and can continue to be followed in the trial as described in this 
protocol.
[ADDRESS_307474] obtain written documented consent to participate in the trial from each 
potential patient in his/her native language. Consent must be documented by [CONTACT_102]'s dated 
signature [INVESTIGATOR_2394] a Consent Form along with the dated signature [CONTACT_199878]. If the patient is illiterate, an impartial witness should be present during the entire 
informed consent reading and discussion. Afterward, the patient should sign and date the 
informed consent, if capable. The impartial witness should also sign and date the informed 
consent along with the individual who read and discussed the informed consent (i.e., trial staff 
personnel). A copy of the signed and dated consent form should be given to the patient.
The initial informed consent form, any subsequent revised written informed consent forms, and 
any written information provided to the patient must receive the IRB/IECs approval/ favorable 
opi[INVESTIGATOR_19349]. The patient or his/her legally acceptable representative should be 
informed in a timely manner if new information becomes available that may be relevant to the 
patientâ€™s willingness to continue participation in the trial. The communication of this 
information will be provided and documented via a revised consent form or addendum to the 
original consent form.
The informed consent form will describe the regular two-way exchange of information that is 
expected to occur between trial physicians and the usual care physicians.  The informed consent 
form will also include a request that the patient provide permission for the collection of medical 
records and copi[INVESTIGATOR_252690].
[ADDRESS_307475] this blood sample drawn. The approval of the 
consent form for analysis and the associated protocol procedures (e.g., collection of a blood 
sample) may, in some cases, proceed independently through Institutional Review Boards, Ethical 
Review Boards, Independent Ethical Review Committees (ERCs), Privacy Committees, etc., 
from the associated clinical trial.
11.[ADDRESS_307476] blood and urine samples, preferably fasting, 
collected at baseline (prior to drug exposure), Year 1, and at the Trial Termination visit. 
Biomarker samples will be stored in at least two aliquots for potential future proteomic and/or 
metabolomic analysis. This is an optional activity, and only those patients who have consented 
to having this biomarker sample collected may have this blood sample drawn. The approval of 
the consent form for analysis and the associated protocol procedures (e.g., collection of a blood 
sample) may, in some cases, proceed independently through Institutional Review Boards, Ethical 
Review Boards, Independent Ethical Review Committees (ERCs), Privacy Committees, etc., 
from the associated clinical trial.
11.[ADDRESS_307477]
Documented approval from appropriate Ethics Committee(s) or Institutional Review Board(s)
must be obtained for all participating centers prior to study start, according to Good Clinical 
Practice (GCP), local laws, regulations and organizations. When necessary, an extension, 
amendment or renewal of the Ethics Committee approval must also be obtained. Ethics 
Committees, upon request, may be required to provide a list of the Ethics Committee members
involved in the vote and a statement to confirm that the Ethics Committee is organized and 
operates according to GCP and applicable laws and regulations. Modifications to the study 
protocol will not be implemented without the agreement of the Executive Committee and 
appropriate ethical approval.
11.[ADDRESS_307478], evaluation, and documentation 
of this study, are designed to ensure that the sponsor and investigator abide by [CONTACT_27727] G uidelines.  
The study will also be carried out in keepi[INVESTIGATOR_39684](s) and regulation(s).  This 
may include an inspection by [CONTACT_142081]/or Regulatory Authority 
representatives at any time.  The investigator must agree to the inspection of study-related 
records by [CONTACT_121352]/sponsor representatives, and must allow direct access to 
source documents to the Regulatory Authority/sponsor representatives.  The investigator must 
notify the sponsor promptly of any inspections scheduled by [CONTACT_12721], and promptly 
forward copi[INVESTIGATOR_252691].
[ADDRESS_307479] or fraud (e.g., loss of medical licensure, debarment).
11.6 Regulatory Authority Approvals/Authorizations
Regulatory Authority approvals/authorizations/notifications, where required, must be in place 
and fully documented prior to study start.
11.7 Confidentiality
All records identifying the patient will be kept confidential and, to the extent permitted by [CONTACT_3999]/or regulations, will not be made publicly available. The patient will be 
identified only by a unique patient ID number on the eCRF.  All documents will be stored 
securely and kept in strict confidence in compliance with the Data Protection Act.
Study findings stored on a computer will be stored in accordance with local data protection laws.  
The patients will be informed in writing that representatives of the sponsor, Ethical Committees, 
Institutional Review Boards or Regulatory Authorities may inspect their medical records to 
verify the information collected, and that all personal information made available for inspection 
will be handled in strictest confidence and in accordance with local data protection laws.
When the results of the study are published, the patientâ€™s identity will remain confidential.  The 
investigator will maintain a list to enable patientsâ€™ records to be identified.
11.[ADDRESS_307480] the sponsor prior to 
destroying any records associated with the study.
The sponsor will notify the investigator when the study records are no longer needed.
If the investigator withdraws from the study (e.g., relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (e.g., another investigator, IRB). Notice of such 
transfer will be given in writing to the sponsor.
11.8.[ADDRESS_307481] safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
The investigator will maintain a signature [CONTACT_109440]/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly 
reviewed, signed, and dated by [CONTACT_20510] a sub -investigator 
and who is delegated this task on the Delegation of Authority Form. For electronic CRFs, review 
and approval/signature [CONTACT_252833]. The 
investigator must retain a copy of the CRFs including records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet training requirements and 
must only access the electronic data capture tool using their unique user account. User accounts 
are not to be shared or reassigned to other individuals.
12 TRIAL MANAGEMENT/GOVERNANCE COMMITTEES
12.1 Executive Committee (EC)
The EC will be responsible for overall management and oversight of the trial. The EC will be 
composed of senior independent academic representatives who are experts in their field and 
representatives from the sponsor.  The Committee will be co-chaired  
   An EC charter will outline the 
committee membership and structure and delineate operating procedures.
The Executive Committee is the main decision- making body for the EXSCEL trial and is 
charged with the overall scientific, professional, and operational conduct of the trial.
The primary functions of the Executive Committee are to:
1. Review and approve the trial protocol and all protocol amendments.
2. Supervise the conduct of the trial in accordance with its responsibilities described in the trial 
protocol and committee charter. 
3. Review and approve the Statistical Analysis Plan. 4. Oversee all trial subcommittees, including but not limited to: 
!Clinical Endpoint Committee
!Data Safety Monitoring Board 
!Operations Committee 
!Strategic Advisory Committee
5. Review and consider recommendations from the Data Safety Monitoring Board (DSMB). 
6. The Executive Committee will determine the time to terminate the trial, based on 
recommendations from the DSMB and other available information. The Executive Committee 
may also find it necessary to terminate the trial under certain circumstances, including but not 
limited to the following reasons: 
48[COMPANY_003]
EXSCEL Protocol Amendment 06
!Animal, human or toxicological test results, in the reasonable determination of the Executive 
Committee, support termination of the trial 
!Ethical or patient safety issues occur that the Executive Committee feels support termination 
of the trial 
!Extraordinary scientific, regulatory or other events that negatively impact the rationale for 
the trial such that the Executive Committee agrees it is appropriate to terminate the trial 
7. Review all sub-study requests and approve where appropriate. 
8. Consider, authorize as appropriate and prioritize requests for access to trial data and/or
genetic and biomarker samples for academic or other collaborations. After the Executive Committee disbands, DCRI, DTU and the sponsor will assume this responsibility. 
9. Approve the communication strategy on how to best communicate information about the 
progress of the trial. 
10. Ensure accurate, uniform, timely, and high quality reporting of the main trial and all 
approved sub-studies. 
11. Serve as the writing group who will prepare and submit for publication the primary 
manuscript describing the main trial results. All members of the Executive Committee will have 
access, in confidence to the draft manuscript describing the primary results paper. 
12. Assume the role of publications committee and review, authorize and prioritize proposals for 
publications which require trial or sub study data, samples, or genetic material and assign writing groups. 
13. Review and comment on any independent publications reporting results from the trial 
following the primary publication. 
12.2 Operations Committee (OC)
The Operations Committee (OC) is composed of Country Leads selected by [CONTACT_252785]. The OC 
will be co-chaired by [CONTACT_252786] (DCRI) 
and the Diabetes Trials Unit (DTU). Balance will be sought between cardiologists and 
endocrinologists. The primary role of the OC is to serve as the interface between the EC and the 
trial sites, and to assist in the progress of th e trial at the regional level. Committee members will 
be instrumental in serving as ambassadors of the trial to encourage recruitment as well as ensure 
trial compliance by [CONTACT_252787]-specific issues. The 
committee will provide a means of transmitting any identified needs, concerns, or suggestions 
from the sites to the EC and assist in disseminating clinical or operational information to the 
sites. The functions and operating procedures of the OC are delineated in a charter. 
12.2.1 Remit of Operations Committee
Specific functions of the OC will include the following: 
1. All members will serve as regional leaders for site investigators. 
2. All members will serve as advocates for the trial. 3. Country Leads will:
49
EXSCEL Protocol Amendment 06
a) Communicate with investigators in the Leadâ€™s country to review country specific 
progress reports, including but not limited to recruitment/retention of patients, event reporting and data collection, and communication between sites and usual care providers. 
b) Liaise with the academic coordinating centers and global Contract Research 
Organizations (CROs) to review and attempt to resolve any operational issues raised 
within a region.
c) Support regulatory submissions, as needed in collaboration with the Sponsorâ€™s 
Regulatory Affairs Department.
4. Committee Co-Chairs will: 
a) Compi[INVESTIGATOR_252692]-specific performance metrics for presentation to the Executive 
Committee. 
b) Liaise with Country Leads, academic coordinating centers (DCRI and DTU project 
teams), sponsors and global AROs/CROs to implement trial policies.
12.[ADDRESS_307482] (DSMB)
The DSMB will be composed of six senior academic individuals, including the DSMB Chair.  
There will be at least one member with high-level expertise for each of cardiology, 
endocrinology, and statistics.  An Independent Statistician (not affiliated with the DCRI, DTU, 
or the Sponsor) will also be in attendance.  All of these individuals will have long -standing 
experience in the operational, medical, and biostatistical aspects of international clinical trials.  
The DTU senior statistician assigned to the trial will oversee the provision of interim masked 
data sets for use by [CONTACT_252788]/DTU trial coordinating centers.  DTU will transfer 
pre-agreed masked datasets to the Independent Statistician who will then prepare unmasked 
confidential reports for the DSMB, using treatment codes provided in advance by [CONTACT_252789].  During the Open Session of the DSMB meetings, representatives of the Executive 
Committee may present updates on the trial status or the safety profile of exenatide, but will not 
be privy to discussions of the unmasked data conducted during the Closed Sessions and will not 
vote.  Proceedings and minutes of the Closed Session will be held in strict confidence and will 
not be shared outside the DSMB while the trial is ongoing.
The DSMB will be responsible for the interests of the patients and, to this end, will undertake 
regular reviews of the safety data.  The DSMB w ill have access to an agreed subset of the trial 
data as listed in the DSMB charter (updated as necessary during the trial) in an unblinded fashion 
throughout the trial duration. In addition, the DSMB will evaluate two interim analyses after 
approximately one-third and two-thirds of the total targeted number of primary composite CV 
events (see Sec 9.10 for details).
If the DSMB finds it necessary to recommend actions regarding interruption of the trial or 
changes to the protocol based on medical rationale that would make it unethical to continue the 
trial in its present form, those recommendations will be forwarded to the EC.  The details of the 
DSMB's functions and the early stoppi[INVESTIGATOR_252693] a separate DSMB charter.
50
EXSCEL Protocol Amendment 06
12.4 Clinical Events Committee (CEC)
The events which constitute the principal endpoints of this trial will be adjudicated by [CONTACT_252790] (CEC), coordinated through the Duke Clinical 
Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a 
coordinator.  The specific endpoints to be adjudicated include:  cause of death (cardiovascular-
related vs. non-cardiovascular), MI, stroke, acute coronary syndrome, pancreatitis, neoplasm, 
ventricular fibrillation/tachycardia, and CHF requiring hospi[INVESTIGATOR_059]. Clinical reviewers will be
board certified or board eligible endocrinologists, cardiologists, neurologists, gastroenterologists, 
or physicians with clinical expertise and prior clinical event classification experience. The CEC 
will review clinical data and adjudicate safety and efficacy endpoints.  The CEC will adjudicate 
clinical events using pre-specified criteria and definitions.  The CEC will be blinded to the 
assigned trial medication. Sites will provide clinical information via the eCRF and also provide 
supplemental information from medical records, when needed. The CEC operations and endpoint 
criteria will be described in a separate charter.
12.[ADDRESS_307483] the right to comment on 
these but the final editorial control remains with the Executive Committee. The Executive 
Committee will draft the manuscript describing the main study results, and oversee publications 
requiring trial data, samples, or genetic material.
In addition, a CSR will be prepared for regulatory purposes.  The Signatory Investigator 
responsible for signing the CSR will be selected by [CONTACT_252791].
51
EXSCEL Protocol Amendment 06
14 REFERENCES
                                                          
1King H, Aubert RE, Herman WH: Global Burden of Diabetes, 1995-2025.  Diabetes Care 
1998; 21:1414-1431.
2[LOCATION_006]PDS Group. Risk factors for coronary artery disease in non-insulin dependent diabetes 
([LOCATION_006]PDS 23). BMJ 1998; 316: 823â€“828. 
3Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of 
cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-
controlled trial. Lancet 2003;361:2005-2016. 
4Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, 
Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of 
cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 
364:685â€“696.
5[LOCATION_006] Prospective Diabetes Study Group ([LOCATION_006]PDS): Tight blood pressure control and risk of 
macrovascular and microvascular complications in type 2 diabetes: [LOCATION_006]PDS 38. BMJ 1998; 
317:703â€“713.
6Menard J, Rahn KH, Wedel H, Westerling S: E ffects of intensive blood-pressure lowering 
and low-dose aspi[INVESTIGATOR_252694]: principal results of the Hypertension 
Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755â€“1762.
7Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in 
type 2 diabetes. N Engl J Med 2008;359:1577â€“1589. 
8Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glu cose on 
cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of 
randomized controlled trials. Lancet 2009;373:1765â€“1772. 
9Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention 
on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591. 
10Shen L, Han J, Yushmanova I, Bruce S, Porter L. Cardiovascular safety of exenatide BID: an 
integrated analysis from long-term controlled clinical trials in subjects with type 2 diabetes.  
Diabetes 2009;58(Suppl 1):A96-97. Abstract 366-OR.
11Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ , 
Rosenstock J. Use of twice-daily exenatide in basal insulin-treated patients with type 2 
diabetes: a randomized, controlled trial. Ann Intern Med 2011;154(2):103-112.
12Drucker DJ, Buse JB, Taylor K, Kendall D, Trautmann M, Zhuang D, Porter L. Once 
Weekly vs Twice daily Exenatide for the Treatment of Type 2 Diabetes. Lancet 
2008;372(9645):1240-1250.
52
EXSCEL Protocol Amendment 06
                                                                                                                                                                                          
13Buse J, Drucker D, Taylor K, Kim T, Wilhelm K, Kendall D, Trautmann M, Zhuang D, 
Porter L. Exenatide once weekly elicits sustained glycaemic control and weight loss over 52 
weeks. Diabetologia 2008;51(Suppl 1):S67. Abstract 146.
14http://www.ngsp.org/prog/index.html
[ADDRESS_307484]
Any clinical event listed in this appendix that meets the cr iteria of an SAE (unless indicated otherwise below) must 
be reported in the Clinical Event eCRF reporting module.
I. Obvious Trial Endpoints 
(These events w ill prom pt the investigator to complete an endpoint package which will then be adjudicated 
according to the Clinical Events Classification [CEC] charter)  
Death
!Cardiovascular (CV) Death (i.e., fatal myocardial infarction [MI] / cerebrovascular accident 
[CVA] / congestive heart failure [CHF] / arrhythmia, cardiac arrest, death following CV intervention)
!Non-CV Death
Nonfatal MIAcute coronary syndromeNonfatal CVACHF requiring hospi[INVESTIGATOR_252695]. Cardiovascular Events of Interest
(Some of these events will result in prompts to answe r additional questions in the eCRF â€“ these questions w ill be 
designed to determine whether or not a primary or secondary outcome of interest has occurred) 
Atrial fibrillation/Atrial flutter
Ventricular fibrillation/tachycardia requiring intervention
Deep Vein Thrombosis (DVT)
Pulmonary embolismPercutaneous Coronary Intervention (PCI) â€“ (including non-serious events)Coronary Artery By[CONTACT_15725] (CABG)Coronary catheterizationStress test (including non-serious events)
Abdominal aortic aneurysm/repair
Carotid endarterectomy/Carotid angioplasty and/or stentingAny hospi[INVESTIGATOR_252696] (i.e., whether or not the hospi[INVESTIGATOR_252697])
Shock/hypotensionAccelerated or malignant hypertension/hypertensive urgency
Transient Ischemic Attack (TIA)
SyncopeRenal artery angioplasty and/or stentingOther arterial angioplasty and/or stenting
III. Expected Events and Diabetic Complications
(Subcategories indicate potential additional information to be captured, usually as an indication of severity)
A. Peripheral Vascular Disease (PVD)
!Limb PCI
!Vascular surgery 
54
EXSCEL Protocol Amendment 06
!Amputation
!Surgical debridement of ulcer
B. Gangrene
C. Severe hypoglycemia (including non-serious events) / Hyperglycemia / Diabetic ketoacidosis / Hyperosmolar 
hyperglycemic nonketotic coma
D. Diabetic eye disease (including non-serious events)
!Photocoagulation or other laser therapy
!Cataract extraction
!Blindness
!Enucleation
!Steroid/Avastin injection
!Scleral buckling or other retinal fixation procedure
E. Diabetic neuropathy (including distal sensorimotor, focal/multifocal, or autonomic) (including non-serious 
events)
!Foot ulcer
F. Diabetic nephropathy (including non-serious events)
!Microalbuminuria
!Macroalbuminuria
G. Renal failure
!Acute renal failure, requiring or associated with hospi[INVESTIGATOR_059]
!Chronic renal failure, requiring peritoneal or hemodialysis, including creation of fistula or other vascular 
access for hemodialysis
!Renal transplant
H. Any hospi[INVESTIGATOR_252698]
I. Infections
!Osteomyelitis
oIV antibiotic therapy vs. debridement
!Cellulitis
oOral vs. IV antibiotic therapy
!Mucormycosis
!Pneumonia
oCommunity acquired vs. hospi[INVESTIGATOR_252699]. IV antibiotic therapy
!Bacteremia
!Sepsis
!Infected joints
oProsthetic joint
!Complicated or serious urinary tract infection (UTI) / Pyelonephritis
oRequiring hospi[INVESTIGATOR_059]
!Malignant external otitis
J. Gastrointestinal (GI) conditions  
55
EXSCEL Protocol Amendment 06
!Abdominal pain
!Nausea / vomiting
!Diarrhea
!Fatty liver disease / Nonalcoholic steatohepatitis (NASH)
!Cholecystitis / cholelithiasis
!Elevated liver enzymes
K. Metabolic Conditions Associated with Diabetes (including non-serious events)
!Hyperlipi[INVESTIGATOR_035] / dyslipi[INVESTIGATOR_035]
!Hypertension
!Gout
56
EXSCEL Protocol Amendment 06
APPENDIX 2 TRIAL PLAN (PROTOCOL BCB109)
Table 1: Trial Plan 
Treatment Initiation Follow-up [4] Drug or Study Termination
EvaluationScreening
Day -1Randomization 
Day 0
Visit 1 [1]Week 1 and
Month 2 
Visit 2 and 3Semi-
Annual AnnualDrug 
Termination [5]Trial 
Termination [8]Post-
Treatment
Follow-up
Contact [9]
Informed Consent/HIPAA [2] and 
Stored Blood Sample Authorization X
Medical History X
Physical Examination X
Height X
Blood Pressure, Heart Rate and 
Body Weight XX X X X X
Calcitonin Blood Sample XX X
Collect and review available 
information including most recent 
HbA 1c, serum creatinine and lipid 
profile X [6] X X X X
Randomization X
If consent obtained, collect blood 
sample for genetic and genomic analysis X [7]
If consent obtained, blood sample 
(serum and plasma) and urine 
sample for archive XYear 1 
only X
Drug Dispensation XX X
Used/Unused Vial Assessment XX X X
Clinical and SAE Event Assessment XX X X X X X
Conmed Assessment XX X X X X X
Confirm competency with 
injections [3] X
EQ-5D CompletionXMonth 6 
only X X
[1]   Wherever possible the screening and randomization visit should be combined.
[2]   Informed Consent Form and if applicable, authorization to use and disclose protected health information.[3]   Patients will return approximately 1 week (Â±3 days) as well as 2 months (Â± 2 weeks) after Day 0 to perform a self-injecti on under the observation of the 
clinical site to confirm competency with injection.  An additional visit can be considered at ~[ADDRESS_307485] themselves.
[4]   Semi-annual (Â±1 month) and Annual Follow-up (Â±1 month) Visits will occur in reference to Visit 1 Day 0 for the duration o f participation in the trial.
57
EXSCEL Protocol Amendment 06
[5]   Patients who terminate study medication are required to have a Drug Termination Visit as part of their next scheduled stu dy visit (unless a separate drug 
termination visit at that point is deemed necessary by [CONTACT_093]).  Patients will continue to be observed following the Drug Termination visit according to 
their planned visit schedule for the remainder of the trial.  All procedures for remaining Semi-annual and Annual Visits are to  be followed with the exception of 
Drug Dispensation.
[6]   It is recommended that serum creatinine value draw dates be within 3 months of randomization but up to 12 months is accep table (however, if > 6 months 
old and value is between 30-40mL/min/1.73m2 it is recommended that a new serum creatinine value is obtained as part of usual care).
[7]   Blood sample for genetic and genomic analysis may be collected at any time during the trial after consent is obtained.[8]   For patients who have been discontinued from trial medication for more than 70 days as of the Trial Termination Visit, th e Trial Termination Visit will be 
the final study follow-up.
[9]   Patients will be contact[CONTACT_252736], serious adverse experiences and hospi[INVESTIGATOR_059] s that occurred within [ADDRESS_307486] dose of trial medication.  (see Section 10.3.1).
58
EXSCEL Protocol Amendment 06
APPENDIX 3 PROTOCOL AMENDMENT 01: SUMMARY OF CHANGES
Exenatide QW Clinical Study Protocol BCB109
PROTOCOL TITLE: A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO 
EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Protocol Number: BCB109Amendment Number: 01Amendment Purpose: Date: [ADDRESS_307487] type 2 diabetes 
with a glycated hemoglobin (HbA 1c) â‰¥7.0 % 
and â‰¤10.0 % on stable doses of up to three 
oral antihyperglycemic agents (AHAs) for at least [ADDRESS_307488] type 2 diabetes with 
a glycated hemoglobin (HbA1c) â‰¥7.0 % and 
â‰¤10.0 % on stable doses of up to three (i.e. 0-3) 
oral antihyperglycemic agents (AHAs) for at least [ADDRESS_307489] 3 months.
5.1 Inclusion Criteriac.  Patient has an HbA
1c of â‰¥ 7.0 % and â‰¤ 
10.0% on stable doses of up to three oral 
AHAs for at least [ADDRESS_307490] 3 months.
A patients whose HbA 1cis > 10.0% may, 
at the discretion of the investigator, have their oral AHA therapy adjusted and be 
re-screened once for HbA
1c randomization 
eligibility ( â‰¥ 7.0 % and â‰¤ 10.0%) 
following a 3-month period on stable AHA doses.c.  Patient has an HbA
1c of â‰¥ 7.0 % and â‰¤ 10.0% 
on stable doses of up to three (i.e. 0-3) oral 
AHAs for at least [ADDRESS_307491] recent reported value should be used.  A patient whose HbA
1cis > 10.0% may, at the 
discretion of the investigator, have their oral AHA therapy adjusted and be re-screened 
once for HbA
1c randomization eligibility ( â‰¥ 
7.0 % and â‰¤ 10.0%) following a 3-month 
period on stable AHA doses.
5.1 Inclusion Criteriad.   Patients with any level of CV risk and 
meeting all other inclusion criteria may be enrolled. Recruitment will be constrained  such that 40% will not have 
had a prior CV event and 60% will have d.  Patients with any level of CV risk and 
meeting all other inclusion criteria may be enrolled. Recruitment will be constrained such that approximately 40% will not have 
had a prior CV event and 60% will have had 
[ADDRESS_307492] 
one of the following:a prior CV event defined as at least one of 
the following:
6.1 Trial ProceduresStudy Design Figure The study design figure has been updated 
6.3  
Method of Assigning 
Patients to 
Treatment Groups (Visit 1)This automated system will assign a unique 
allocation number to eligible patients and dispense double-blind trial medication.  This automated system will randomize eligible 
patients and dispense double-blind trial medication. 
6.8 Calcitonin Sample Collection(this is a new subsection; subsequent 
subsections have been renumbered accordingly )Serum calcitonin concentrations will be 
monitored throughout the patientâ€™s participation in the trial.  Samples will be collected at baseline, annually and trial/early termination.
6.9 
Genetic and 
Biomarker Sample Collection(previously 
Section 6.8 )These fasting specimens will be obtained at 
baseline (prior to drug exposure), and either 
at one year of treatment or at the time of drug discontinuation (if occurring within the first year).These specimens (preferably fasting) will be 
obtained at baseline (prior to drug exposure), 
annually and trial/early termination.
6.12 Early Discontinuation of Trial Medication(previously 
Section 6.11 )Unless consent to follow the patient is 
specifically withdrawn, patients should continue to be followed as outlined in Section 6.[ADDRESS_307493] be stored 
between 2Â°C and 27Â°C (36Â°F and 81Â°F).  The EQW or matching placebo dose is prepared by [CONTACT_252792].  Specific instructions for 
dose preparation of the injection will be 
provided in the Directions For Use (DFU).  The Microsphere Diluent must be stored 
between 2Â°C and 25Â°C (36Â°F and 77Â°F).  The EQW or matching placebo dose is prepared by [CONTACT_252792].  Specific instructions for dose 
preparation of the injection will be provided in 
the Patient Instructions For Use (PIU).  
7.3 Dispensing of Trial MedicationStudy materials will be provided to subjects 
by [CONTACT_252793] 1572, or other qualified study-site personnel.  
Under no circumstance will the investigator 
or subinvestigators allow the study medication to be used other than as directed by [CONTACT_252794].Study materials will be provided to subjects by 
[CONTACT_093], medically qualified subinvestigator or other qualified study-site personnel.  Under no circumstance will the 
investigator or subinvestigators allow the study 
medication to be used other than as directed by [CONTACT_252795].
60
EXSCEL Protocol Amendment 06
SECTION ORIGINAL PROTOCOL TEXT AMENDMENT 01 TEXT
7.4 
Dose Administration Procedure, Route and ScheduleDoses of EQW or matching placebo are to be 
injected into subcutaneous (SC) tissue of the abdomen.  The site of injection should be rotated on a regular basis so that the same site is not used repeatedly.Doses of EQW or matching placebo are to be 
injected into subcutaneous (SC) tissue of the abdomen, thigh or back of the upper arm.  The site of injection should be rotated on a regular basis so that the same site is not used 
repeatedly. The same anatomical region can be 
used for the injection but the site should be rotated (e.g. different quadrants of the abdomen can be used in a weekly rotation).
7.[ADDRESS_307494] call the IVRS 
at all subsequent visits (except Study Termination) to record the visit and confirm the kit assignment.The study-site personnel must call the IVRS at 
all subsequent visits (except Visits 2, 3 and Study Termination) to record the visit and confirm the kit assignment
7.6
Drug 
AccountabilityDrug accountability will be the responsibility 
of the study-site personnel.  Upon receipt of 
study medication, study site personnel should open the shipment, verify that the amount and identity of the contents match that stated on the enclosed shippi[INVESTIGATOR_52861], indicate the 
condition of the contents on the form, and 
then sign and date the form.  The study-site personnel should make a copy of the shippi[INVESTIGATOR_252700]'s file, and return the original completed form to the sponsor (or designee).  In addition, the study-site 
personnel will contact [CONTACT_252796].  Drug accountability will be the responsibility of 
the study-site personnel.  Upon receipt of study 
medication, study site personnel should open the shipment, verify that the amount and identity of the contents match that stated on the enclosed shippi[INVESTIGATOR_52861], indicate the condition 
of the contents on the form, and then sign and 
date the form.  In addition, the study-site personnel will contact [CONTACT_252797].  
9.8.3Safety PopulationSerious AEs and AEs leading to 
discontinuation of study medication, any of which occurred within [ADDRESS_307495] dose of study medication, will be collected.   
10.1  Definitions !Is otherwise medically significant (i.e. 
withdrawal reactions, all accidental or 
intentional overdoses whether they result in an adverse event or not, or any event which the investigator considers significant but which is not covered by [CONTACT_31714].)!Is otherwise medically significant (i.e. 
withdrawal reactions, all accidental or 
intentional overdoses of study medication whether they result in an adverse event or not, or any event which the investigator considers significant but which is not covered by [CONTACT_31714].)
10.3 
Classification 
and Reporting of Adverse EventsTable 1. ( additional footnote included to 
clarify collection of pancreatitis and 
neoplasia )** All epi[INVESTIGATOR_252701].  
10.[ADDRESS_307496] be recorded in this 
module (or faxed to Lilly if EDC is 
unavailable) within 1 day of a trial site 
61
EXSCEL Protocol Amendment 06
SECTION ORIGINAL PROTOCOL TEXT AMENDMENT 01 TEXT
information on the clinical course of the 
event, treatment, and relevant diagnostic, laboratory or other investigations will be collected on the eCRF. Epi[INVESTIGATOR_81719], diagnoses of thyroid carcinoma 
and pancreatic cancer will be collected and 
reported as Ancillary Events.  All Ancillary Events will be reported to the appropriate regulatory agencies in a manner and timeframe consistent with all applicable laws and regulations (Section 10.3.1). 
Additionally, any SAE considered by [CONTACT_26368] a qualified physician to be possibly, probably, or definitely related to the investigational product that is brought to the attention of the investigator after study closeout must be reported within the above 
timeline to Amylin/Eli Lilly.  All patients 
with serious adverse events must be followed to assess outcome until resolution or until designated permanent.becoming aware of the event.  Brief 
information on the clinical course of the event, treatment, and relevant diagnostic, laboratory or other investigations will be collected on the eCRF. All epi[INVESTIGATOR_252702].  All Ancillary Events will be reported to the appropriate regulatory agencies in a manner and timeframe consistent with all applicable laws and regulations (Section 10.3.1). 
Note : Events which meet the criteria to be 
classified as an Ancillary Event which result in death and are deemed to be possibly related to study drug will be collected and reported as 
Ancillary Events.
Additionally, any SAE considered by [CONTACT_26368] a qualified physician to be possibly, probably, or definitely related to the 
investigational product that is brought to the 
attention of the investigator after study closeout 
must be reported within the above timeline to Amylin/Eli Lilly.  All patients with serious adverse events must be followed to assess outcome until resolution or until designated permanent.
10.4 
Calcitonin 
Monitoring(this is a new subsection; subsequent 
subsections have been renumbered 
accordingly )Studies in rodents have indicated an increased 
incidence of thyroid C-cell tumors (adenomas, 
carcinomas) with EQW treatment. The relevance of these findings to human safety is currently unknown and is being investigated.  In clinical studies, there was no difference between exenatide (BID or once weekly) and 
comparators with respect to thyroid neoplasms.  
A detailed summary of findings in rodents and clinical studies is available in the Exenatide Investigator Brochure.   Measurement of calcitonin has recently been added to newly 
initiating clinical trials of EQW to characterize 
any effects of exenatide or comparator treatment on calcitonin levels over time to better assess evidence of a biologic effect on c-cells.  In clinical trials, no difference in calcitonin was observed between exenatide and 
comparators.
Calcitonin concentrations will be monitored at baseline, annually and at trial/early termination.  Investigators and participants will be blinded to calcitonin values.  If the baseline value exceeds 100 ng/L, the site will be informed and directed 
to have the patient terminate study medication.  
If a concerning calcitonin value is identified during trial follow-up, the site investigator will 
62
EXSCEL Protocol Amendment 06
SECTION ORIGINAL PROTOCOL TEXT AMENDMENT 01 TEXT
be notified and will alert the usual care 
physician.  Calcitonin concentrations will be monitored by [CONTACT_4318], which will include a thyroid expert.  
10.5.2 Reporting of Overdose
(previously 
section 10.4.2)If an adverse experience(s) is associated with 
(â€œresults fromâ€) the overdose of test drug, the 
adverse experience(s) is reported as a serious 
adverse experience, even if no other criteria for seriousness are met.If an adverse experience(s) is associated with 
(â€œresults fromâ€) the overdose of study 
medication, the adverse experience(s) is 
collected as a serious adverse experience, even if no other criteria for seriousness are met.
10.6 Reporting of Pregnancy(previously 
Section 10.5)All patients who become pregnant must stop 
taking blinded trial medication and be followed to the completion/termination of the pregnancy. If the pregnancy continues to 
term, the outcome (health of infant) must 
also be reported.All patients who become pregnant must stop 
taking blinded trial medication and be followed to the completion/termination of the pregnancy. All occurrences of pregnancy must be reported 
via the Lilly Pregnancy/Breastfeeding Exposure 
Form. If the pregnancy continues to term, the outcome (health of infant) must also be reported.
11.3Consent and Collection of 
Biomarker 
SpecimensPatients providing informed consent will 
have a fasting blood sample collected at baseline (prior to drug exposure), and either 
at one year of treatment or at the time of drug 
discontinuation (if occurring within the first year).Patients providing informed consent will have a 
blood and urine samples, preferably fasting, collected at baseline (prior to drug exposure), 
annually, and at the time of trial termination.
12.[ADDRESS_307497] (DSMB)The DSMB will be composed of five senior 
academic individuals, including the DSMB Chair.  The DSMB will be composed of six senior 
academic individuals, including the DSMB Chair.
12.5 Strategic Advisory Committee(this is a new subsection ) The Strategic Advisory Committee will provide 
oversight for the operational conduct of the study across all participating institutions.  It will be composed of senior management from the Sponsors, AROs and the contracted CRO, who are experts in the operational aspects of 
the conduct of clinical trials and the EXSCEL 
Clinical Leads.  
Appendix 2Trial Plan (Protocol BCB109)Please refer to Appendix 2 for specific 
changes.  Please refer to Appendix 2 for specific changes.  
Significant changes are summarized below:
!Calcitonin samples will be collected 
annually and at trial/early termination 
visits.
!Heart rate will be measured at 
randomization, all six-monthly visits (e.g. semi-annual and annual), and drug or trial/early termination visits.
!Clarification that consent is required 
for the biomarker assessment
!Samples for future biomarker 
assessments will now be collected annually trial/early termination rather than at one year only.
63
EXSCEL Protocol Amendment 06
APPENDIX 4 PROTOCOL AMENDMENT 02: SUMMARY OF CHANGES
Exenatide QW Clinical Study Protocol BCB109
PROTOCOL TITLE: A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO 
EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE 
WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Protocol Number: BCB109Amendment Number: 02Amendment Purpose: Date: 10 May 2011
The purpose of Amendment 02 is to allow insulin use prior to randomization, lower the calcitonin exclusion 
threshold to >40 ng/L, define the calcitonin exit threshold to be â‰¥50 ng/L, and clarify reporting of Clinical Events, 
Serious Adverse Events, and deaths.  Additional clarifi cations and edits are included.  Notable changes are detailed 
in the table below.
SECTION AMENDMENT [ADDRESS_307498], has been 
shown in randomized clinical trials to improve glycemic control, augment endogenous insulin secretion, to reduce blood pressure and promote weight loss with a meta-analysis of exenatide twice-daily 
(BY[CONTACT_252747]) trials (9) showing a trend to 
lower relative risk for CV events versus pooled comparators of 0.70 (95% confidence interval 0.38 - 1.31).  BY[CONTACT_252747] (exenatide) injection is currently available in 
the US and in many countries worldwide for 
people with type [ADDRESS_307499], has been 
shown in randomized clinical trials to improve glycemic control, augment endogenous insulin secretion, to reduce blood pressure and promote weight loss with a meta-analy sis of exenatide twice-d aily 
(BY[CONTACT_252747]) trials (9) showing a trend to 
lower relative risk for CV events versus pooled comparators of 0.70 (95% confidence interval 0.38 - 1.31). BY[CONTACT_252747] (exenatide) injection is currently available in 
the US and in many countries worldwide for 
people with type 2 diabetes who are unable to achieve good glycemic control with common oral therapi[INVESTIGATOR_014].  The addition of BY[CONTACT_252798] (not currently an approved indication) has 
also been demonstrated to improve glycemic 
control without an increased risk of hypoglycemia in patients receiving concomitant diet/exercise, metformin, or metformin+pi[INVESTIGATOR_252670] (exenatide enhances insulin secretion in a glucose-
dependent manner, thus minimizing the risk 
of hypoglycemia in the absence of an insulin secretagogue) (13).
[ADDRESS_307500] type 2 diabetes with a glycated hemoglobin (HbA1c) â‰¥7.0% 
and â‰¤10.0 % on stable doses of up to three 
(i.e. 0-3) oral antihyperglycemic agents (AHAs) for at least [ADDRESS_307501] 3 months. Patients enrolled will be at a wide range of CV risk with approximately 60% having had 
a prior CV event.EXSCEL will be a multinational, placebo-
controlled, double-blind, randomized, parallel-group pragmatic clinical trial. Eligible patients will have type 2 diabetes with a glycated hemoglobin (HbA1c) â‰¥7.0 
% and â‰¤10.0 % on stable doses of up to 
three (i.e. 0-3) oral antihyperglycemic agents (AHAs) for at least [ADDRESS_307502] 3 months. A stable dose of insulin (Â±20% of the scheduled total daily insulin dose), either 
alone or in combination with a stable dose 
of metformin for at least 3 months, will also be permitted. Patients enrolled will be at a wide range of CV risk with approximately 60% having had a prior CV event. 
5.1 Inclusion 
Criteriac.  Patient has an HbA
1c of â‰¥ 7.0 % and 
â‰¤10.0% on stable doses of up to three (i.e. 
0-3) oral AHAs for at least [ADDRESS_307503] recent reported value should be used.  A patient whose HbA
1cis >10.0% may, at the 
discretion of the investigator, have their oral AHA therapy adjusted and be re-
screened once for HbA
1c randomization 
eligibility ( â‰¥ 7.0 % and â‰¤ 10.0%) following 
a 3-month period on stable AHA doses.c. Patient has an HbA 1cof â‰¥ 7.0 % and â‰¤10.0% 
!A stable dose of up to three (i.e. 0-3) oral 
AHAs for at least 3 months will be allowed 
(i.e. no oral AHA adjustments in the past 3 months).  
oConcomitant use of DPP-4 inhibitors is 
permitted.
oA stable dose of insulin (Â±20% of the 
scheduled total daily insulin dose) either alone or in combination with a stable dose of metformin for at least 3 months is permitted. The use of basal and prandial insulins is permitted in any combination 
of individual or premixed insulins. If the 
prescribed insulin regimen includes adjustments, the total dose should not vary by [CONTACT_726] 20% from day to day over the preceding [ADDRESS_307504] recent reported value should be used.  A patient whose HbA1c is>10.0% may, at the discretion of the investigator, have 
their oral AHA or insulin therapy 
adjusted and be re-screened once for HbA1c randomization eligibility ( â‰¥ 7.0 % 
and â‰¤ 10.0%) following a 3-month period 
on stable AHA doses.
65
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
5.2 Exclusion 
Criteriab. Patient has taken insulin within 2 weeks of 
screening visit or for greater than 1 week within 3 months of screening visit.  
l. Personal or family history of medullary 
thyroid cancer or MEN2 (Multiple Endocrine 
Neoplasia Type 2) or calcitonin level of 100
ng/L or greater.
o.No original protocol text; new to this versionb. Patient has a history ( â‰¥ 2 epi[INVESTIGATOR_1841]) of severe 
hypoglycemia within 12 months of enrollment.
l. Personal or family history of medullary 
thyroid cancer or MEN2 (Multiple Endocrine 
Neoplasia Type 2) or calcitonin level > 40 
ng/L at baseline.
o. Is an employee of Eli Lilly and Company or 
Amylin Pharmaceuticals
66
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
6.5 
Concomitant TherapyDuring the double-blind treatment period, trial 
investigators are expected to monitor patientsâ€™ AHA regimens and communicate with usual care physicians, who will be responsible for adjusting the AHA regimen in 
order to achieve locally-appropriate HbA
1c
goals. These goals will be individualized, 
with the understanding that currently applicable glycemic guidelines may vary among different geographic regions. With adherence to local custom and laws 
(including privacy regulations such as 
HIPAA), types of communication may be informal e.g.email or telephone exchanges, 
to enhance frequency and ease of two-way communication.   In addition, the degree of locally-appropriate HbA
1c goal-attainment at 
each site will be monitored centrally and sites 
with unusually low goal attainment will be advised accordingly.
Usual care providers should be notified that 
adjustments to the AHA regimen are not 
recommended until HbA1c levels begin 
reflect the effect of randomized therapy. Any AHA agent, with the exception of GLP-1 receptor agonists, is acceptable.  If HbA1c goals are not met following adjustment with oral AHAs in patients not receiving insulin, 
an insulin regimen may be initiated, 
preferably without discontinuing or down-titrating some or all of the existing AHAs, as clinically appropriate.  Ideally, patients should generally remain on the baseline AHA therapi[INVESTIGATOR_252703], 
unless the baseline AHA is no longer 
clinically appropriate. However, this should be at the discretion of the usual care provider.  In addition, patients should be reminded to keep taking their blinded trial drug following initiation of insulin.During the double-blind treatment period, trial 
investigators are expected to monitor patientsâ€™ AHA regimens and communicate with usual care physicians, who will be responsible for adjusting the AHA regimen in 
order to achieve locally-appropriate HbA
1c
goals. The Executive Committee (EC) and 
Operations Committee (OC) will provide abrief list of guidelines for usual care based on clinical care practice guidelines published by [CONTACT_252799] T2DM 
evolves over the course of the trial. These goals will be individualized, with the understanding that currently applicable glycemic guidelines may vary among different geographic regions. With adherence 
to local custom and laws (including privacy 
regulations such as HIPAA), types of communication may be informal e.g.email or 
telephone exchanges, to enhance frequency and ease of two-way communication.   In 
addition, the degree of locally-appropriate 
HbA
1c goal-attainment at each site will be 
monitored centrally and sites with unusually low goal attainment will be advised accordingly.
Usual care providers should be notified that 
adjustments to the AHA regimen are not 
recommended until HbA1c levels begin reflect the effect of randomized therapy. Any AHA agent, with the exception of GLP-1 receptor agonists, is acceptable.  If HbA1c goals are not met following adjustment with 
oral AHAs in patients not receiving insulin, 
an insulin regimen may be initiated, preferably without discontinuing or down-titrating some or all of the existing AHAs, as clinically appropriate.  Patients already receiving insulin therapy may up-titrate 
insulin during the trial if necessary. Ideally, 
patients should generally remain on the baseline AHA therapi[INVESTIGATOR_252703], unless the baseline AHA is no longer clinically appropriate. However, 
this should be at the discretion of the usual 
care provider.  In addition, patients should be reminded to keep taking their blinded trial drug following initiation of insulin.
67
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
6.9 Genetic 
and Biomarker Sample CollectionIn a subset of sites, patients enrolled in the trial 
will be asked to consent separately to provide a whole blood sample for future pharmacogenomic analyses. The objective of collecting blood samples from which genetic 
analyses can be performed is to investigate 
the relationships between genetic make-up and clinical events.  These samples will be drawn at baseline, or at any point in the trial at which consent is obtained from the patient.
Patients enrolled in the trial will be asked to 
consent separately to provide two blood and 
two urine samples for future biomarker analyses.  These specimens (preferably fasting) will be obtained at baseline (prior to drug exposure), annually and trial/early termination.In a subset of sites, patients enrolled in the trial 
will be asked to consent separately to provide a whole blood sample for future pharmacogenomic analyses. The objective of collecting blood samples from which genetic 
analyses can be performed is to investigate 
the relationships between genetic make-up and clinical events.  These samples will be drawn at baseline, or at any point in the trial at which consent is obtained from the patient.
Patients enrolled in the trial will be asked to 
consent separately to provide one serum 
sample, one plasma sample, and one urine sample for future biomarker analyses.  These specimens (preferably fasting) will be obtained at baseline (prior to drug exposure), annually and trial/early termination. All 
samples will be divided and stored in [ADDRESS_307505] Trial 
Telephone Contact[CONTACT_25078]:  All patients should have an End of 
Trial Visit. (Patients who have discontinued 
trial drug must, at minimum, have an End of 
Trial telephone contact [CONTACT_765].)NOTE:  All patients should have an End of 
Trial Visit. (Patients who have discontinued 
trial drug prior to the end of the trial must, 
at minimum, have an End of Trial telephone contact [CONTACT_765].)
6.12 Early Discontinuation of Trial MedicationFollowing randomization, it is expected that 
patients will remain on study medication for the duration of trial participation.  However, it is recognized that patients may need to 
discontinue trial medication, in some cases 
permanently, for protocol-specified reasons (Section 6.14), due to the judgment of the primary investigator or because the patient withdraws consent.  The Trial Hotline should be contact[CONTACT_252764] a site is considering 
interrupting or discontinuing trial drug 
(Section 6.17).  Following randomization, it is expected that 
patients will remain on study medication for the duration of trial participation.  However, it is recognized that patients may need to 
discontinue trial medication, in some cases 
permanently, for protocol-specified reasons (Section 6.14), due to the judgment of the primary investigator or the decision of the patient.  The Trial Hotline should be contact[CONTACT_252764] a site is considering 
interrupting or discontinuing trial drug 
(Section 6.17).  
6.14 Permanent Discontinuation of Trial Drug Per ProtocolNo original text e)Annual calcitonin measurement â‰¥ 50 ng/L 
[ADDRESS_307506].  Upon completion of the study, all used and unused remaining EQW or matching placebo, empty containers, 
and copi[INVESTIGATOR_252704] (or designee). A clinical supplies return authorization form will be prepared by [CONTACT_252800]. The clinical supplies return form should 
be enclosed with the return drug shipment.  
The study site personnel must maintain documentation of any missing or unreturned study medication.A drug disposition form will be provided to 
record all study medication dispensed to or returned from each subject.  U pon 
completion of the study, all used and unused remaining EQW or matching placebo, empty 
containers, and copi[INVESTIGATOR_252705] (or designee). A clinical supplies return authorization form will be prepared by [CONTACT_252800]. The clinical supplies return form should 
be enclosed with the return drug shipment; 
however, if the site manager/CRA approves, the site can destroy the material instead of returning the used and unused study drug.  The study site personnel must maintain documentation of any missing or unreturned 
study medication.
10.1 
DefinitionsEvents meeting the above definition as SAEs 
and will be recorded in the safety trial database as either Clinical or Ancillary Events (definitions and criteria are summarized in Table 1).
Serious Adverse Event (SAE)
This is defined as any untoward medical 
occurrence or effect in a patient treated on a study protocol which does not necessarily have a causal relationship with the study treatment, that also, at any dose:
!Results in death
!Is life-threatening
!Results in persistent or significant or 
disability/incapacity
!Requires in-patient hospi[INVESTIGATOR_252706]
!Results in a congenital anomaly or 
birth defect
!Is otherwise medically significant (i.e. 
withdrawal reactions, all accidental or intentional overdoses of study 
medication whether they result in an 
adverse event or not, or any event which the investigator considers significant but which is not covered by [CONTACT_31714].)Text removed
Serious Adverse Event (SAE)
This is defined as any untoward medical 
occurrence or effect in a patient treated on a study protocol which does not necessarily have a causal relationship with the study treatment, that also, at any dose:
!Results in death
!Is life-threatening
!Results in persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions
!Requires in-patient hospi[INVESTIGATOR_252706]
!Results in a congenital anomaly or 
birth defect
!Is otherwise medically significant (i.e. 
withdrawal reactions, all accidental or 
intentional overdoses of study 
medication whether they result in an adverse event or not, or any event which the investigator considers significant but which is not covered by [CONTACT_31714].)
[ADDRESS_307507]â€™s participation, including the [ADDRESS_307508]-trial drug follow-up period or 
withdrawal.  Adverse events reported by [CONTACT_252801] a given event meets the criteria for a serious event (described in Section 10.1).  Any adve rse event that does 
not meet the definition of a serious event will 
be considered non-serious and will not be 
recorded.Adverse events will be monitored over the 
course of the trial, starting from the time of randomization and through the duration of the subjectâ€™s participation, including the [ADDRESS_307509]-trial drug follow-up period or 
withdrawal.  Adverse events reported by [CONTACT_252801] a given event meets the criteria for a serious event (described in Section 10.1).  Any adve rse event that does 
not meet the definition of a serious event will 
be considered non-serious and will not be 
recorded in the eCRF, with the exception of events noted in Section 10.3.
10.[ADDRESS_307510] (Appendix 1).  The Clinical Events List is inclusive of SAEs th at are: (1) com ponents of 
the primary or secondary composite 
cardiovascular endpoi nts, (2) ot her trial 
endpoints, (3) potential components of the CV endpoint that are included among terms sent for review by [CONTACT_15741]; (4) expected sequelae of type 2 diabetes; (5) expected 
events based on information noted in the 
exenatide investigator brochure.  SAE which meet these criteria will be reported in the Clinical Events eCRF module .  SAE which 
are not included on the Clinical Events List will be considered Ancillary events and will 
be reported in the Ancillary Events eCRF 
module .
The Clinical Events List will be reviewed and 
the eCRF will be completed during every visit to determine if a patient has experienced 
one or more of the listed events.  SAE should 
be reviewed for all patients randomized regardless of whether the patient is currently on trial medication. SAEs will be recorded in the Clinical Events 
or SAE eCRF modules. Guidelines for 
events which qualify as Clinical Events are provided in Appendix 1. Events to be recorded in the Clinical Events eCRF
module include SAEs that are: (1) 
components of the primary or secondary composite cardiovascular endpoints, (2) other trial endpoints, (3) potential components of the CV endpoint that are included among terms sent for review by [CONTACT_15741]; (4) 
expected sequelae of type 2 diabetes  (Table 
1).  These events represent trial outcomes and expected events for this population.  In addition, non-serious adverse events of stress tests, severe hypoglycemia, diabetic eye disease, foot ulcer, microalbuminurea, 
proteinuria, hyperlipi[INVESTIGATOR_035] / dyslipi[INVESTIGATOR_035], 
hypertension, and gout also will be recorded in the Clinical Events eCRF module (see 
Appendix I).
Any SAE which is not included among the 
expected events on the Clinical Events List 
will be recorded in the SAE eCRF module. 
Events of neoplasia and pancreatitis should 
be reported on the SAE eCRF even if the 
event does not meet serious criteria.
Note: The events listed in Appendix 1 are 
Clinical Events that are trial endpoints or 
expected events for this population, and do not generally fit the definition of a S[LOCATION_003]R,including those events with an outcome of 
death.  However, if the investigatorâ€™s 
assessment of an event is that it meets 
S[LOCATION_003]R criteria despi[INVESTIGATOR_252687] a 
Clinical Event, the event may be reported as a S[LOCATION_003]R as long as it does not require adjudication.  If the investigator feels that a Clinical Event meets S[LOCATION_003]R criteria the SAE eCRF should be used to report the 
event.
The Clinical Events List will be reviewed and 
the eCRF will be completed during every visit to determine if a patient has experienced one or more of the listed events.  SAE should 
be reviewed for all patients randomized 
regardless of whether the patient is currently on trial medication.
71
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
10.3.2 Safety 
Reporting(Formerly Section 10.3) SAE recorded on the 
Clinical Events eCRF represent those events which are components of the composite CV endpoint, other trial endpoints, potential components of the CV endpoint that require 
adjudication, expected sequelae of T2DM, or 
are expected based on information provided in the exenatide investigator brochure.  Clinical events will be monitored by [CONTACT_252802], probably or 
definitely drug-related and meet SAE criteria.
Regardless of relationship to trial drug, 
Clinical Events will not be reported by [CONTACT_252803], nor in 
the format of a line listing as part of an 
Annual Safety Report.   Events reported via 
this module will be regularly monitored by [CONTACT_252804] a trial endpoint will be 
adjudicated by [CONTACT_15741]. 
As described above, all SAEs that are not 
included in the Clinical Events List will be recorded by [CONTACT_252805].  These events must be recorded in this module (or faxed to Lilly if EDC is 
unavailable) within 1 day of a trial site 
becoming aware of the event.  Brief information on the clinical course of the event, treatment, and relevant diagnostic, laboratory or other investigations will be collected on the eCRF. All epi[INVESTIGATOR_252707].  All Ancillary Events will be reported to the appropriate regulatory agencies in a manner and timeframe consistent with all applicable laws and 
regulations (Section 10.3.1). 
Note: Events which meet the criteria to be 
classified as an Ancillary Event which result in death and are deemed to be possibly related to study drug will be collected and 
reported as Ancillary Events.The DSMB will monitor the totality of 
collected safety data (i.e. events recorded on both the Clinical Events and SAE eCRFs) on a semi-annual basis regardless of event classification.  SAE recorded on the Clinical 
Events eCRF represent those events which 
are components of the composite CV endpoint, other trial endpoints, potential components of the CV endpoint that require adjudication or are expected sequelae of T2DM.  SAE recorded as Clinical Events, 
including death related to an event in the 
Clinical Events List, and will not be reported 
to the Sponsor, regulatory agencies or ethics 
committees, regardless of relationship to 
trial drug even though they may be 
considered possibly, probably or definitely 
drug-related and meet SAE criteria. In 
addition to the un-blinded review by [CONTACT_4318], events reported via this module thatmay be associated with a trial endpoint will be adjudicated by [CONTACT_15741]. As described 
above, all SAEs that are not included in the 
Clinical Events List will be recorded by [CONTACT_252741].  These events must be recorded in this module (or faxed to Lilly if EDC is unavailable) within [ADDRESS_307511] to expedited reporting as per current legislation.  Brief information on the clinical course of the event, treatment, and relevant diagnostic, laboratory or other investigations will be collected on the eCRF. 
All epi[INVESTIGATOR_252666].  All events recorded in the SAE eCRF module will be reported to the appropriate regulatory agencies in a manner and timeframe 
consistent with all applicable laws and 
regulations (Section 10.3.2). All S[LOCATION_003]RS
will be reported in an expedited manner with the exception of those fulfilling the criterion of an efficacy endpoint (as detailed in Section 
1 of Appendix 1: Primary or Secondary Trial 
Endpoints) which will be handled as Clinical Events.
72
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
10.3.3 Sponsor 
Responsibility for Reporting Serious Adverse 
Events(Formerly Section 10.3.1)
The Sponsor will ens ure that all appropriate 
regulatory agencies confirm that the approach for monitoring Clinical Events, described in the Safety Assessments Section is acceptable 
to them.  All Ancillary SAE will be reported 
to regulatory agencies, IRB/IECs, and investigators in accordance with all applicable global laws and regulations.The Sponsor will ensure that all appropriate 
regulatory agencies confirm that the approach for monitoring Clinical Events, described in the Safety Assessments Section is acceptable to them.  SAE that are not recorded as Clinical 
Events will be reported to regulatory agencies, 
IRB/IECs, and investigators in accordance with all applicable global laws and regulations.
10.4 Calcitonin MonitoringCalcitonin concentrations will be monitored at 
baseline, annually and at trial/early termination.  Investigators and participants 
will be blinded to calcitonin values.  If the 
baseline value exceeds 100 ng/L, the site will be informed and directed to have the patient terminate study medication.  If a concerning calcitonin value is identified during trial follow-up, the site investigator will be 
notified and will alert the usual care 
physician.  Calcitonin concentrations will be monitored by [CONTACT_4318], which will include a thyroid expert.  Calcitonin concentrations will be monitored at 
baseline, annually and at trial/early termination.  Investigators and participants 
will be blinded to calcitonin values.  If the 
baseline value exceeds 40 ng/L, the site will be informed and directed to have the patient terminate study medication.  If a concerning calcitonin value ( â‰¥50 ng/L) is identified 
during trial follow-up, the site investigator 
will be notified and will alert the usual care 
physician and study medication will be discontinued.  Calcitonin concentrations will be monitored by [CONTACT_4318], which will include a thyroid expert.  
10.[ADDRESS_307512] the trial hotline physician, available 24hrs/day to discuss the case and determine 
the course of action; however, it is the 
prerogative of the treating physician to insist that their patient should be unblinded.
73
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
12.4 Clinical 
Events Committee (CEC)The events which constitute the principal 
endpoints of this trial will be adjudicated by [CONTACT_252806] (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which 
will be comprised of approximately 5-7 
physicians and a coordinator.  The specific endpoints to be adjudicated include:  cause of death (cardiovascular-related vs. non-cardiovascular), MI, stroke, acute coronary syndrome, and CHF requiring hospi[INVESTIGATOR_059]. 
Clinical reviewers will be board certified or 
board eligible endocrinologists, cardiologists, neurologists, gastroenterologists, or physicians with clinical expertise and prior clinical event classification experience. The CEC will review clinical data and adjudicate 
safety and efficacy endpoints.  The CEC will 
adjudicate clinical events using pre-specified criteria and definitions for the diagnoses of MI, stroke, acute coronary syndrome, and CHF requiring hospi[INVESTIGATOR_059].  The CEC will 
be blinded to the assigned trial drug. Sites 
will provide clinical information via the eCRF and also provide supplemental information from medical records, when needed. The CEC operations and endpoint criteria will be described in a separate 
charter. The events which constitute the principal 
endpoints of this trial will be adjudicated by [CONTACT_252806] (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which 
will be comprised of approximately 5-7 
physicians and a coordinator.  The specific endpoints to be adjudicated include:  cause of death (cardiovascular-related vs. non-cardiovascular), MI, stroke, acute coronary syndrome, pancreatitis, neoplasm, ventricular 
fibrillation/tachycardia, and CHF requiring 
hospi[INVESTIGATOR_059]. Clinical reviewers will be board certified or board eligible endocrinologists, cardiologists, neurologists, gastroenterologists, or physicians with 
clinical expertise and prior clinical event 
classification experience. The CEC will 
review clinical data and adjudicate safety and efficacy endpoints.  The CEC will adjudicate clinical events using pre-specified criteria and definitions.  The CEC will be blinded to the 
assigned trial drug. Sites will provide 
clinical information via the eCRF and also provide supplemental information from medical records, when needed. The CEC operations and endpoint criteria will be described in a separate charter. 
References No original text 13. Buse JB, Bergenstal RM, Glass LC, 
Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a 
randomized, controlled trial. Ann Intern 
Med. 2011;154(2):103-112.
Appendix [ADDRESS_307513] (TO BE 
INCORPORATED INTO ECRF)
The following list of events would be 
recorded in the eCRF at the time of the trial visit, but not reported to the Sponsor or 
regulatory agencies urgently regardless of 
relationship to trial drug. Included are trial endpoints as well as events that are expected 
to occur in this trial population. CLINICAL EVENTS LIST (TO BE 
RECORDED IN THE CLINICAL EVENTS eCRF)
Deleted existing text
74
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
Appendix 1 I. A.  Obvious trial endpoints (These events 
will prompt the investigator to complete an endpoint package which will then be adjudicated according to the Clinical Events Classification [CEC] charter)  
   
   Death
!Cardiovascular (CV) Death (i.e., fatal 
myocardial infarction [MI]/cerebrovascular accident [CVA]/ congestive heart failure 
[CHF]/arrhythmia, cardiac arrest, death 
following CV intervention)
!Non-CV DeathI.A.  Obvious trial endpoints (These events 
will prompt the investigator to complete an endpoint package which will then be adjudicated according to the Clinical Events Classification [CEC] charter)  
Death
!Cardiovascular (CV) Death (i.e., fatal 
myocardial infarction [MI]/cerebrovascular accident [CVA]/ congestive heart failure 
[CHF]/arrhythmia, cardiac arrest, death 
following CV intervention)
!Deleted existing text
Appendix 1 Section II. C. Hypoglycemia / Hyperglycemia 
/Diabetic ketoacidosis / Hyperosmolar 
hyperglycemic nonketotic comaSection II. C. Severe hypoglycemia / 
Hyperglycemia /Diabetic ketoacidosis / 
Hyperosmolar hyperglycemic nonketotic coma
Appendix 1 No original text Added  the term â€œ(including non-serious 
events)â€ to the existing events:
-stress test-diabetic eye disease-diabetic neuropathy-diabetic nephropathy
-metabolic conditions associated with diabetes
75
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 01 TEXT AMENDMENT 02 TEXT
Appendix 1 III. Terms listed in the exenatide 
Investigator Brochure
A. Allergic/Hypersensitivity Reactions
!Injection site reactions
!Pruritis and/or urticaria
!Rash
!Angioedema
!Anaphylactic reaction
B. Gastrointestinal reactions
!Nausea
!Vomiting and/or diarrhea 
resulting in dehydration
!Abdominal distension or pain
!Eructation
!Constipation
!Flatulence
!Diarrhea 
C. Renal and Urinary Disorders
!Altered renal function, including 
acute or worsened chronic renal failure 
!Renal impairment
!Increased serum creatinine 
D. Development of antibodies to 
exenatide
E. For all other terms please refer to the 
current Investigator BrochureDeleted Section III.
76
EXSCEL Protocol Amendment 06
APPENDIX 5 PROTOCOL AMENDMENT 03: SUMMARY OF CHANGES
Exenatide QW Clinical Study Protocol BCB109
PROTOCOL TITLE: A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO 
EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE 
WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Protocol Number: BCB109Amendment Number: 03Amendment Purpose: Date: 23 April 2012
The purpose of Amendment 03 is to alter inclusion criteria to allow patients with an HbA1c â‰¥6.5% and using 
insulin, alone or in combination with oral antihyperglycemic medications, to be eligible to enroll in the study.  In 
addition, the requirement for patients to have been on a stable dose of oral antihyperglycemic medication has been 
removed.  Additional safety language regarding hypoglycemia has been included for patients using concomitant insulin and/or sulfonylurea.  In addition, patients discontinued due to pregnancy can resume study medication following completion of the pregnancy and cessation of breastfeeding (if applicable).  Finally, clarifications regarding events requiring adjudications were added.  Minor editorial changes have also been included to improve clarity and consistency.  Notable changes are detailed in the table below.
SECTION AMENDMENT [ADDRESS_307514] of the 
StudyThe addition of BY[CONTACT_252807] (not currently an approved 
indication) has also been demonstrated toimprove glycemic control without an increased risk of hypoglycemia in patients receiving concomitant diet/exercise, metformin, or metformin+pi[INVESTIGATOR_252670] (exenatide 
enhances insulin secretion in a 
glucose-dependent manner, thus minimizing the risk of hypoglycemia in the absence of an insulin secretagogue) (13). Exenatide once weekly (EQW), a new formulation of exenatide that is administered once weekly 
rather than twice daily, is under development 
and currently being reviewed by [CONTACT_55257].The addition of BY[CONTACT_252807] (not currently an approved 
indication) has also been demonstrated to 
improve glycemic control without an increased 
risk of hypoglycemia in patients receiving concomitant diet/exercise, metformin, or metformin+pi[INVESTIGATOR_252670] (exenatide 
enhances insulin secretion in a 
glucose-dependent manner, thus minimizing the risk of hypoglycemia in the absence of an insulin secretagogue) (13). Exenatide once weekly (EQW), a new formulation of exenatide that is administered once weekly rather than 
twice daily, has been approved by [CONTACT_252808] [ADDRESS_307515] not achieved adequate glycemic control. is under development and currently 
being reviewed by [CONTACT_55257].
Section 2.2
Secondary 
Objectives(4) Hospi[INVESTIGATOR_19934] (CHF) (4) Hospi[INVESTIGATOR_252708] (CHF)
Section [ADDRESS_307516] type 2 diabetes with 
a glycated hemoglobin (HbA 1c) â‰¥7.0 % and 
â‰¤10.0 % on stable doses of up to three (i.e. 0-3) 
oral antihyperglycemic agents (AHAs) for at least [ADDRESS_307517] 3 months. A stable dose of insulin (Â±20% of the scheduled total daily insulin 
dose), either alone or in combination with a 
stable dose of metformin for at least [ADDRESS_307518] type 2 diabetes with 
a glycated hemoglobin (HbA
1c) â‰¥7.0 % an 
HbA 1câ‰¥6.5% and â‰¤10.0 % on stable doses of
up to three (i.e., 0-3) oral antihyperglycemic 
agents (AHAs) for at least [ADDRESS_307519] 3 months. A 
stable dose of or insulin either alone or in 
combination with up to 2 (i.e., 0-2) oral AHAs.
(Â±20% of the scheduled total daily insulin 
dose), either alone or in combination with a 
stable dose of metformin for at least 3 months, 
will also be permitted.
Section 4.1
Design 
DescriptionPer usual care, HbA 1cvalues should be 
measured locally using a NGSP (National 
Glycohemoglobin Standardization Program) certified HbA
1cassay (12).Per usual care, HbA 1cvalues should be 
measured locally. using a An NGSP (National 
Glycohemoglobin Standardization Program) 
certified HbA 1cassay should be used if 
available (12).
[ADDRESS_307520] their 
vital status ascertained, if possible, at the end 
of the trial.
Section 5.1
Inclusion 
Criteriac. Patient has an HbA 1c of â‰¥ 7.0 % and 
â‰¤10.0%
!A stable dose of up to three (i.e., 0-3) 
oral AHAs for at least 3 months will be allowed ( i.e.no oral AHA 
adjustments in the past 3 months).  o Concomitant use of DPP-4 
inhibitors is permitted.  
oA stable dose of insulin (Â±20% of 
the scheduled total daily insulin dose) either alone or in combination with a stable dose of 
metformin for at least 3 months 
is permitted. The use of basal and prandial insulins is permitted in any combination of individual or premixed insulins. If the prescribed insulin regimen 
includes adjustments, the total 
dose should not vary by [CONTACT_726] 20% from day to day over the preceding [ADDRESS_307521] recent reported value should be used.  A patient whose HbA
1c
is>10.0% may, at the discretion of the 
investigator, have their oral AHA or insulin therapy adjusted and be re-screened once for HbA
1c randomization eligibility ( â‰¥7.0 % and 
â‰¤10.0%) following a 3-month period on stable 
AHA doses.c. Patient has an HbA 1c of â‰¥6.5 % â‰¥ 7.0 %
and â‰¤10.0% and is currently using one of 
the following treatment regimens:
!Treatment with up to three (i.e., 0-3) 
oral AHAs (concomitant use of DPP-4 inhibitors is permitted).
!Insulin therapy, either alone or in 
combination with up to two (ie., 0-2) 
oral AHAs (use of basal and prandial insulins is permitted in any combination of individual or premixed insulins)
All patients should be on a stable diabetes 
management regimen, as assessed by [CONTACT_093], at the time of enrollment.
!
A stable dose of up to three (i.e., 0-3) 
oral AHAs for at least 3 months will 
be allowed ( i.e.no oral AHA 
adjustments in the past 3 months).  
o Concomitant use of DPP-4 
inhibitors is permitted.  
oA stable dose of insulin (Â±20% of 
the scheduled total daily insulin 
dose) either alone or in 
combination with a stable dose of 
metformin for at least 3 months is 
permitted. The use of basal and 
prandial insulins is permitted in 
any combination of individual or 
premixed insulins. If the 
prescribed insulin regimen 
includes adjustments, the total 
dose should not vary by [CONTACT_26813] 20% from day to day over 
the preceding [ADDRESS_307522] recent reported value should be used.  A patient whose HbA
1c
is>10.0% may, at the discretion of the 
investigator, have their oral AHA or insulin therapy adjusted and be re-screened once for HbA
1c randomization eligibility ( â‰¥6.5 % 
â‰¥7.0 % and â‰¤10.0%). following a 3-month 
period on stable AHA doses
79
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 02 TEXT AMENDMENT 03 TEXT
Section 5.1
Inclusion 
CriteriaoHistory of ischemic stroke.  
Strokes not known to be 
hemorrhagic will be allowed as part of this criterion;oHistory of ischemic stroke; strokes
not known to be hemorrhagic will 
be allowed as part of this criterion;transient ischemic attacks (TIAs) are not included
Section 5.2Exclusion 
CriteriaNone Each patient meeting any of the following 
criteria will be excluded from this trial.
Section 5.2
Exclusion Criteriai. Patient has end-stage renal disease or an 
estimated glomerular filtration rate (eGFR) derived from serum creatinine (using the simple MDRD-4 formula) of <30 mL/min/1.73 m
2.i. Patient has end-stage renal disease or an 
estimated glomerular filtration rate (eGFR) derived from serum creatinine (using the simple MDRD-4 formula) of <30 mL/min/1.73 m
2(see Appendix 2).
Section 5.2
Exclusion 
CriteriaNOTE: Serum for calcitonin measurement will 
be drawn at baseline.  Patients may be 
randomized and initiate study medication prior to the results of the calcitonin measure being 
available.  If a randomized patient is found to 
have an exclusionary serum calcitonin concentration, they will stop study medication and patients will continue to have follow-up for vital status and be part of the intention totreat analysis.NOTE: Serum for calcitonin measurement will 
be drawn at baseline.  Patients may be 
randomized and initiate study medication prior to the results of the calcitonin measure being 
available.  If a randomized patient is found to 
have an exclusionary serum calcitonin concentration, they will stop study medication and patients will continue to have follow-up and be part of the Intent-to-Treat intention to 
treat analysis.
Section 6.1
Trial ProceduresAt baseline (Visit 1) patients will be provided 
with the patientsâ€™ instruction brochure and be trained by [CONTACT_252809].At randomization baseline (Visit 1) patients 
will be provided with the patientsâ€™ instruction
for use (IFU) brochure and be trained by [CONTACT_252810].
Section 6.[ADDRESS_307523] 
3 months, obtained as part of usual care prior to Visit 1 (recommended guidance for management of serum creatinine values will be provided to each site).
Section 6.[ADDRESS_307524] of care, serum creatinine 
should be, at minimum, among labs drawn 
annually.
80
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 02 TEXT AMENDMENT 03 TEXT
Section 6.4
Treatments 
AdministeredIf the need for drug discontinuation is 
confirmed, the patient will be invited back to 
the trial site for an unscheduled visit to explain the situation, to stop the study drug and to encourage the patient to continue follow up off study drug until the end of the trial.If the need for drug discontinuation is 
confirmed, the situation will be explained to the 
patient and the patient will be asked to stop the study drug and encouraged the patient will be 
invited back to the trial site for an unscheduled 
visit to explain the situation, to stop the study 
drug and to encourage the patient to continue 
follow up off study drug until the end of the trial.  If deemed necessary by [CONTACT_093], an unscheduled visit can be performed to discuss study drug discontinuation and the importance of subsequent follow up.
Section 6.6
Precautions to 
Minimize Rates 
of HypoglycemiaAt the screening/enrollment visit and all 
subsequent visits, the symptoms and 
appropriate management of hypoglycemia will be reviewed with participants.  At the screening/randomization enrollment visit 
and all subsequent visits, the symptoms and 
appropriate management of hypoglycemia will be reviewed with patients. participants
Section 6.6Precautions to 
Minimize Rates 
of HypoglycemiaNone Combination therapi[INVESTIGATOR_252709].  To minimize this risk, patients 
whose diabetes is well controlled may require a 
reduction in the insulin or sulfonylurea dose when allocated study medication.  EXSCEL will employ both patient- and investigator-directed education to minimize the risk of hypoglycemia.  Patients receiving 
sulfonylurea/insulin combinations will be 
explicitly reminded of the symptoms and proper management of hypoglycemia before starting study drug.  The EXSCEL study team will also provide investigators with training materials to demonstrate best practice for 
minimizing hypoglycemia risk in these 
patients.
Section 6.7
Laboratory and 
Anthropometric 
MeasurementsBlood pressure, heart rate, height, and body 
weight will be collected by [CONTACT_252811].Blood pressure, heart rate, height, and body 
weight will be collected by [CONTACT_252812] 2. in the flow chart
Section 6.10Resource 
Utilization 
Quality of Life Data for Economic EvaluationThis instrument will be administered at 
baseline, at 6 months and annually thereafter.This instrument will be administered at 
baseline, at 6 months, at subsequent annual 
visits, and at the trial/early termination visit. 
and annually thereafter
Section 6.11
Trial/Early 
Termination Visit and Post Trial Telephone Contact[CONTACT_8985] 6.[ADDRESS_307525] Trial Telephone 
Contact[CONTACT_8985] 6.11
End of Trial Trial/Early Termination Visit and 
Post Trial Telephone Contact
81
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 02 TEXT AMENDMENT 03 TEXT
Section 6.11
Trial/Early Termination Visit and Post Trial Telephone 
Contact[CONTACT_252813]/Early Termination Visit
Section 6.[ADDRESS_307526] a medication discontinuation visit (as described in Section 6.13) as soon as possible after 
stoppi[INVESTIGATOR_252710].Unless resumption of trial medication is 
considered unsafe or is refused by [CONTACT_102],
participant the patient will be expected to 
resume regular use of the blinded trial 
medication after a period of temporary 
discontinuation.  Should a patient participant
stop taking trial medication, either permanently or temporarily, the reasons for discontinuation and length of time the patient 
stopped taking trial medication will be 
assessed and recorded.  All randomized patients who permanently discontinue trial medication should have a drug terminationmedication discontinuation visit (as described 
in Section 6.13) as part of their next scheduled 
study visit (unless a separate drug termination 
visit at that point is deemed necessary by [CONTACT_093]). as soon as possible after 
stoppi[INVESTIGATOR_252710].
Section 6.12Early Discontinuation 
of Trial 
MedicationNone NOTE:  After trial medication is discontinued 
due to pregnancy, re-initiation of study 
medication can be considered following completion of the pregnancy and breastfeeding (if applicable).
[ADDRESS_307527] a drug termination medication discontinuation visit as 
part of their next scheduled visit (unless a separate drug termination visit is deemed 
necessary by [CONTACT_093]). soon as possible 
after stoppi[INVESTIGATOR_252710].  Necessary 
procedures are indicated in Appendix 2. the
Flow Chart.   All efforts should be made to 
reinforce with patients that this would be a 
medication discontinuation visit, not a trial
discontinuation visit. Patients will be asked to continue with all other trial follow up until the completion of the trial, including semi-annual in-person visits and/or telephone calls, as well as the annual calcitonin measurement.  IVRS should be contact[CONTACT_252814].
Section 6.14Permanent 
Discontinuation 
of Trial Medication Per Protocolb) Pregnancy, as confirmed by [CONTACT_252815]. 
Patient must stop taking blinded trial 
medication, and be followed if she becomes pregnant during the trial (Section 10.6)Deleted; remaining items in list renumbered
Section 6.[ADDRESS_307528] guidance by [CONTACT_252816]-titrating AHAs in the presence of hypoglycemia.
Section 6.14
Permanent 
Discontinuation 
of Trial Medication Per Protocold) Severe, irreversible renal dysfunction 
(eGFR <30 ml/min/1.73m
2) or renal 
replacement therapy.c) Severe, irreversible renal dysfunction 
(confirmed by [CONTACT_252767] 
<30 ml/min/1.73m2) or renal replacement 
therapy.
Section 6.15
Follow-up for 
Patients who Permanently Discontinue Trial MedicationEnd of Trial Visit End of Trial Trial/Early Termination Visit
Section 7.2
Formulation, 
Packaging, and 
StorageSpecific instructions for dose preparation of 
the injection will be provided in the Patient 
Instructions for Use (PIU).Specific instructions for dose preparation of the 
injection will be provided in the Patient 
Instructions for Use (IFU PIU).
[ADDRESS_307529].  Upon completion of the study, all used and unused remaining 
EQW or matching placebo, empty containers, 
and copi[INVESTIGATOR_252711] (or designee).A drug accountability log disposition form will 
be provided to record all study medication 
dispensed to or returned from each patientsubject.  Upon completion of the study, all used 
and unused EQW or matching placebo vialsempty containers, and copi[INVESTIGATOR_252712] (or designee).
Section 9.7
Secondary 
Analyses5. Hospi[INVESTIGATOR_19934] (CHF) 5. Hospi[INVESTIGATOR_252708] (CHF)
Section 9.8.[ADDRESS_307530] taken a study 
medication for the entire duration of the study 
that is different from that to which he/she was 
randomized then the patient is counted in the treatment group of the drug he/she actually received.  If a patient is found to have taken a study 
medication for any the entire duration of the 
study that is different from that to which he/she was randomized, then the patient is counted in the treatment group of the drug he/she actually received.  
Section 9.10Subgroup Analyses!Region (North/South America or Canada, 
Europe or South Africa, ROW)!Region (North/South America or Canada, 
Europe or South Africa, Rest of worldROW)
Section 10.3.1
Recording 
Adverse EventsSAEs will be recorded in the Clinical Events 
or SAE eCRF modules.SAEs will be recorded in the Clinical Events 
or SAE eCRF modules as appropriate (see 
Table 1).
Section 10.3.1
Recording 
Adverse EventsIn addition, non-serious adverse events of 
stress tests, severe hypoglycemia, diabetic eye 
disease, foot ulcer, microalbuminurea, proteinuria, hyperlipi[INVESTIGATOR_035]/dyslipi[INVESTIGATOR_035], hypertension, and gout also will be recorded in 
the Clinical Events eCRF module (see 
Appendix I).In addition, non-serious adverse events of 
percutaneous coronary intervention (PCI), 
stress tests, severe hypoglycemia, diabetic eye disease, foot ulcer, microalbuminuria, proteinuria, macroalbuminuria, hyperlipi[INVESTIGATOR_035]/
dyslipi[INVESTIGATOR_035], hypertension, or and gout also 
will be recorded in the Clinical Events eCRF
module (see Appendix 1).
84
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 02 TEXT AMENDMENT 03 TEXT
Section 10.3.1
Recording 
Adverse EventsNote: The events listed in Appendix 1 are 
Clinical Events that are trial endpoints or 
expected events for this population, and do not generally fit the definition of a S[LOCATION_003]R,including those events with an outcome of 
death.  However, if the investigatorâ€™s
assessment of an event is that it meets S[LOCATION_003]R 
criteria despi[INVESTIGATOR_252687] a Clinical Event, 
the event may be reported as a S[LOCATION_003]R as long as it does not require adjudication.  If the investigator feels that a Clinical Event meets S[LOCATION_003]R criteria the SAE eCRF should be used 
to report the event.Note: The events listed in Appendix 1 are 
Clinical Events that are trial endpoints or 
expected events for this population, and do not generally fit the definition of a S[LOCATION_003]R,including those events with an outcome of 
death.  However, if the investigatorâ€™s 
assessment of an event is that it meets S[LOCATION_003]R 
criteria despi[INVESTIGATOR_252687] a Clinical Event, 
the event may be reported as a S[LOCATION_003]R via the SAE eCRF as long as it is not a possible
Primary or Secondary trial endpoint (i.e. all 
events listed in Appendix 1 Section I).  If the 
investigator feels that a Clinical Event meets 
S[LOCATION_003]R criteria the SAE eCRF should be used 
to report the event.
Table 1 Table format updated for clarity
Section 10.3.2
Safety 
ReportingAll S[LOCATION_003]RS will be reported in an expedited 
manner with the exception of those fulfilling 
the criterion of an efficacy endpoint (as detailed in Section I of Appendix 1: Primary or Secondary Trial Endpoints) which will be handled as Clinical Events.All S[LOCATION_003]RS will be reported in an expedited 
manner with the exception of Primary and 
Secondary trial endpoints as detailed in Section I of Appendix 1, which will be handled as Clinical Events. fulfilling the criterion of an 
efficacy endpoint (as detailed in Section I of 
Appendix 1: Primary or Secondary Trial 
Endpoints) which will be handled as Clinical 
Events.
Section 10.4
Calcitonin 
MonitoringIf a concerning calcitonin value ( â‰¥50 ng/L) is 
identified during trial follow-up, the site 
investigator will be notified and will alert the usual care physician and study medication will be discontinued.  If a concerning calcitonin value ( â‰¥50 ng/L) is 
identified during trial follow-up, the site 
investigator will be notified and they should call the Trial Hotline for advice, where they will be instructed to alert the usual care provider and permanently discontinue study 
medication.  and will alert the usual care 
physician and study medication will be 
discontinued.  
Section 10.5.[ADDRESS_307531] the 
investigational site, and/or healthcare provider 
in the event of an overdose [ADDRESS_307532] the 
investigational site, and/or healthcare provider 
in the event of an overdose [ADDRESS_307533] (TO BE 
RECORDED IN THE CLINICAL EVENTS 
eCRF)CLINICAL EVENTS LIST (TO BE 
RECORDED IN THE CLINICAL EVENTS 
eCRF)
Any clinical event listed in this appendix that 
meets the criteria of an SAE (unless indicated 
otherwise below) must be reported in the Clinical Event eCRF reporting module.
85
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 02 TEXT AMENDMENT 03 TEXT
Appendix 1 Percutaneous Coronary Intervention (PCI) Percutaneous Coronary Intervention (PCI) â€“
including non-serious events
Appendix 1 C. Severe hypoglycemia / Hyperglycemia 
/Diabetic ketoacidosis / Hyperosmolar 
hyperglycemic nonketotic comaC. Severe hypoglycemia (including 
non-serious events) / Hyperglycemia 
/Diabetic ketoacidosis / Hyperosmolar 
hyperglycemic nonketotic coma
Appendix 1 F. Diabetic nephropathy (including non-
serious events)
!Microalbuminuria
!ProteinuriaF. Diabetic nephropathy (including 
non-serious events)
!Microalbuminuria
!Macroalbuminuria Proteinuria
Appendix 1 G. Renal failure/peritoneal or 
hemodialysis/renal transplant (including 
creation of fistula or other vascular access for hemodialysis) G. Renal failure/peritoneal or 
hemodialysis/renal transplant (including 
creation of fistula or other vascular access 
for hemodialysis)
!Acute renal failure, requiring or 
associated with hospi[INVESTIGATOR_059]
!Chronic renal failure, requiring 
peritoneal hemodialysis, including 
creation of fistula or other vascular access for hemodialysis
!Renal transplant
Appendix 2 [5]  Patients who terminate study medication 
are required to have a Drug Termination 
Visit as soon as possible following the 
cessation of study medication.  Patients will continue to be observed following the Drug Termination visit according to their planned visit schedule for the remainder of 
the trial.  All procedures for remaining 
Semi-annual and Annual Visits are to be followed with the exception of Drug Dispensation.[5] Patients who terminate study medication 
are required to have a Drug Termination 
Visit as part of their next scheduled study 
visit (unless a separate drug termination visit at that point is deemed necessary by [CONTACT_093]). as soon as possible 
following the cessation of study 
medication. Patients will continue to be 
observed following the Drug Termination visit according to their planned visit schedule for the remainder of the trial.  All procedures for remaining Semi-annual and Annual Visits are to be followed with the 
exception of Drug Dispensation.
Appendix 2 None [6]  It is recommended that serum creatinine 
value draw dates be within 3 months of randomization but up to 12 months is acceptable (however, if > 6 months old and value is between 30-40mL/min/1.73m
2 it is 
recommended that a new serum creatinine 
value is obtained as part of usual care).
Appendix 2 None [7]  Blood sample for genetic and genomic analysis 
may be collected at any time during the trial 
after consent is obtained.
Appendix 4 None Added Protocol Amendment 02 Summary of 
Changes
86
EXSCEL Protocol Amendment 06
APPENDIX 6 PROTOCOL AMENDMENT 04: SUMMARY OF CHANGES
Exenatide QW Clinical Study Protocol BCB109
PROTOCOL TITLE: A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO 
EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE 
WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Protocol Number: BCB109Amendment Number: 04Amendment Purpose: Date: [ADDRESS_307534] been included in the safety section to clarify reporting of serious adverse events, given 
the change in sponsorship.  Notable changes are detailed in the table below.
SECTION AMENDMENT 03 TEXT AMENDMENT 04 TEXT
Global Change Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, LLC
Title Page Eli Lilly and Company
Title Page Throughout this protocol, unless otherwise 
specified, the term â€œLillyâ€ is used to refer to 
Eli Lilly and Company and its affiliates, acting as a representative of Amylin Pharmaceuticals, 
Inc.  Amylin Pharmaceuticals, Inc. sponsors 
the Investigational New Drug Application in the US and Puerto Rico and will serve as the sponsor for the Clinical Trial Application in Canada.  Amylin Pharmaceuticals, Inc. 
transfers the clinical sponsor obligations to 
Lilly for the conduct of this study outside the US, Puerto Rico and Canada.  For investigative sites outside of the US, Puerto Rico and Canada, Lilly will serve as the study sponsor.  The applicable party will hereinafter be 
referred to as the â€œsponsorâ€.Amylin Pharmaceuticals, LLC sponsors the 
Investigational New Drug Application. 
List of 
AbbreviationsAlliance Amylin/Lilly exenatide consortium
Amylin Amylin Pharmaceuticals, Inc.Amylin Amylin Pharmaceuticals, LLC
Section [ADDRESS_307535] of approximately eleven 
individuals, comprising nine senior independent academic representatives who are experts in their field and sponsor representatives.  
Section 3
Trial 
GovernanceEXSCEL will be Co-Chaire  
 
ut sponsored and funded by 
[CONTACT_252817] (Amylin & Eli Lilly). EXSCEL will be Co-Chaired  
 
ut sponsored and funded by 
[CONTACT_252753]. 
Section 5.2Exclusion
Criteriao. Is an employee of Eli Lilly and Company 
or Amylin Pharmaceuticalso. Is an employee of Amylin Pharmaceuticals ,
LLC
87[COMPANY_003] [COMPANY_003]
EXSCEL Protocol Amendment [ADDRESS_307536] be recorded in this module 
(or faxed to Lilly if EDC is unavailable) within 
[ADDRESS_307537] be recorded in this module 
(or faxed to the number provided on the SAE 
report form if EDC is unavailable) within [ADDRESS_307538] be reported within the above timeline to Amylin/Eli Lilly.  Additionally, any SAE considered by [CONTACT_26368] a qualified physician to be possibly, probably, or definitely related to the 
investigational product that is brought to the 
attention of the investigator after study closeout must be reported within the above timeline. 
Section 10.6Reporting of PregnancyAll occurrences of pregnancy must be reported 
via the Lilly Pregnancy/Breastfeeding Exposure Form.  All occurrences of pregnancy must be reported 
via the Pregnancy/Breastfeeding Exposure Form.  
Appendix 5 None Added Protocol Amendment 03 Summary of 
Changes
88
EXSCEL Protocol Amendment 06
APPENDIX 7 PROTOCOL AMENDMENT 05: SUMMARY OF CHANGES
Exenatide QW Clinical Study Protocol BCB109
PROTOCOL TITLE: A RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO 
EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE 
WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Protocol Number: BCB109
Amendment Number: 05Amendment Purpose: Date: [ADDRESS_307539], a number of measures will be taken in 
protocol amendment 05:
1.  The power of the study to achieve the primary objective of superiority of exenatide once weekly versus placebo 
with regard to the primary composite CV endpoint has b een reduced from 90% to 85% resulting in a reduction of 
the targeted number of events from 1591 to 1360.
2.  The total number of patients to be enrolled in order to achieve the targeted number of events is being increased 
from 9500 to [ZIP_CODE].
3.  The proportion of patients enrolled with a prior history of a CV event is being increased from 60% to 80% (for 
newly enrolled patients).  Since more than [ADDRESS_307540] been enrolled under the 60:40 scheme, it is anticipated that the ratio of patients with prior history of CV event to those with no prior CV event will be approximately 70:30 
at study end.  It is anticipated that more than 4000 patients (around 30%) without any prior CV history will be 
enrolled in the study.
In addition, the following changes are being made throughout this protocol amendment:
4.  The secondary hypothesis of non-inferiority of exenatide on ce weekly compared with placebo with regard to the 
primary composite CV endpoint is updated to a primary safety hypothesis.
5.  The end of study procedures have been clarified.6.  Clarifications have been made to the specifications around withdrawal of consent, lost-to-follow-up procedures, 
and the follow-up phone call for safety purposes after end-of-study discontinuation of study treatment.
7.  Update to planned interim analyses as specified in the DSMB charter.
8.  Administrative changes, such as, requirements for reporting of a potential serious breach of GCP, record 
retention, source documentation, case report form completion and the Clinical Study Report have been made.
Notable changes are detailed in the table below.
89
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
Throughout Trial / Early Termination Visit Trial Termination Visit
1.[ADDRESS_307541] of the 
StudyExenatide once weekly (EQW), a new 
formulation of exenatide that is administered 
once weekly rather than twice daily, has been 
approved by [CONTACT_252818] [ADDRESS_307542] not achieved adequate glycemic control. Exenatide once weekly (EQW; BY[CONTACT_28578]), is 
an extended release formulation of exenatide that 
is administered once weekly rather than twice 
daily.  EQW has been approved by [CONTACT_252818] [ADDRESS_307543] to metformin, a sulfonylurea (SU), a 
thiazolidinedione (TZD), a combination of 
metformin and SU, or a combination of metformin and TZD therapy to improve glycemic control in adult patients with type [ADDRESS_307544] of EQW, used in conjunction 
with the current usual care for glycemic control, 
on major macrovascular events when administered to patients with type 2 diabetes.
Objective:  To compare the impact of including 
EQW as part of usual care vs. usual care 
without exenatide on major CV outcomes as measured by [CONTACT_252819], nonfatal myocardial infarction (MI), or nonfatal stroke.
Hypothesis:  EQW, when used as part of usual 
care, is superior to usual care without exenatide with regard to the risk of developi[INVESTIGATOR_007] a confirmed event in the primary CV composite endpoint. The primary objective of EXSCEL will be to 
evaluate the effect of EQW, used in addition to 
the current usual care for glycemic control, on 
major macrovascular events when administered to patients with type 2 diabetes.
Objective:  To compare the impact of including 
EQW in addition to usual care vs. usual care 
without EQW on major CV outcomes as measured by [CONTACT_252819], nonfatal myocardial infarction (MI), or nonfatal stroke.
Hypotheses:
Efficacy:  EQW, when used in addition to usual 
care, is superior to usual care without EQW with regard to the risk of developi[INVESTIGATOR_007] a confirmed event in the primary CV composite endpoint. 
Safety:  EQW, when used in addition to usual 
care, is non-inferior to usual care without EQW 
with regard to the risk of developi[INVESTIGATOR_007] a confirmed event in the primary CV composite endpoint.
2.[ADDRESS_307545] of EQW treatment used in conjunction with the current usual care for glycemic control on:The secondary objectives of EXSCEL are to 
evaluate the effect of EQW treatment used in addition to the current usual care for glycemic control on:
2.[ADDRESS_307546] of EQW treatment used in 
conjunction with the current usual care for glycemic control on:Additional objectives of EXSCEL are to 
evaluate the effect of EQW treatment used in 
addition to the current usual care for glycemic control on:
90
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
3  Trial 
Governance EXSCEL is a multinational pragmatic trial that 
will be conducted in approximately 500 sites worldwide.  It will be run jointly by [CONTACT_252724] (DCRI) and the University of Oxford Diabetes Trials Unit 
(DTU) Academic Research Organizations 
(AROs), in an academic collaboration with Amylin Pharmaceuticals, LLC (Amylin). EXSCEL will be Co Chaire
 
but sponsored and funded by 
[CONTACT_252753].
The EXSCEL Executive Committee (EC) will 
have overall responsibility for the oversight and management of the trial (Figure 1).  The EC will consist of approximately eleven 
individuals, comprising nine senior independent 
academic representatives who are experts in their field and two sponsor representatives.  It will be Co-Chaired 
with other academic 
members comprising four further diabetologists 
and three further cardiologists.  Geographical balance will be sought.  Decision making will be by [CONTACT_21128].  EXSCEL is a multinational pragmatic trial that 
will be conducted in approximately 800 sites worldwide.  It will be run jointly by [CONTACT_252724] (DCRI) and the University of Oxford Diabetes Trials Unit 
(DTU) Academic Research Organizations 
(AROs), in an academic collaboration with Amylin Pharmaceuticals, LLC (Amylin), a wholly owned subsidiary of Bristol-Myers Squibb. EXSCEL will be Co Chaire
 
and sponsored and 
funded by [CONTACT_252753].
The EXSCEL Executive Committee (EC) will
have overall responsibility for the oversight and management of the trial (Figure 1).  The EC will consist of senior independent academic 
representatives who are experts in their field and 
sponsor representatives.  It will be Co-Chaired 
 
(see Section 12.1).  
91[COMPANY_003]
P
PD
[COMPANY_003][COMPANY_003]
EXSCEL Protocol Amendment [ADDRESS_307547] type 2 diabetes with an HbA1c â‰¥6.5% 
and â‰¤10.0 % on up to three (i.e., 0-3) oral 
AHAs or insulin either alone or in combination 
with up to 2 (i.e., 0-2) oral AHAs.  Patients enrolled will be at a wide range of CV risk with approximately 60% having had a prior CV event.
Approximately 9500 patients meeting all 
enrollment criteria will be recruited in to the 
trial over an approximately three year period, randomly allocated to treatment with either EQW 2 mg or matching placebo subcutaneous injections once weekly in a 1:[ADDRESS_307548] (DSMB) advises otherwise.  
The trial will assess the impact of EQW therapy 
upon CV outcomes in a large population from a 
heterogeneous group of countries and practice environments.  Approximately one-third of patients will be enrolled in the Americas (North/South America & Canada), one-third in Europe and one-third in the Asia/Australasia.  
Given that this population will be at elevated 
CV risk, it is anticipated that patients will see their usual care provider at least twice per year for routine care.  Trial follow up will consist of a blend of trial visits and phone calls during the double-blind placebo-controlled treatment 
period, which is expected to provide an average 
5.[ADDRESS_307549] type 2 diabetes with an HbA1c âˆ€6.5% 
and #10.0 % on up to three (i.e., 0-3) oral 
antihyperglycemic agents (AHAs) or insulin 
either alone or in combination with up to 2 (i.e., 0-2) oral AHAs.  Patients enrolled will be at a 
wide range of CV risk with approximately 70% 
having had a prior CV event (see Section 6.3).
Approximately 14,000 patients meeting all 
enrollment criteria will be recruited in to the trial over approximately a five year period, randomly allocated to treatment with either EQW 2 mg or 
matching placebo subcutaneous injections once 
weekly in a 1:[ADDRESS_307550] (DSMB) advises otherwise.  It is anticipated that the EXSCEL Executive Committee will monitor the accrual of the aggregate number of adjudicated primary 
endpoint events and will determine the primary 
endpoint event cut-off date (i.e., the date at which the anticipated number of events is expected to have accrued); all patients will be expected to have follow-up through this date (Section 6).
The trial will assess the impact of EQW therapy 
upon CV outcomes in a large population from a heterogeneous group of countries and practice environments; patients will be enrolled in the Americas (North/South America), Europe and Asia/Australasia.  Given that this population will 
be at elevated CV risk, it is anticipated that 
patients will see their usual care provider at least twice per year for routine care.  Trial follow up will consist of a blend of trial visits and phone calls during the double-blind placebo-controlled treatment period. 
[ADDRESS_307551] Trial Access to TherapyNew Section in Amendment 05 At the end of the trial, the sponsor will not 
continue to supply study drug to patients/investigators. The investigator should ensure that the patient receives appropriate standard of care to treat the condition under 
study according to national treatment guidelines.
5.1  Inclusion 
Criteriad.  Patients with any level of CV risk and 
meeting all other inclusion criteria may be enrolled. Recruitment will be constrained such that approximately 40% will not have had a prior CV event and 60% will have had a prior 
CV eventd.  Patients with any level of CV risk and 
meeting all other inclusion criteria may be enrolled. Recruitment will be constrained (see Section 6.3) such that approximately 30% will not have had a prior CV event and 70% will 
have had a prior CV event
5.[ADDRESS_307552] e.g., BY[CONTACT_252747] (exenatide), EQW, VICTOZA (liraglutide),or taspoglutide
o.  Is an employee of Amylin Pharmaceuticals, 
LLC. c.  Patient has ever been treated with an 
approved or investigational GLP-[ADDRESS_307553] e.g., BY[CONTACT_252747] (exenatide), BY[CONTACT_28578] (EQW), VICTOZA (liraglutide), LYXUMIA (lixisenatide), albiglutide, taspoglutide, or dulaglutide
o.  Is an employee of Amylin Pharmaceuticals, 
LLC, Bristol-Myers Squibb Company, or [COMPANY_008] 
[ADDRESS_307554] been accrued.  It is anticipated that the EXSCEL Executive Committee will monitor the accrual of the 
aggregate number of adjudicated primary 
endpoint events and will determine the primary endpoint event cut-off date (i.e., the date at which the anticipated number of events is expected to have accrued; all patients will be expected to have follow-up through this date).  
Based on the primary endpoint event cut-off 
date, a window of time for conduct of the Trial Termination Visit will be established.
NOTE:  Patients who have temporarily or 
permanently discontinued trial medication should continue with their regular visit schedule.  
ALL patients should have a Trial Termination 
Visit (including patients who have previously discontinued trial medication). 
After the Trial Termination Visit patients will be 
contact[CONTACT_252820][INVESTIGATOR_252713] [ADDRESS_307555] their final 
assessment of serious adverse experiences and hospi[INVESTIGATOR_252714].
Note that all serious adverse experiences, 
hospi[INVESTIGATOR_602], and reportable study events 
with an onset date after the primary endpoint 
event cut-off date established by [CONTACT_252744] (see Section 10.3.1).
6.3  Method of Assigning 
Patients to 
Treatment Groups (Visit 1)New addition in Amendment 05 The IVRS will be programmed to ensure the 
expected overall proportion of randomized 
patients with a prior CV event is approximately 
70%.  With transition to Amylin-labeled trial medication (beginning in 2013), the IVRS was programmed to ensure at least 80% of newly randomized patients have a history of a prior CV event (previously was programmed to ensure 
approximately 60% of patients had a prior CV 
event).
94
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
6.5  Concomitant 
TherapyDuring the double-blind treatment period, 
investigators are expected to monitor patientsâ€™ AHA regimens and communicate with usual care providers, who will be responsible for adjusting the AHA regimen in order to achieve
locally-appropriate HbA1c goals.  The 
Executive Committee (EC) and Operations Committee (OC) will provide a brief list of guidelines for usual care based on clinical care practice guidelines published by [CONTACT_252821] T2DM evolves over the 
course of the trial.  During the double-blind treatment period, 
investigators are expected to monitor patientsâ€™ AHA regimens and communicate with usual care providers, who will be responsible for adjusting the AHA regimen in order to achieve locally-
appropriate HbA1c goals based on clinical care 
practice guidelines published by [CONTACT_252761].  
6.[ADDRESS_307556] practice for minimizing 
hypoglycemia risk in these patients.
6.9  Genetic and 
Biomarker Sample 
CollectionPatients enrolled in the trial will be asked to 
consent separately to provide one serum sample, one plasma sample, and one urine sample for 
future biomarker analyses.  These specimens 
(preferably fasting) will be obtained at baseline (prior to drug exposure), annually and trial/early termination.  All samples will be divided and stored in 2 aliquots at the Laboratory Corporation of America facility in Kannapolis, 
North Carolina, [LOCATION_003].In addition, a subset of patients enrolled in the 
trial will be asked to consent separately to provide one serum sample, one plasma sample, 
and one urine sample for future biomarker 
analyses.  These specimens (preferably fasting) will be obtained at baseline (prior to drug exposure), year 1 and at the Trial Termination visit.
95
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
6.11  Temporary 
or Permanent Discontinuation of Trial MedicationAmendment 04 Section 6.12 Temporary 
Discontinuation of Trial Medication, Section 6.13 Permanent Discontinuation of Trial Medication Visit Procedures, and Section 6.15 Follow-up for Patients who Permanently 
Discontinue Trial Medication, were combined 
in Amendment 05 Section 6.11Following randomization, it is expected that 
patients will remain on study medication for the duration of trial participation. However, it is recognized that patients may need to discontinue trial medication, in some cases permanently, for 
when protocol-specified reasons apply (Section 
6.12), due to the judgment of the primary investigator or the decision of the patient.  The Trial Hotline should be contact[CONTACT_252764] a site is considering interrupting or discontinuing trial medication (Section 6.18).
Unless resumption of trial medication is 
considered unsafe or is refused by [CONTACT_102], the patient will be expected to resume regular use of the blinded trial medication after a period of temporary discontinuation.  Should a patient stop taking trial medication, either permanently 
or temporarily, the reasons for discontinuation 
and length of time the patient stopped taking trial medication will be assessed and recorded.
All randomized patients who permanently 
discontinue trial medication should have a drug 
termination visit as part of their next scheduled 
study visit (unless a separate drug termination visit at that point is deemed necessary by [CONTACT_093]).  Necessary procedures are indicated in Appendix 2.  All efforts should be made to reinforce with patients that this would 
be a medication discontinuation visit, not a trial 
discontinuation visit; patients should continue with their regular visit schedule until the end of the trial, including semi-annual in-person visits, as well as the annual calcitonin measurement.  If patients cannot attend visits in person, they will 
be followed via telephone contact [CONTACT_252822].  
NOTE:  After trial medication is discontinued 
due to pregnancy, re-initiation of study medication can be considered following completion of the pregnancy and breastfeeding 
(if applicable).
6.12  Permanent 
Discontinuation of Trial Medication Per ProtocolNote:  The patient and the Investigator will 
notify the usual care provider of severe hypoglycemic events. The usual care provider should make a thorough attempt to down-titrate and/or modify co-interventional and baseline 
therapi[INVESTIGATOR_252715]. The usual care provider will be provided with standard guidance by [CONTACT_252823]-titrating AHAs in the presence of hypoglycemia.Note:  The patient and the Investigator will 
notify the usual care provider of severe hypoglycemic events. The usual care provider should make a thorough attempt to down-titrate and/or modify co-interventional and baseline 
therapi[INVESTIGATOR_252715].
[ADDRESS_307557]-
Treatment Telephone 
Contact[CONTACT_11827] 04 Section 6.11 Trial/Early 
Termination Visit and Post-Trial Telephone Contact [CONTACT_252824] 6.[ADDRESS_307558] of the Trial Termination Visits will be established; this window will be a period of time following the primary endpoint event cut-off date.  At the Trial Termination Visit, all patients must be 
discontinued from trial medication; the 
investigator should ensure that the patient receives appropriate standard of care. For procedural details of the Trial Termination Visit, refer to Appendix 2.
NOTE:  All patients should have a Trial 
Termination Visit. (Patients who have 
discontinued trial medication prior to the end of the trial must, at minimum, have a Trial Termination telephone contact.)
If a patient fails to return or otherwise becomes 
difficult to contact, it is the investigatorâ€™s 
responsibility to make every effort to maintain contact [CONTACT_252825]/or endpoint 
adjudication as of the primary endpoint event 
cut-off date.
6.[ADDRESS_307559] been discontinued from trial medication for more than 70 days as of the Trial Termination Visit, the Trial Termination Visit will be the final study 
follow-up.  Note that all serious adverse 
experiences, hospi[INVESTIGATOR_602], and reportable study events with an onset date after the primary endpoint event cut-off date established by [CONTACT_252826] (see Section 10.3.1).
[ADDRESS_307560] with him/her or persons 
previously authorized by [CONTACT_252769]. 
Patients should notify the investigator of the 
decision to withdraw consent from future follow-up in writing, whenever possible. The 
withdrawal of consent should be explained in 
detail in the medical records by [CONTACT_252770]. In the event that vital status (whether the patient is alive or dead) is being measured, publicly available information should be used to 
determine vital status only as appropriately 
directed in accordance with local law.
When a patient withdraws consent from future 
follow-up prior to trial completion, all applicable activities scheduled for the final trial visit should 
be performed at that time (Section 6.13).
[ADDRESS_307561] to follow-up is 
defined by [CONTACT_252771] 
a minimum of three documented phone calls, as well as lack of response by [CONTACT_252827]. All attempts should be documented in the patientâ€™s medical records. If it is determined that the patient has died, the site 
will use permissible local methods to obtain the 
date and cause of death.
If an investigatorâ€™s use of a third-party 
representative to assist in the follow-up portion of the study has been included in the patientâ€™s informed consent, then the investigator may use 
a Sponsor-retained third-party representative to 
assist site staff with obtaining patientâ€™s contact [CONTACT_53983]-up portion of the study. Where specific consent has been 
obtained from the participant, the site staff and 
representative will consult publicly available sources, such as public health registries and databases, in order to obtain updated contact [CONTACT_3031]. If after all attempts, the patient remains lost to follow-up, then the last known 
alive date as determined by [CONTACT_252828]â€™s medical records.
6.17  Breaking the Blind
AND10.7  UnblindingNew addition in Amendment 05 Patients whose treatment has been unblinded can 
continue to receive trial medication and can continue to be followed in the trial as described in this protocol.
8  Efficacy 
AssessmentsTrial endpoints will be defined based on clinical 
standards, regulatory precedent, and historical 
trials. These definitions will be provided in a separate document, along with the description of the Clinical Events Classification Committee (CEC).  Patients will be asked at each trial visit 
about procedures and hospi[INVESTIGATOR_252716].Trial endpoints will be defined based on clinical 
standards, regulatory precedent, and historical 
trials. The definitions of the events to be adjudicated by [CONTACT_252806] (CEC) and the committee procedures will be included in the CEC Charter (Section 
12.4).  Patients will be asked at each trial visit 
about procedures and hospi[INVESTIGATOR_252717].
8.[ADDRESS_307562] confirmed CV event for each 
component of the primary composite endpoint 
Defined as time from randomization to a 
confirmed CV-related death, fatal or nonfatal 
MI, or fatal or nonfatal stroke.
99
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
8.2  Secondary 
Efficacy EndpointsTime to hospi[INVESTIGATOR_252718], inotropes, or vasodilator therapy.Time to hospi[INVESTIGATOR_252719], inotropes, or vasodilator therapy.
9.2  Sample Size The planned sample size for this study is 9500 
patients, randomized 1:1 to each of the two 
treatment arms assuming:
â€¢ An annual composite cardiovascular 
primary endpoint event rate estimated to be 3.8% per year for the population to be enrolled. 
â€¢ A planned accrual period of 3 years
â€¢ A minimum treatment period of 4 years
â€¢ An estimated annual lost-to-follow up rate 
of 1%
â€¢ An anticipated treatment discontinuation 
rate of 5% per year
The number of cardiovascular primary endpoint 
events required is commensurate with a 90% 
power to detect a 15% relative risk decrease in the EQW group, i.e. a true hazard ratio of 0.85 relative to placebo, with a two-sided alpha=0.05.  For an exponential maximum 
likelihood test of equality of survival curves, a 
total of [ADDRESS_307563] confirmed CV event 
defined as a CV-related death, nonfatal MI or nonfatal stroke.  The study is designed to assess the primary efficacy objective of superiority of EQW to placebo through the following hypothesis:
H0:  upper limit of the 95% CI of the HR 
[exenatide:placebo] â‰¥ 1
versusH1: upper limit of the 95% CI of the HR 
[exenatide:placebo] < [ADDRESS_307564] the above hypothesis with 85% 
power and 2-sided Î±=0.05, a total number of 
1360 composite CV events are required assuming a risk reduction of 15% on EQW 
compared with placebo.  With this number of 
events, the power will be much larger than 90% to assess the primary safety objective of non-inferiority of EQW compared with placebo.
In addition, with the following assumptions 
made for this study,
â€¢ An annual composite cardiovascular 
primary endpoint event rate estimated to be around 2.2% per year for the population to be enrolled
â€¢ A planned accrual period of 5-6 yearsâ€¢ An estimated annual lost-to-follow up rate 
of 1%
â€¢ An anticipated treatment discontinuation 
rate of 5% per year
it is expected that a total of [ZIP_CODE] patients need 
to be randomized in a 1:[ADDRESS_307565] to the primary composite cardiovascular outcome, with the participants analyzed according to their allocated treatment (intention to treat).The primary efficacy hypothesis is that EQW 
will be superior to placebo with respect to the primary composite cardiovascular endpoint, defined as the time from randomization to the first confirmed CV-related death, nonfatal MI or 
nonfatal stroke with the patients analyzed as 
randomized.
The primary safety hypothesis is that EQW will 
be non-inferior to placebo with respect to the 
primary composite cardiovascular endpoint, with 
patients analyzed as randomized.
Secondary 
HypothesisThis section (9.5) from Amendment [ADDRESS_307566] event, with participants analyzed according to their allocated treatment (intention to treat).
A log rank test will be performed first, with 
Kaplan-Meier curves for time to event used to depi[INVESTIGATOR_252720].  The hazard ratio for the time of occurrence of the composite endpoint for the EQW and placebo 
treated groups and its 95% confidence interval 
will then be estimated using a Cox proportional hazards model without covariate adjustment.  Secondary Cox proportional hazards model analyses using covariate adjustments will also 
be performed as detailed in the SAP.The primary statistical analysis will be based 
upon adjudicated CV events with patients who discontinue prematurely from treatment followed until the end of the study, i.e. until the requisite number of primary composite events has been 
accrued.  It is anticipated that the Executive 
Committee will monitor the accrual of the aggregate number of primary composite CV events to determine the primary endpoint event cut-off date (i.e., the date at which the anticipated number of events is expected to have 
accrued).  All patients will be expected to have 
follow-up through this date.  Analysis of the primary composite cardiovascular outcome will be based on the time from randomization to the occurrence of the first event, with patients analyzed according to their randomized 
treatment.   The primary analysis will include all 
adjudicated CV events with onset dates up to and including the primary endpoint event cut-off date.
Kaplan-Meier curves for time to the first 
occurrence of a primary composite endpoint 
event will be used to depi[INVESTIGATOR_252720].  The hazard ratio for the time to first occurrence of the primary composite endpoint event for the EQW treated group to that 
of the placebo treated group and its 95% 
confidence interval will then be estimated using a Cox proportional hazards model stratified by [CONTACT_252829] (prior CV event or no prior CV event) and using treatment group as covariate.
The primary safety hypothesis will be assessed 
by a non-inferiority analysis with the non-inferiority margin of 1.30, i.e., non-inferiority will be concluded if the upper limit of the confidence interval is less than 1.30.
The primary efficacy hypothesis of superiority 
will be then assessed by [CONTACT_941] 95% confidence 
interval for the hazard ratio of EQW to placebo, i.e., superiority will be concluded if the 95% confidence interval does not include 1 (upper limit of 95% confidence interval < 1).
102
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
9.6  Secondary 
Efficacy AnalysesSecondary analyses will be conducted with 
participants analyzed according to their allocated treatment (intention to treat) with a Hochberg adjustment for multiple testing.  These analyses will examine:
1. All cause mortality
2. Fatal or nonfatal myocardial infarction3. Fatal or nonfatal stroke4. Hospi[INVESTIGATOR_252721] (ACS)
5. Hospi[INVESTIGATOR_126042] 
(CHF)The secondary efficacy endpoints are the time to 
confirmed occurrence of:
1. All cause mortality2. CV-related death3. Fatal or nonfatal myocardial infarction
4. Fatal or nonfatal stroke
5. Hospi[INVESTIGATOR_252671] 
(ACS)
6. Hospi[INVESTIGATOR_126042] 
(CHF)
Details of the testing strategy of the secondary 
efficacy endpoints will be provided in the 
Statistical Analysis Plan (SAP).
9.7.[ADDRESS_307567] taken a study medication for the entire duration of the study that is different from that to which he/she was randomized will be counted in the 
treatment group of the drug to which he/she was 
randomized.The ITT population consists of all randomized 
patients.  Evaluation will include all events which occurred from randomization to the primary endpoint event cut-off date, regardless of the time interval between patient 
discontinuation of study drug and final contact.  
Patients who do not have any events during the study will be censored at the primary endpoint event cut-off date.  Every effort will be made to collect CV events through the primary endpoint 
event cut-off date even in those who have 
discontinued study medication or the study.  For the ITT population, patients will be analyzed as randomized.
[IP_ADDRESS]  On-Treatment AnalysisNew addition in Amendment [ADDRESS_307568] one dose of study medication and will include in their analysis all data collected prior to any major protocol violations such as: 
â€¢ Initiation of an open-label prohibited 
medication i.e. a GLP-[ADDRESS_307569].  Evaluation will include all data up to the day of the initiation of the prohibited medication.
â€¢ Discontinuation from study medication.  
Evaluation will include events which occurred 
from randomization to [ADDRESS_307570] 
dose of study medication. 
â€¢ Taking incorrect study medication for more 
than three months. 
All such protocol violations will be identified 
prior to unblinding of the data.  Events that 
occurred after protocol violation will be 
excluded from the analysis. If a patient is found to have taken a study medication for any duration of the study that is different from that to which he/she was randomized, then the 
patient is counted in the treatment group of the 
drug he/she actually received.  Patients who do not have any events during the study will be censored [ADDRESS_307571] one dose of study medication and will include in their analysis all data collected prior to any major protocol violations (or primary endpoint 
event cut-off date, whichever occurs first), such 
as: 
â€¢ Initiation of an open-label prohibited 
medication i.e. a GLP-[ADDRESS_307572].  Evaluation will include all data up to the day of the initiation of the prohibited medication.
â€¢ Early discontinuation from study 
medication.  Evaluation will include events which occurred from randomization to [ADDRESS_307573]. 
â€¢ Taking incorrect study medication for more 
than three months. 
All protocol violations will be specified in the 
statistical analysis plan prior to unblinding of the data.  Events that occurred after protocol 
violation will be excluded from the analysis. 
Patients will be analyzed as randomized.
The primary safety and primary efficacy 
analyses will be repeated with the per-protocol population as sensitivity analyses.
9.7.[ADDRESS_307574] 
dose of study medication, will be summarized.
9.9  Subgroup AnalysesThe subgroups will be divided by [CONTACT_252830].The subgroups will be divided by [CONTACT_252830].
104
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
9.10  Interim 
AnalysesThe DSMB will review available data every 6 
months or more frequently if the committee deems it appropriate as outlined in the DSMB Charter.  Stoppi[INVESTIGATOR_252722].  The overall alpha=0.[ADDRESS_307575] for superiority using a Haybittle-Peto spending function where the study termination guideline 
for overwhelming superiority will be p-value < 
0.[ADDRESS_307576] interim analysis and p-value <0.001 for the second interim analysis.  This will ensure a significance level of 0.0499 for the final analysis.
If the stoppi[INVESTIGATOR_252723], the DSMB may 
recommend terminating the study earlier than planned.  The DSMB may, however, also advise terminating the study early for safety or ethical reasons.
The interim analyses will be performed by [CONTACT_252831].  Further details of the interim analyses are provided in the DSMB Charter.  
10.2  Adverse Event AssessmentAdverse events will be monitored over the 
course of the trial, starting from the time of randomization and through the duration of the 
patientâ€™s participation, including the [ADDRESS_307577] 
trial medication follow-up period or withdrawal.Adverse events will be monitored over the 
course of the trial, starting from the time of randomization and through the duration of the 
patientâ€™s participation, including the [ADDRESS_307578] 
trial medication follow-up period.
10.3.1  Recording Adverse EventsSAEs will be recorded in the Clinical Events or 
SAE eCRF modules as appropriate (see Table 1).  Guidelines for events which qualify as Clinical Events are provided in Appendix 1.  Events to be recorded in the Clinical Events 
eCRF module include SAEs that are: (1) 
components of the primary or secondary composite cardiovascular endpoints, (2) other trial endpoints, (3) potential components of the CV endpoint that are included among terms sent 
for review by [CONTACT_15741]; (4) expected sequelae of 
type 2 diabetes  (Table 1).  These events represent trial outcomes and expected events for this population.  SAEs will be recorded in the Clinical Events or 
SAE eCRF modules as appropriate (see Table 1) through the primary endpoint event cut-off date; ALL SAEs with onset dates AFTER the primary endpoint event cut-off date will be recorded in 
the SAE eCRF module.  Guidelines for events 
which qualify as Clinical Events are provided in Appendix 1.  Events to be recorded in the Clinical Events eCRF module include SAEs that are: (1) Obvious trial endpoints, (2)  
Cardiovascular Events of Interest, (3) Expected 
Events and Diabetic Complications.
Table 1:  List of events to be recorded in each 
eCRF reporting 
moduleSAE eCRF:
Any event meeting the criteria of an SAE (see 
Section 10.1 for definition of SAE) that are not 
listed in Appendix 1SAE eCRF:
Any event meeting the criteria of an SAE (see 
Section 10.1 for definition of SAE) that are not 
listed in Appendix [ADDRESS_307579] and â€œClinical Eventsâ€ with onset dates after the primary endpoint event cut-off date will be recorded by [CONTACT_252741].  
10.3.2  Safety 
ReportingNew addition in Amendment 05 Note that pancreatitis and pancreatic neoplasms / 
malignancies are events of special interest for 
GLP-1 based therapi[INVESTIGATOR_014], such as exenatide.  As described above, all events of pancreatitis and allneoplasms (including pancreatic cancer) are to be reported on both the Clinical Events eCRF and the SAE eCRF, even if the event does not 
meet seriousness criteria.  These events are 
reviewed by [CONTACT_252784].
10.6  Reporting of PregnancyAlthough not considered an adverse experience, 
it is the responsibility of investigators or their designees to report any pregnancy in a patient (spontaneously reported to them) which occurs 
during the trial or within 90 days of completing 
the trial.  Although not considered an adverse experience, 
it is the responsibility of investigators or their designees to report any pregnancy in a patient (spontaneously reported to them) which occurs 
during the trial or within [ADDRESS_307580] a 
blood and urine samples, preferably fasting, collected at baseline (prior to drug exposure), annually, and at the time of trial termination.  Patients providing informed consent will have 
blood and urine samples, preferably fasting, collected at baseline (prior to drug exposure), Year 1, and at the Trial Termination visit.  
11.[ADDRESS_307581] or 
fraud (e.g., loss of medical licensure, 
debarment).
[ADDRESS_307582] the sponsor prior to destroying any records associated with the study.
The sponsor will notify the investigator when the 
study records are no longer needed.
If the investigator withdraws from the study 
(e.g., relocation, retirement), the records shall be transferred to a mutually agreed upon designee (e.g., another investigator, IRB). Notice of such transfer will be given in writing to the sponsor.
11.8.[ADDRESS_307583] safety. CRFs may be requested for 
AEs and/or laboratory abnormalities that are reported or identified during the course of the study.
The investigator will maintain a signature [CONTACT_252834]/or corrections on 
CRFs. 
The completed CRF, including any paper or 
electronic SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by [CONTACT_20510] a sub-
investigator and who is delegated this task on the 
Delegation of Authority Form. For electronic CRFs, review and approval/signature [CONTACT_252833]. The investigator must retain a 
copy of the CRFs including records of the 
changes and corrections.
Each individual electronically signing electronic 
CRFs must meet training requirements and must only access the electronic data capture tool using their unique user account. User accounts are not 
to be shared or reassigned to other individuals.
107
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
12.1  Executive 
Committee (EC)The EC will be composed of approximately 
eleven individuals consisting of nine senior independent academic representatives who are experts in their field and two representatives from the Alliance.  The Committee will be co-
chaired  
  The other academic 
members will comprise four further diabetologists and three further cardiologists.  Geographical balance will be sought. Decision 
making will be by [CONTACT_21128].  An EC charter 
will delineate operating procedures.
The Executive Committee is the main decision-
making body for EQW and is charged with the overall scientific, professional, and operational conduct of the trial.The EC will be composed of senior independent 
academic representatives who are experts in their field and representatives from the sponsor.  The Committee will be co-chaired  
 
An EC charter will outline the 
committee membership and structure and delineate operating procedures.
The Executive Committee is the main decision-
making body for the EXSCEL trial and is charged with the overall scientific, professional, 
and operational conduct of the trial.
12.[ADDRESS_307584] (DSMB)DTU will transfer pre-agreed masked datasets 
to the Independent Statistician who will then 
prepare unmasked confidential reports for the DSMB, using treatment codes provided in advance by [CONTACT_1034].  
In addition, the DSMB will evaluate interim 
analyses of the data every six months (or on an 
ad hoc basis if needed) to determine if it believes either the trial should be terminated early because the exenatide arm (with respect to the placebo arm) demonstrates (a) clear inferiority, i.e., it is not in patient's best interest 
to continue taking blinded therapy; or (b) clear 
superiority, i.e., it is not in patient's best interest to continue taking blinded placebo.DTU will transfer pre-agreed masked datasets to 
the Independent Statistician who will then 
prepare unmasked confidential reports for the DSMB, using treatment codes provided in advance by [CONTACT_109424].  
In addition, the DSMB will evaluate two interim 
analyses after approximately one-third and two-
thirds of the total targeted number of primary composite CV events (see Sec 9.10 for details).
13  Disclosure of Data, Publications, and Clinical Study 
ReportFollowing submission for publication of the 
main trial results, a copy of the database will be transferred to the Sponsor.  
New addition in Amendment 05:Following submission for publication of the 
main trial results, a copy of the database will be 
transferred to the Sponsor.  
In addition, a Clinical Study Report (CSR) will 
be prepared for regulatory purposes.  The 
Signatory Investigator responsible for signing the CSR will be selected by [CONTACT_252832].
Appendix 1:  Clinical Events 
ListList re-organized from:
I.  Primary or Secondary Trial Endpoints
     A.  Obvious Trial Endpoints
     B.  Cardiovascular Events of InterestII.  Expected Events and Diabetic 
ComplicationsI.  Obvious Trial Endpoints
II.  Cardiovascular Events of Interest
III.  Expected Events and Diabetic 
Complications
108[COMPANY_003][COMPANY_003]
EXSCEL Protocol Amendment 06
SECTION AMENDMENT 04 TEXT AMENDMENT 05 TEXT
Appendix 1:  
Clinical Events List (Obvious Trial Endpoints)Death
!  Cardiovascular (CV) Death (i.e., fatal 
myocardial infarction [MI]/cerebrovascular 
accident [CVA]/ congestive heart failure [CHF]/arrhythmia, cardiac arrest, death following CV intervention)Death
!  Cardiovascular (CV) Death (i.e., fatal 
myocardial infarction [MI] /cerebrovascular 
accident [CVA] / congestive heart failure [CHF] / arrhythmia, cardiac arrest, death following CV intervention)
!  Non-CV Death
Appendix 1:  
Clinical Events 
List (Expected 
Events and Diabetic Complications)G.  Renal Failure
â€¢ Chronic renal failure, requiring 
peritoneal hemodialysis, including creation 
of fistula or other vascular access for hemodialysisG.  Renal Failure
â€¢ Chronic renal failure, requiring 
peritoneal orhemodialysis, including 
creation of fistula or other vascular access for hemodialysis
Appendix 2:  Trial Plan New addition in Amendment 05 Added â€œPost-Treatment Follow-up Contactâ€
Appendix 2:  
Trial PlanBlood sample (serum and plasma) and urine 
sample for archive - specimens obtained at 
baseline (prior to drug exposure), annually and 
trial/early termination.  Blood sample (serum and plasma) and urine 
sample for archive - specimens obtained at 
baseline (prior to drug exposure), Year 1 and at 
the Trial Termination visit.
Appendix 2:  Trial PlanEQ-5D Completion listed for â€œDrug 
Termination Visitâ€EQ-5D Completion removed from â€œDrug 
Termination Visitâ€ consistent with Section 6.10
Appendix 6 None Added Protocol Amendment 04 Summary of 
Changes
109